



**VIENNA**

30 SEP - 3 OCT 2026

TOGETHER FOR BETTER

# SCIENTIFIC PROGRAMME

### *Editorial / Publisher*

European Academy of Dermatology & Venereology (EADV)

Via S. Balestra 22B, 6900 Lugano – Switzerland

Corporate website: [eadv.org](https://eadv.org)

Further information about this event: [eadv.org/congress](https://eadv.org/congress)

### *Destination management company*

BCO Congresos

- [Official booking platform](https://www.bcocongresos.com)
- [bcocongresos.com](https://bcocongresos.com)

Contacts:

- +34 938 823 878
- [eadv2026@bcocongresos.com](mailto:eadv2026@bcocongresos.com)

### *Internet access / Wi-Fi*

Free Wi-Fi will be available in all areas of the venue including the session and meeting rooms.

Network: **EADV2026**

### *Download the official app!*



#### **On-demand content**

Play all the scientific sessions on demand

#### **Scientific programme**

Access the full programme and create your own agenda

#### **Abstracts and ePosters**

Access the latest research

#### **Certificates**

Download your certificates

#### **Session evaluations**

Evaluate sessions and gain credits

Learn more

[eadv.org/congress/app/](https://eadv.org/congress/app/)

### **Join the conversation #EADVCongress**

Follow the EADV social media channels for news and updates!



Facebook



Instagram



LinkedIn



Youtube

## Table of contents

|                                                                                           |            |
|-------------------------------------------------------------------------------------------|------------|
| <b>Welcome from the EADV President.....</b>                                               | <b>4</b>   |
| <b>Welcome from the EADV Scientific Programming Committee .....</b>                       | <b>5</b>   |
| <b>The Academy.....</b>                                                                   | <b>6</b>   |
| <b>Continuing Medical Education – Continuing Professional Development (CME-CPD) .....</b> | <b>7</b>   |
| <b>Abstract reviewers .....</b>                                                           | <b>8</b>   |
| <b>Subspecialty and international societies .....</b>                                     | <b>9</b>   |
| <b>Scientific Programme.....</b>                                                          | <b>10</b>  |
| Session types.....                                                                        | 10         |
| Wednesday, 30 September 2026 .....                                                        | 11         |
| Networking symposium .....                                                                | 12         |
| Thursday, 1 October 2026 .....                                                            | 47         |
| Friday, 2 October 2026 .....                                                              | 76         |
| Saturday, 3 October 2026.....                                                             | 105        |
| <b>Practical workshops.....</b>                                                           | <b>129</b> |
| <b>Patient organisations area .....</b>                                                   | <b>131</b> |
| <b>General information.....</b>                                                           | <b>132</b> |
| Congress venue.....                                                                       | 132        |
| First aid room and emergency numbers .....                                                | 132        |
| Onsite facilities and opening hours .....                                                 | 132        |
| Other services.....                                                                       | 133        |
| Childcare facility.....                                                                   | 133        |
| Venue floor plans.....                                                                    | 134        |
| <b>Scientific information.....</b>                                                        | <b>139</b> |
| Official language .....                                                                   | 139        |
| Session access.....                                                                       | 139        |
| Abstracts and ePosters.....                                                               | 139        |
| Certificates and accreditation.....                                                       | 140        |
| <b>Speaker information.....</b>                                                           | <b>140</b> |
| Speaker preview room.....                                                                 | 140        |
| <b>Registration .....</b>                                                                 | <b>141</b> |
| Press information for journalists and media representatives.....                          | 142        |
| <b>Healthcare Professional information and definition .....</b>                           | <b>143</b> |
| <b>Privacy .....</b>                                                                      | <b>144</b> |
| <b>Exhibition.....</b>                                                                    | <b>145</b> |
| Exhibition floor plans.....                                                               | 145        |
| Exhibitor list .....                                                                      | 146        |
| Sponsors .....                                                                            | 148        |



## Welcome from the EADV President

*Dear Colleagues, Dear Friends, and Esteemed Members of the EADV Community,*

*It is with great pleasure that I welcome you to the 35th EADV Congress 2026, taking place from 30 September to 3 October in the elegant city of Vienna. Renowned for its rich cultural heritage and longstanding tradition in science and medicine, Vienna provides an inspiring setting for our annual gathering.*

*The EADV Congress continues to showcase the latest science, research, and best practices across the full spectrum of dermatovenereology. This year's scientific programme offers a comprehensive and dynamic selection of sessions, including subspecialty tracks, hands-on workshops, and industry presentations, all designed to support continuous learning and professional exchange. I warmly encourage you to explore the programme and engage with the many opportunities it offers.*

*We are proud to bring together leading experts from across the world, alongside rising stars, to share knowledge, present new data, and discuss the evolving challenges and innovations shaping our field. The keynote Speaker Salim S. Abdool Karim, MD, PhD, FRS Director, Centre for the AIDS Programme of Research, South Africa will address the implications faced for future generations due to COVID19 and the infodemic.*

*The Congress remains a vital platform for collaboration, education, and inspiration for dermatologists and venereologists at every stage of their careers. In addition to the scientific sessions, the Congress will feature an extensive exhibition area where participants can discover the latest technologies, treatments, and products driving advancements in patient care. This vibrant space fosters dialogue between clinicians, researchers, and industry partners, strengthening the connections that advance our specialty.*

*The Austria Center Vienna, with its exceptional facilities and expansive congress space, will host this year's event, ensuring a comfortable and engaging experience for all attendees. To further facilitate your stay, full Congress registration includes access to Vienna's public transport network, making it easy to navigate and enjoy the city.*

*Whether you are joining us for the first time or returning once again, I encourage you to take full advantage of this unique opportunity to learn, connect, and be inspired.*

*On behalf of the EADV Executive Committee, I look forward to welcoming you to Vienna for what promises to be an outstanding Congress.*

*With warmest regards,*



**Prof. Branka Marinović**  
EADV President



## Welcome from the EADV Scientific Programming Committee

*Dear Colleagues,*

*We are excited to welcome you to the 35th EADV Congress in Vienna! This year's event brings together science, clinical excellence, and innovation to shape the future of dermatology and venereology.*

*The scientific program features our core tracks, like Updates, Training and Education and Controversies, along with Focus on sessions dedicated to "JAK inhibitors" and "Practical diagnostic and therapeutic algorithms".*

*Highlights include the third edition of the EADV Games, dedicated abstract-based sessions to clinical cases, a wide selection of aesthetic dermatology sessions and the unmissable "Late breaking news" sessions, featuring the best "late breaking abstracts". The plenary sessions will showcase advances in biomarkers, phototherapy, clinical photography, tumour microenvironment, algorithms, social media and fibromyalgia. And speaking of plenary lectures, we are honored to have a keynote lecture by Professor Salim Abdool Karim, with his talk called "From COVID-19 to the Infodemic: Implications for the future".*

*Moreover, the selected Subspecialty Societies developed an extensive programme, with each society focusing on its dermatological topic and offering important insights into the latest developments in that field.*

*If you are looking for a more practice-based learning approach, hands-on Workshops are a great opportunity to immediately implement newly learned skills, to gain practical experience and quickly acquire knowledge on the subject.*

*Last but not least, if you submitted an abstract to the event, you may be able to showcase your latest research in a Late-Breaking News session, a Free Communication, and/or such as an ePoster.*

*For those unable to attend in person, the Congress will be fully live-streamed, making it accessible worldwide.*

*Join us in Vienna, or online, for what promises to be an unforgettable 35th EADV Congress.*

*With warm regards,*

**Prof. Lidia Rudnicka**  
Chair of the Scientific  
Programming Committee



**EADV Scientific Programming Committee:**  
Lidia Rudnicka, Rolland Gyulai, Christina Has,  
Paola Pasquali, Eli Sprecher, Thrasyvoulos Tzellos



## The Academy

EADV is committed to building the international community that develops, shares, and adopts best practices within dermatology and venereology.

With over 14'000 members and an active community of more than 20'000 professionals around the world, our goal is to be the trusted source for proven scientific advancements and practices in the prevention, diagnosis, and treatment of skin and venereal diseases.

Skin and venereal diseases are continuously evolving, as are the science and practices for preventing, diagnosing, and treating them. Advancements are being made every day that have the potential to have a significant impact on the ongoing battle to improve skin and sexual health around the world. Enabling these advancements to be validated and ensuring all professionals adopt the best practices ultimately moves dermatology and venereology forward.

EADV and its international community of passionate professionals define and spread best practices in dermatology and venereology for the benefit of all. We are a true platform for collaboration and progress across borders and sub-specialties.

Expert task forces shape standards and develop best practice guidelines, while our events, publications, and educational courses share them with our members and the broader community so they can adopt them for maximum impact.

### EADV Vision

*drives the future of dermatology and venereology by leading progress, empowering a diverse professional community, improving patient care and setting new standards of excellence across Europe and beyond.*

### EADV Mission

*advancing care, education, and research in dermatology and venereology by connecting professionals and fostering innovation worldwide, through events and education opportunities.*

Discover more on [eadv.org](https://eadv.org)



## Continuing Medical Education – Continuing Professional Development (CME-CPD)

The EADV Congress 2026, Vienna, 30/09/2026 - 03/10/2026, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s).

### CME credits

Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process or online access).

Here below please find the breakdown of credits per day:

|                        |     |                                                                                                                                                                                             |                                                                                     |
|------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Wednesday, 30 Sep 2026 | 6.0 | The accreditation system is based on<br><b>1 ECMEC per hour.</b><br><br>No credits will be provided for the following sessions:<br>industry sessions, subspecialty sessions and EADV Games. |  |
| Thursday, 1 Oct 2026   | 6.0 |                                                                                                                                                                                             |                                                                                     |
| Friday, 2 Oct 2026     | 6.0 |                                                                                                                                                                                             |                                                                                     |
| Saturday, 3 Oct 2026   | 6.0 |                                                                                                                                                                                             |                                                                                     |

### Procedure to gain your credits

Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.

The EADV offers individual CME-CPD participation through scanning the bar code and completing the speaker/session evaluation, which will be available until 31 December 2026.

1. **Scan your badge** as you pass through the entrance of each session hall, and your data will be transmitted to the system (or access the online session on demand).
2. **Complete the anonymous online evaluation** for each attended session. Access the evaluation system in the “My Area” section on the online Congress platform.
3. **Download your CME-CPD certificate** and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

### Conversion of Credits

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

### Information regarding the conversion of EACCME® credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at <https://edhub.ama-assn.org/pages/applications> to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.



## Abstract reviewers

**EADV is grateful to the following reviewers who gave their time and expertise in reviewing the submitted abstracts.**

|                         |                           |                           |
|-------------------------|---------------------------|---------------------------|
| Alpsoy Erkan            | Hafner Jürg               | Raap Ulrike               |
| Badawi Ashraf           | Heller-Vitouch Claudia    | Reich Adam                |
| Balato Anna             | Hijnen Dirk Jan           | Romagnuolo Maurizio       |
| Balieva Flora           | Iorizzo Matilde           | Roque Ferreira Bárbara    |
| Barbarot Sébastien      | Kazandjieva Jana          | Rustemeyer Thomas         |
| Basic Marcela           | Kluger Nicolas            | Sadoughifar Roxanna       |
| Bata-Csorgo Zsuzsanna   | Kolkhir Pavel             | Samimi Mahtab             |
| Bauer Johann            | Kolyadenko Kateryna       | Schmuth Matthias          |
| Bauer Andrea            | Kostaki Maria             | Sibaud Vincent            |
| Bewley Anthony          | Koumaki Dimitra           | Simeonovski Viktor        |
| Bilgic Asli             | Krastev Dimitar           | Simon Dagmar              |
| Bobko Svetlana          | Laffitte Emmanuel         | Skerlev Mihael            |
| Böhler Kornelia         | Laubach Hans-Joachim      | Skiljevic Dusan           |
| Briatico Giulia         | Leclerc-Mercier Stéphanie | Skov Lone                 |
| Brunner Patrick         | Leone Giovanni            | Soares de Almeida Luis    |
| Calzavara-Pinton        | Liakou Aikaterini         | Miguel                    |
| Piergiacomo             | Liguori Simone            | Solak Berna               |
| Carrascosa Jose-Manuel  | Lui Harvey                | Soura Efthymia            |
| Carugno Andrea          | Lvov Andrei               | Spuls Phyllis             |
| Chanal Johan            | Marini Susanna            | Srinivasan Sundaramoorthy |
| Chernyshov Pavel        | Marzano Angelo Valerio    | Stefaniak Aleksandra      |
| Crisan Diana            | Misery Laurent            | Stephan Brigitte          |
| Csoma Zsanett Renáta    | Monnier Jilliana          | Stingl Georg              |
| Dahmen Robert Artur     | Moody Brent               | Su-Kucuk Ozlem            |
| Damiani Giovanni        | Moreno-Ramírez David      | Svensson Åke              |
| DeBerker David          | Mrowietz Ulrich           | Taieb Alain               |
| Dessinioti Clio         | Nagore Eduardo            | Tasanen Kaisa             |
| Didona Dario            | Nikkels Arjen Fokko       | Temiz Selami Aykut        |
| Doss Nejib              | Nisavic Milos             | Todorovic Danica          |
| Drenovska Kossara       | Olszewska Malgorzata      | Türsen Ümit               |
| Edek Yusuf Can          | Olteanu Rodica            | van den Reek Juul         |
| El Barch Maha           | Özkaya Esen               | Vassileva Snezhina        |
| Fagnoli Maria Concetta  | Patsatsi Aikaterini       | Velthuis Peter            |
| Fattore Davide          | Pereira Manuel            | Vestergaard Christian     |
| Fida Monika             | Pesqué David              | Vink Liselot              |
| Finlay Andrew Y.        | Peternel Sandra           | Warren Richard B.         |
| Fritz Klaus             | Pietkiewicz Pawel         | Wikonkal Norbert          |
| Gieler Uwe              | Preto Gomes Nuno Miguel   | Yayli Savaş               |
| Giménez-Arnau Ana       | Prohić Asja               | Zuberbier Torsten         |
| Gkini Maria-Angeliki    | Puig Lluís                |                           |
| González-Cantero Álvaro | Quaglino Pietro           |                           |



## Subspecialty and international societies

The following societies develop and manage scientific sessions during the EADV Congress 2026 after approval from the EADV Scientific Programming Committee.

Each society has a specific focus on a dermatological topic and offers important insights into the latest developments in that field.

- Austrian Society of Dermatology and Venereology (ÖGDV)
- ASDV - African Society of Dermatology and Venereology
- CILAD - Colegio Ibero-Latinoamericano de Dermatología
- Euromelanoma
- EHSF - European Hidradenitis Suppurativa Foundation
- ENS - European Nail Society
- European Nurse Dermatology Task Force
- ERN-Skin - European Reference Network
- ESCAD - European Society for Cosmetics and Aesthetic Dermatology
- ESDaP - European Society for Dermatology and Psychiatry
- ESLD - European Society for Lasers and Energy-Based Devices
- ESTP – European Society of Tattoo and Pigment Research
- EURO-PDT - European Society for Photodynamic Therapy in Dermatology
- ESDP - European Society of Dermatopathology
- ESPD - European Society of Photodermatology
- ETFAD - European Task Force of Atopic Dermatitis
- GRAPPA - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- IADV - Indian Association of Dermatologists, Venereologists and Leprologists
- IDS - International Dermoscopy Society
- IEC - International Eczema Council
- IPS - International Peeling Society
- IPC - International Psoriasis Council
- ISD - International Society of Dermatology
- MEIDAM - Middle East International Dermatology and Aesthetic Medicine
- PALD - Pan Arab League of Dermatology
- SSDDS - Saudi Society of Dermatology and Dermatologic Surgery
- SPIN-FRT - Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine
- SOCS - Skin Of Color Society
- STDV - Tunisian Society of Dermatology and Venereology
- WDS - Women's Dermatologic Society



## Scientific Programme

The scientific programme has been organised on full or half-day tracks. Each track has a specific topic and a structured programme.

### Session types

Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives.

The following session types will be scheduled throughout the duration of the Congress and are available to all registered participants.

-  **Plenary sessions:** Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.
-  **Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology / epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.
-  **Updates:** These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.
-  **Controversies:** Controversial topics in dermatology will be discussed from different points of view in the form of a debate, giving delegates extensive insights into the latest findings.
-  **Training and education:** These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics.
-  **Clinical cases:** Authors of the highest-ranked clinical case abstracts, as assessed by a selected panel of abstract reviewers, are invited to deliver a 10-minute oral presentation.
-  **Free communications:** Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.
-  **Miscellaneous:** The miscellaneous track includes a variety of scientific sessions featuring contributions from selected task forces and committees, as well as sessions related to JEADV and other topics of scientific and educational interest.
-  **Subspecialty sessions:** Subspecialty and International Society meetings are scientific sessions developed and managed by the individual societies after approval from the EADV Scientific Programming Committee.
-  **EADV Games:** The EADV will host a quiz for residents during the congress, an event which will gather 18 European countries to compete against each other in a thrilling quiz focusing on various Dermatology topics.
-  **Workshops \* :** Workshops are a great opportunity to immediately implement newly learned skills, to gain practical experience and quickly acquire knowledge on the subject. Workshops also promote interaction between instructors and participants.

*\* All Workshops require a pre-registration and a pre-payment. Class sizes are limited to 35 places each and registrants are accepted on a first-paid, first-served basis. More info [eadv.org/congress/scientific/workshops](https://eadv.org/congress/scientific/workshops)*



**Wednesday, 30 September 2026**

|           |                                                                                                       |                                                                                     |                                                                  |                                             |  |
|-----------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------|--|
|           |                                                                                                       | 12:00 – 13:00                                                                       |                                                                  | 17:45 – 19:00                               |  |
| Hall A    |                                                                                                       | Plenary lectures<br>A                                                               |                                                                  | Plenary session with<br>keynote lecture     |  |
|           | 08:30 – 10:00                                                                                         | 10:15 – 11:45                                                                       | 14:15 – 15:45                                                    | 16:00 – 17:30                               |  |
| Hall A    |                                                                                                       |                                                                                     | Late breaking news                                               | Late breaking news                          |  |
| Hall D    | European Task Force on Atopic Dermatitis (ETFAD)                                                      | International Dermoscopy Society (IDS)                                              | Hidradenitis suppurativa                                         | Hidradenitis suppurativa                    |  |
| Hall B    | Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine (SPIN-FRT) | European Society for Cosmetic and Aesthetic Dermatology (ESCAD)                     | Oral diseases                                                    | Vitiligo                                    |  |
| Hall C    | European Nail Society (ENS)                                                                           | Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)     | JAK inhibitors                                                   | JAK inhibitors                              |  |
| Hall F1   | International Society of Dermatology (ISD)                                                            | Austrian Society of Dermatology and Venereology (ÖGDV)                              | Mohs surgery                                                     | Off-label use of dermatological medications |  |
| Hall F2   | Skin Of Color Society (SOCS)                                                                          | European Society For Laser and Energy Based Devices in Dermatology (ESLD)           | Paraneoplastic diseases                                          | Rosacea                                     |  |
| Hall E1   | International Psoriasis Council (IPC)                                                                 | European Hidradenitis Suppurativa Foundation (EHSF)                                 | Lasers and energy-based devices (Part 1)                         | Lasers and energy-based devices (Part 2)    |  |
| Hall E2   | European Society for Photodermatology (ESPD)                                                          | Women's Dermatologic Society (WDS)                                                  | Advanced interventional cosmetic treatments                      | Open questions in aesthetic dermatology     |  |
| Hall G    | International Peeling Society (IPS)                                                                   | The Middle East International Dermatology & Aesthetic Medicine Association (MEIDAM) | Bullous diseases: diagnostic procedures and treatment guidelines | Non-invasive skin imaging techniques        |  |
| Hall M    |                                                                                                       | European Dermatology Nurse Task Force                                               | Bacterial skin infections                                        | Dermatology of ageing skin                  |  |
| Hall K    | European Reference Network for Rare Skin Diseases (ERN-Skin)                                          | Colegio Ibero-Latinoamericano de Dermatología (CILAD)                               | Chronic leg ulcers                                               | Managing skin diseases during pregnancy     |  |
| Hall N    | Euromelanoma                                                                                          | European Society for Photodynamic Therapy in Dermatology (EURO-PDT)                 | STIs                                                             | STIs                                        |  |
| 1.61-1.62 | STI diagnosis and treatment                                                                           |                                                                                     | Dermal fillers                                                   |                                             |  |
| 1.85-1.86 | Allergology: environmental induced contact dermatitis and urticaria                                   |                                                                                     | Basics of ultrasound imaging and echo guided injections          |                                             |  |



**Wednesday, 30 September 2026**Session type: **Plenary**Room **Hall A****Plenary lectures A**Chairs: Martin Röcken (Tübingen, Germany)  
Paola Pasquali (Cambrils, Spain)12:00 **Biomarkers that will change clinical practice**  
Emma Guttman-Yassky (New York, United States)12:20 **The future of phototherapy in dermatology**  
Lajos Kemény (Szeged, Hungary)12:40 **Modern clinical photography in dermatology**  
Harvey Lui (Vancouver, Canada)Session type: **Plenary**Room **Hall A****Plenary session with keynote lecture**Chairs: Lidia Rudnicka (Warsaw, Poland)  
Branka Marinovic (Zagreb, Croatia)17:45 **Welcome from the EADV President**  
Branka Marinovic (Zagreb, Croatia)17:55 **Welcome from the President of the Austrian Society of Dermatology**  
Robert Muellegger (Vienna, Austria)18:05 **Keynote speaker introduction**  
Lidia Rudnicka (Warsaw, Poland)18:10 **From COVID-19 to the Infodemic: Implications for the future**  
Salim Abdool Karim (Durban, South Africa)18:45 **Discussion, Q&A****Networking symposium**

Following the plenary session, we invite you to join us for a networking reception to celebrate the start of the 2026 EADV Congress.

- Wednesday, 30 September
- Starting at 19:00
- Entrance Hall – Level 0



Wednesday, 30 September 2026

Session type: Updates

Room Hall A

|          |       |                                                                                                                                                                                                                                                                                  |
|----------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D1T01.I  |       | <b>Late breaking news</b><br>Chairs: Jo LW Lambert (Ghent, Belgium)<br>Peter Wolf (Graz, Austria)                                                                                                                                                                                |
| D1T01.IA | 14:15 | <b>A Phase 2b Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Adults With Moderate to Severe Hidradenitis Suppurativa</b><br>Alexa B. Kimball (Boston, United States)                                                                            |
| D1T01.IB | 14:30 | <b>Efficacy and Safety of Otuikibart in Adults with Prurigo Nodularis: 52-Week Results from a Phase 3 Trial</b><br>Jianzhong Zhang (Beijing, China)                                                                                                                              |
| D1T01.IC | 14:45 | <b>Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: Results from the Phase II Portion of the Randomized, Double-Blind, Placebo-Controlled BEACON Trial</b><br>Aaron Mangold (Scottsdale, United States)                                                             |
| D1T01.ID | 15:00 | <b>SPOTLIGHT-204: Primary Results of Intralesional BO-112 in Resectable Basal Cell Carcinoma</b><br>Maria Teresa Fernández-Figueras (Barcelona, Spain)                                                                                                                           |
| D1T01.IE | 15:15 | <b>Bempikibart, a novel IL-7R<math>\alpha</math> antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial</b><br>Arash Mostaghimi (Boston, United States) |
| D1T01.IF | 15:30 | <b>Daxdilimab in Moderate-to-Severe Discoid Lupus Erythematosus: Efficacy and Safety Results from a Phase 2, Randomised, Placebo-controlled Trial</b><br>Victoria Werth (Wynnewood, United States)                                                                               |



Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall A**

|          |       |                                                                                                                                                                                                                                                                 |
|----------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DIT01.2  |       | <b>Late breaking news</b><br>Chairs: Antonio Torrelo (Madrid, Spain)<br>Dilek Seckin (Istanbul, Türkiye)                                                                                                                                                        |
| DIT01.2A | 16:00 | <b>Lutikizumab Targets Neutrophilic Inflammation and Fibroblast Activation to Drive Response in Hidradenitis Suppurativa</b><br>Johann Gudjonsson (Ann Arbor, United States)                                                                                    |
| DIT01.2B | 16:15 | <b>Efficacy and Safety of Zumilokibart (APG777), a Half-Life-Extended Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis: Primary Results From the Phase 2 APEX Part B Dose-Regimen-Finding Study</b><br>Melinda Gooderham (Peterborough, ON, Canada) |
| DIT01.2C | 16:30 | <b>Multi-omic profiling identifies early molecular responses to rezpegaldesleukin, a novel regulatory T cell-inducing therapy, in atopic dermatitis</b><br>Meredith Manson (New York, United States)                                                            |
| DIT01.2D | 16:45 | <b>Efficacy and Safety of MG-K10 Administered at 600 mg Every 8 Weeks Versus 300 mg Every 4 Weeks in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: Results of a Randomized Phase 2 Study</b><br>Yi Xiao (Changsha, China)                           |
| DIT01.2E | 17:00 | <b>Efficacy and safety of lunsekimig in moderate-to-severe atopic dermatitis: Results from the phase 2b VELVET trial</b><br>Robert Bissonnette (Montreal, Canada)                                                                                               |
| DIT01.2F | 17:15 | <b>Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADTouch Trial</b><br>Patrick Brunner (New York, United States)                                             |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall D**

**European Task Force on Atopic Dermatitis (ETFAD)**

Chairs: Magdalena Trzeciak (Gdansk, Poland)  
Dirk Jan Hijnen (Rotterdam, Netherlands)  
Andreas Wollenberg (Munich, Germany)

08:30 **Eczema in inborn errors of immunity with atopy: frequency, timing, and phenotypic clustering**  
Hélène Aubert Wastiaux (NANTES CEDEX 1, France)

08:40 **Atopic dermatitis, and later onset of type-I and II diabetes mellitus**  
Laura von Kobyletzki (Malmö, Sweden)

08:50 **Eczema of the elderly and atopic dermatitis: new insights from mRNA profiling of skin samples**  
Susanne Radonjic-Hoesli (Bern, Switzerland)

09:00 **JAK1 inhibition with abrocitinib promotes epidermal recovery and reshapes keratinocyte states in atopic dermatitis**  
Melina Fonfara (Kiel, Germany)

09:10 **Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry**  
Dora Stölzl (Kiel, Germany)

09:20 **Selective modulation of circulating and cutaneous immune responses following tralokinumab treatment in atopic dermatitis**  
Margot Starrenburg (Utrecht, Netherlands)

09:30 **LC-OCT skin profiling of clinical and morphological treatment response in pediatric moderate-to-severe atopic dermatitis treated with dupilumab versus baricitinib**  
Ester Del Duca (New York, United States)

09:40 **Impact of minimal disease activity on patient-reported outcomes in atopic eczema patients: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR)**  
Carsten Flohr (London, United Kingdom)

09:50 **Patient treatment needs and individualized benefit assessment in moderate-to-severe atopic dermatitis: insights from a nationwide registry**  
Stephan Traidl (Hannover, Germany)



*Wednesday, 30 September 2026*

Session type: **Subspecialty**

Room **Hall D**

**International Dermoscopy Society (IDS)**

Chairs: Caterina Longo (Modena, Italy)  
Zoe Apalla (Thessaloniki, Greece)  
John Paoli (Gothenburg, Sweden)


10:15 **Dermoscopy clues that I forgot to publish**  
Aimilios Lallas (Thessaloniki, Greece)

10:35 **Dermoscopy clues that I forgot to publish**  
Susana Puig (Barcelona, Spain)

10:55 **Challenging scenario in 2026**  
Giuseppe Argenziano (Naples, Italy)

11:05 **The robot that will replace me**  
Harald Kittler (Vienna, Austria)

11:25 **Discussion**



## Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                              |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------------|
| <b>DIT02.1</b>  |       | <b>Hidradenitis suppurativa</b><br>Chairs: Ditte Marie L. Saunte (Virum, Denmark)<br>Christos C. Zouboulis (Dessau, Germany) |
| <b>DIT02.1A</b> | 14:15 | <b>Modifying the patient journey</b><br>Ditte Marie L. Saunte (Virum, Denmark)                                               |
| <b>DIT02.1B</b> | 14:35 | <b>Phenotypes and comorbidities</b><br>Lukasz Matusiak (Wroclaw, Poland)                                                     |
| <b>DIT02.1C</b> | 14:55 | <b>Novel outcome measures</b><br>Christos C. Zouboulis (Dessau, Germany)                                                     |
| <b>DIT02.1D</b> | 15:15 | <b>Defining disease progression and remission</b><br>Francesca Prignano (Florence, Italy)                                    |
| <b>DIT02.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                   |

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                          |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------|
| <b>DIT02.2</b>  |       | <b>Hidradenitis suppurativa</b><br>Chairs: Aikaterini I. Liakou (Athens, Greece)<br>Thrasylvoulos Tzellos (Bodø, Norway) |
| <b>DIT02.2A</b> | 16:00 | <b>Optimising the use of topical and systemic treatments</b><br>Erkan Alpsoy (Antalya, Türkiye)                          |
| <b>DIT02.2B</b> | 16:20 | <b>Optimising the use of biologic agents</b><br>Aikaterini I. Liakou (Athens, Greece)                                    |
| <b>DIT02.2C</b> | 16:40 | <b>Imaging-guided surgery</b><br>Antonio Martorell (Valencia, Spain)                                                     |
| <b>DIT02.2D</b> | 17:00 | <b>Upcoming treatments</b><br>Thrasylvoulos Tzellos (Bodø, Norway)                                                       |
| <b>DIT02.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                               |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall B**

**Skin Inflammation & Psoriasis International Network, action of the Fondation René Touraine (SPIN-FRT): Core outcome set in dermatology**

Chairs: Phyllis I. Spuls (Amstelveen, Netherlands)  
Amit Garg (New York, United States)

08:30 **SPIN – who we are, and what is in there for you?**  
Tiago Torres (Porto, Portugal)

08:40 **What is a core outcome set, and why is it important to your patients?**  
Phyllis I. Spuls (Amstelveen, Netherlands)

08:50 **Checklist and manual core outcome set development**  
Jan Kottner (Berlin, Germany)

09:05 **Dermatology-specific patient-reported outcome measures (PROMs): a scoping review emphasizing the need for further studies of measurement properties**  
Sandrine Herbelet (Belgium)

09:20 **COSEB**  
Eva Korte (Groningen, Netherlands)

09:30 **Historic**  
Amit Garg (New York, United States)

09:40 **HOME uptake**  
Yael Leshem (Tel Aviv, Israel)

09:50 **Panel discussion**  
Amit Garg (New York, United States)



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall B**

**European Society for Cosmetic and Aesthetic Dermatology (ESCAD)**

Chairs: Peter Velthuis (Rotterdam, Netherlands)  
Miray Al-Mustafa (Oslo, Norway)

10:15

**Introduction**

Peter Velthuis (Rotterdam, Netherlands)

10:20

**Skin and exposome**

Hok Bing Thio (Rotterdam, Netherlands)

10:35

**The post-hyaluronidase syndrome: what is it all about?**

Peter Velthuis (Rotterdam, Netherlands)

10:50

**Why is everyone starting to look the same?**

Miray Al-Mustafa (Oslo, Norway)

11:05

**Imaging techniques in dermatology: an overview**

Ferial Fanian (Paris, France)

11:20

**Choosing the right injectable collagen stimulator: calcium hydroxyapatite vs PLLA**

Emanuel Marques (Lisbon, Portugal)

11:35

**Q&A**



## Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                    |
|-----------------|-------|----------------------------------------------------------------------------------------------------|
| <b>DIT03.1</b>  |       | <b>Oral diseases</b><br>Chairs: Raimonds Karls (Daugmale, Latvia)<br>Mahtab Samimi (Tours, France) |
| <b>DIT03.1A</b> | 14:15 | <b>Oral candidosis</b><br>Mahtab Samimi (Tours, France)                                            |
| <b>DIT03.1B</b> | 14:35 | <b>Recurrent aphthous stomatitis</b><br>Jane Setterfield (London, United Kingdom)                  |
| <b>DIT03.1C</b> | 14:55 | <b>Oral cancer</b><br>Monika Arenbergerova (Prague, Czech Republic)                                |
| <b>DIT03.1D</b> | 15:15 | <b>Leukoplakia</b><br>Raimonds Karls (Daugmale, Latvia)                                            |
| <b>DIT03.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                         |

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                          |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------|
| <b>DIT03.2</b>  |       | <b>Vitiligo</b><br>Chairs: Viktoria Eleftheriadou (Wolverhampton, United Kingdom)<br>Julien Seneschal (Bordeaux, France) |
| <b>DIT03.2A</b> | 16:00 | <b>From pathogenesis to emerging therapeutic targets</b><br>Reinhart Speeckaert (Gent, Belgium)                          |
| <b>DIT03.2B</b> | 16:20 | <b>Vitiligo in skin of colour</b><br>Vinay Keshava Murthy (Chandigarh, India)                                            |
| <b>DIT03.2C</b> | 16:40 | <b>Relevant comorbidities</b><br>Julien Seneschal (Bordeaux, France)                                                     |
| <b>DIT03.2D</b> | 17:00 | <b>Novel therapies</b><br>Viktoria Eleftheriadou (Wolverhampton, United Kingdom)                                         |
| <b>DIT03.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                               |



Wednesday, 30 September 2026

Session type: **Subspecialty**

Room **Hall C**

**European Nail Society (ENS)**

Chairs: Bertrand Richert (Brussels, Belgium)  
Matilde Iorizzo (Lugano, Switzerland)  
Nilton Gioia Di Chiacchio (Sao Paulo, Brazil)

08:30 **Introduction**

08:32 **Clinical case**  
Lourdes Navarro Campoamor (Madrid, Spain)

08:37 **Intralesional injections at the nail unit: when, what, and how?**  
Bertrand Richert (Brussels, Belgium)

08:49 **Clinical case**  
Francesca Pampaloni (Bologna, Italy)

08:54 **Nail surgery: ordering from an expanding menu**  
Andre Lencastre (Alcabideche, Portugal)

09:06 **Clinical case**  
Pembegül Güneş (Istanbul, Türkiye)

09:11 **Dermoscopic tips of differential diagnosis of nail warts and nail squamocell carcinoma**  
Michela Starace (Bologna, Italy)

09:23 **Clinical case**  
Florence Lamoline (Woluwe-Saint-Lambert, Belgium)

09:28 **Ingrowing nails: 3 easy surgical techniques that can save your patient**  
Nilton Gioia Di Chiacchio (Sao Paulo, Brazil)

09:40 **Clinical case**  
Elisabeth Weeger-Marek (Vienna, Austria)

09:45 **Q&A**

09:55 **Conclusion/Announcements**



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall C**

**Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Advancing personalized care in psoriatic disease: from early detection to precision therapeutics**

Chairs: Joseph F. Merola (Dallas, United States)  
April W. Armstrong (Los Angeles, United States)

10:15 **Introduction**

10:20 **What's hot in psoriatic arthritis 2026 for the dermatologist: therapeutics, screening, and emerging concepts**

Joseph F. Merola (Dallas, United States)  
Leandro Linhares Leite (Sao Paulo, Brazil)

10:33 **Beyond efficacy: can we match psoriasis patients to the treatment they will actually prefer and use?**

April W. Armstrong (Los Angeles, United States)

10:46 **Measuring MSK symptoms: learning from psoriasis and applying concepts across HS, IBD, and other immune-mediated diseases**

Alice Gottlieb (Dallas, United States)

10:59 **Difficult-to-treat psoriasis: developing a common framework through IPC-GRAPPA collaboration**

Lone Skov (Hellerup, Denmark)

11:12 **Personalised medicine approaches to psoriasis therapeutics: from immune signatures to treatment selection**

Kilian Eyerich (Freiburg, Germany)

11:25 **Combination therapy in psoriatic disease: AFFINITY, COMBO, and beyond**

Ahmet Ugur Atilan (Denizli, Türkiye)

11:38 **Panel discussion and audience Q&A: toward practical algorithms for dermatologists**



**Wednesday, 30 September 2026**

Session type: **Focus on**

Room **Hall C**

|                 |       |                                                                                                                          |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------|
| <b>DIT04.1</b>  |       | <b>JAK inhibitors</b><br>Chairs: Ignasi Figueras-Nart (Barcelona, Spain)<br>Melinda Gooderham (Peterborough, ON, Canada) |
| <b>DIT04.1A</b> | 14:15 | <b>Understanding the mechanism of action</b><br>Melinda Gooderham (Peterborough, Canada)                                 |
| <b>DIT04.1B</b> | 14:35 | <b>Emerging JAK inhibitors and combination treatments</b><br>Bruno Duarte (Lisbon, Portugal)                             |
| <b>DIT04.1C</b> | 14:55 | <b>Safety profile of JAK inhibitors</b><br>Ignasi Figueras-Nart (Barcelona, Spain)                                       |
| <b>DIT04.1D</b> | 15:15 | <b>Evidence for long-term use of JAK inhibitors</b><br>Seemal R Desai (Plano, United States)                             |
| <b>DIT04.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                               |

Session type: **Focus on**

Room **Hall C**

|                 |       |                                                                                                         |
|-----------------|-------|---------------------------------------------------------------------------------------------------------|
| <b>DIT04.2</b>  |       | <b>JAK inhibitors</b><br>Chairs: Stephan Weidinger (Kiel, Germany)<br>Axel De Greef (Brussels, Belgium) |
| <b>DIT04.2A</b> | 16:00 | <b>JAK inhibitors in alopecia areata</b><br>Axel De Greef (Brussels, Belgium)                           |
| <b>DIT04.2B</b> | 16:20 | <b>JAK inhibitors in atopic dermatitis</b><br>Stephan Weidinger (Kiel, Germany)                         |
| <b>DIT04.2C</b> | 16:40 | <b>JAK inhibitors in vitiligo</b><br>Annunziata Dattola (Rome, Italy)                                   |
| <b>DIT04.2D</b> | 17:00 | <b>Off-label use of JAK inhibitors: What is the evidence?</b><br>Lajos Vince Kemeny (Budapest, Hungary) |
| <b>DIT04.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                              |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall F1**

**International Society of Dermatology (ISD)**

Chairs: Trilokraj Tejasvi (Ann Arbor, United States)  
Martin Kassir (Dallas, United States)  
Lally Mekokishvili (Tbilisi, Georgia)

08:30 **Future of healthcare**  
Roni Dodiuk-Gad (Haifa, Israel)

08:37 **AI in medical education**  
Lillia Correa (Tampa, United States)

08:45 **Digital education and capacity building in global dermatology**  
Ichechiek Ujile (Portharcourt, Nigeria)

08:53 **Availability of technology and the digital divide: lessons from tele dermatology in Africa**  
Salva Nicas (Moshi, Tanzania)

09:01 **Global AI, local solutions: adapting dermatology innovations to the realities of Latin America**  
Monica Ramos (Mexico)

09:09 **AI in dermatology in South Asia: what is available, what is being used, and by who**  
Madhulika Mhatre (Mumbai, India)

09:17 **AI and tele dermatology, European perspective**  
Elvira Moscarella (Naples, Italy)

09:25 **Integrating AI into a virtual care practice in Canada**  
Juthika Thakur (Ontario, Canada)

09:33 **AI and the digital divide in South Asian dermatology: is it reaching the needy or leaving them further behind?**  
Aseem Sharma (Mumbai, India)

09:41 **AI and technology – an update**  
Amanda Margaret Oakley (Hamilton, New Zealand)

09:49 **Q&A**



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall F1**

**Austrian Society of Dermatology and Venereology: Austrian Dermatovenereology: from the morphological ages to the molecular era**

Chairs: Georg Stingl (Vienna, Austria)  
Wolfram Hoetzenecker (Linz, Austria)  
Peter Wolf (Graz, Austria)

10:15 **From morphology to AI diagnosis**  
Harald Kittler (Vienna, Austria)

10:30 **Cutaneous sarcoidosis in the precision medicine era**  
Georg Stary (Vienna, Austria)

10:45 **What makes phototherapy so effective in the treatment of CTCL?**  
Peter Wolf (Graz, Austria)

11:00 **Ticks, transcripts, and the bull's-eye: a modern view on cutaneous Lyme disease**  
Johanna Strobl (Vienna, Austria)

11:15 **Targeting the genome in dermatology**  
Johann Bauer (Salzburg, Austria)

11:30 **Atopic dermatitis - not only immunology/allergy**  
Matthias Schmuth (Innsbruck, Austria)



## Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall F1**

|          |       |                                                                                                                 |
|----------|-------|-----------------------------------------------------------------------------------------------------------------|
| DIT05.1  |       | <b>Mohs surgery</b><br>Chairs: Mihaela Leventer (Bucharest, Romania)<br>Jivko Kamarachev (Zurich, Switzerland)  |
| DIT05.1A | 14:15 | <b>Mohs surgery in Europe: Past, present and future</b><br>Marcus Muche (Hoorn, Netherlands)                    |
| DIT05.1B | 14:35 | <b>Mohs surgery beyond traditional indications</b><br>Mihaela Leventer (Bucharest, Romania)                     |
| DIT05.1C | 14:55 | <b>Imaging techniques for improved case selection in Mohs surgery</b><br>Javiera Perez-Anker (Barcelona, Spain) |
| DIT05.1D | 15:15 | <b>How to avoid histopathological pitfalls during Mohs surgery</b><br>Jivko Kamarachev (Zurich, Switzerland)    |
| DIT05.1E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                      |

Session type: **Updates**

Room **Hall F1**

|          |       |                                                                                                                                             |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------------|
| DIT05.2  |       | <b>Off-label use of dermatological medications</b><br>Chairs: Ana-Maria Forsea (Bucharest, Romania)<br>Anna Lopez-Ferrer (Barcelona, Spain) |
| DIT05.2A | 16:00 | <b>Botulinum toxin</b><br>Øystein Grimstad (Tromsø, Norway)                                                                                 |
| DIT05.2B | 16:20 | <b>Anti-IL-4R/13/31 biologics</b><br>Anna Lopez-Ferrer (Barcelona, Spain)                                                                   |
| DIT05.2C | 16:40 | <b>Anti-TNF and anti-IL-23/17</b><br>Péter Holló (Budapest, Hungary)                                                                        |
| DIT05.2D | 17:00 | <b>Imiquimod and photodynamic therapy</b><br>Ana-Maria Forsea (Bucharest, Romania)                                                          |
| DIT05.2E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                                  |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall F2**

**Skin Of Color Society (SOCS)**

Chairs: Henry W. Lim (Grosse Pointe, MI, United States)  
Ncoza Dlova (Durban, South Africa)

08:30 **SOCS video**

08:35 **Recalibrating the clinical lens in skin of color dermatology**

Alia Galadari (Dubai, United Arab Emirates)

08:53 **Hidradenitis suppurativa in skin of color: clinical pearls and practice considerations**

Julia Riley (Austria)

09:12 **Update of management of vitiligo**

Henry W. Lim (Grosse Pointe, MI, United States)

09:30 **The many faces of facial pigmentation**

Ncoza Dlova (Durban, South Africa)

09:49 **Q&A**



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall F2**

**European Society For Laser and Energy Based Devices in Dermatology (ESLD)**

Chairs: Ashraf Badawi (Oakville, Canada)  
Albert Wolkerstorfer (Amsterdam, Netherlands)  
Johan Snauwaert (Brasschaat, Belgium)

10:15 **Advanced PDT rejuvenation**  
Leonardo Marini (Trieste, Italy)

10:23 **Lasers and rosacea**  
Johan Snauwaert (Brasschaat, Belgium)

10:32 **High-Intensity Focused Ultrasound (HIFU): a novel treatment modality for skin lesions – Results from a prospective dual-centre clinical investigation on cutaneous neurofibromas**  
Katrine Elisabeth Karmisholt (Copenhagen, Denmark)

10:41 **The power of fractional picoseconds: expanding the spectrum of laser practice in aesthetic dermatology**  
Ahmed Sadek (Cairo, Egypt)

10:50 **Picosecond 1064nm Nd:YAG laser in pigmentation due to Lichen Planus Pigmentosus: efficacy and safety profile**  
Achraf Ellouadghiri El Idrissi (Rabat, Morocco)

10:59 **Fractional CO2 laser and pruritus, a novel interesting application**  
Samia Esmat (Cairo, Egypt)

11:08 **Laser intervention in burn scars, when is the right time?**  
Abeer Tawfik (October City, Egypt)

11:17 **Skin cancer prevention with lasers and EBDs**  
Merete Haedersdal (Copenhagen, Denmark)

11:26 **When aesthetic procedures go wrong: viral complications, social media narratives and scientific evidence**  
Mara Madalina Mihai (Bucharest, Romania)

11:35 **Selected clinical cases from the ESLD forum**  
Albert Wolkerstorfer (Amsterdam, Netherlands)



## Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                        |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------|
| <b>DIT06.1</b>  |       | <b>Paraneoplastic diseases</b><br>Chairs: Victoria Werth (Wynnewood, United States)<br>Eli Sprecher (Tel Aviv, Israel) |
| <b>DIT06.1A</b> | 14:15 | <b>Paraneoplastic pemphigus</b><br>Rikke Bech (Aarhus, Denmark)                                                        |
| <b>DIT06.1B</b> | 14:35 | <b>Dermatomyositis</b><br>Victoria Werth (Wynnewood, United States)                                                    |
| <b>DIT06.1C</b> | 14:55 | <b>Palmoplantar keratoderma</b><br>Eli Sprecher (Tel Aviv, Israel)                                                     |
| <b>DIT06.1D</b> | 15:15 | <b>Paraneoplastic Raynaud's phenomenon</b><br>Bent Deleuran (Aarhus, Denmark)                                          |
| <b>DIT06.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                             |

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                       |
|-----------------|-------|-------------------------------------------------------------------------------------------------------|
| <b>DIT06.2</b>  |       | <b>Rosacea</b><br>Chairs: Katerina Grafanaki (Patras, Greece)<br>Martin Steinhoff (Freiburg, Germany) |
| <b>DIT06.2A</b> | 16:00 | <b>Trigger factors and comorbidities</b><br>Katerina Grafanaki (Patras, Greece)                       |
| <b>DIT06.2B</b> | 16:20 | <b>Topical and systemic treatments</b><br>Giovanni Damiani (Milan, Italy)                             |
| <b>DIT06.2C</b> | 16:40 | <b>Energy-based devices</b><br>Alin Laurentiu Tatu (Galati, Romania)                                  |
| <b>DIT06.2D</b> | 17:00 | <b>New targets and emerging treatments</b><br>Martin Steinhoff (Freiburg, Germany)                    |
| <b>DIT06.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                            |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall E1**

**International Psoriasis Council (IPC): At last! Personalised medicine for psoriasis**

Chairs: Catherine Smith (London, United Kingdom)  
Alexander Navarini (Basel, Switzerland)

08:30 **Welcome and introduction**  
Catherine Smith (London, United Kingdom)

08:35 **Approaches to personalised medicine: from the clinical to the molecular**  
Curdin Conrad (Lausanne, Switzerland)

08:55 **Therapeutic drug monitoring and dose optimisation: clinical and practical considerations**  
Satveer Mahil (London)

09:15 **Digital technologies: what's out there for psoriasis?**  
Alexander Navarini (Basel, Switzerland)  
Tamar Nijsten (Rotterdam, Netherlands)

09:35 **Panel discussion**  
Peter van de Kerkhof (Belleair Bluffs, United States)  
Dina ElDisouki (Cairo, Egypt)

09:55 **Closing comments**  
Alexander Navarini (Basel, Switzerland)



Wednesday, 30 September 2026

Session type: **Subspecialty**

Room **Hall E1**

|       |                                                                                                                                                                                                                                       |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | <b>European Hidradenitis Suppurativa Foundation (EHSF) e.V.</b><br>Chairs: Farida Benhadou (Anderlecht, Belgium)<br>Brian Kirby (Dublin, Ireland)<br>Afsaneh Alavi (Rochester, United States)<br>Francesca Prignano (Florence, Italy) |
| 10:15 | <b>Introduction by the Chairs</b>                                                                                                                                                                                                     |
| 10:16 | <b>Does the presence of hidradenitis suppurativa affect the intestinal immune status?</b><br>Reka Palatka (Hungary)                                                                                                                   |
| 10:23 | <b>Beyond the skin: precision comorbidity screening in hidradenitis suppurativa</b><br>Ozge Karstarlı (Denizli, Türkiye)                                                                                                              |
| 10:30 | <b>Does alexithymia affect patients with hidradenitis suppurativa?</b><br>Marta Szepletowska (Cracow, Poland)                                                                                                                         |
| 10:37 | <b>Long-wave medical infrared thermography (MIT): an objective clinical biomarker of inflammation in hidradenitis suppurativa</b><br>Eleni Kourtellari (Dessau, Germany)                                                              |
| 10:44 | <b>Lesion burden, non-inflammatory or metabolic indices predict biologic treatment response in hidradenitis suppurativa: a multicenter real-world study</b><br>Berna Solak (Sakarya, Türkiye)                                         |
| 10:51 | <b>Discussion</b>                                                                                                                                                                                                                     |
| 11:00 | <b>Introduction by the Chairs</b>                                                                                                                                                                                                     |
| 11:02 | <b>The impact of recurrent antibiotic burden during biologic treatment in hidradenitis suppurativa</b><br>Elia Rosi (Florence, Italy)                                                                                                 |
| 11:09 | <b>Cold plasma in hidradenitis suppurativa – from bench to bedside</b><br>Mara Madalina Mihai (Bucharest, Romania)                                                                                                                    |
| 11:16 | <b>Real-world outcomes of bimekizumab in hidradenitis suppurativa from the Italian landscape hidradenitis suppurativa group</b><br>Mario Valenti (Milan, Italy)                                                                       |
| 11:23 | <b>Real-world effectiveness and safety of secukinumab and bimekizumab in hidradenitis suppurativa: an updated systematic review and meta-analysis</b><br>Samed Şahin (Ankara, Türkiye)                                                |
| 11:30 | <b>Optimizing surgical success: a comparative analysis of excision techniques and recurrence patterns in hidradenitis suppurativa</b><br>Yusuf Can Edek (Ankara, Türkiye)                                                             |
| 11:37 | <b>A centre of excellence model for hidradenitis suppurativa / acne inversa</b><br>Berna Solak (Sakarya, Türkiye)                                                                                                                     |
| 11:42 | <b>Discussion</b>                                                                                                                                                                                                                     |



**Wednesday, 30 September 2026**

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                      |
|-----------------|-------|------------------------------------------------------------------------------------------------------|
| <b>DIT07.1</b>  |       | <b>Lasers and energy-based devices (Part 1)</b><br>Chair: Hans-Joachim Laubach (Geneva, Switzerland) |
| <b>DIT07.1A</b> | 14:15 | <b>Vascular lasers</b><br>Marcin Ambroziak (Warsaw, Poland)                                          |
| <b>DIT07.1B</b> | 14:35 | <b>Pigment lasers</b><br>Steven Paul Nisticò (Rome, Italy)                                           |
| <b>DIT07.1C</b> | 14:55 | <b>Tattoos removal</b><br>Keyvan Nouri (Miami, United States)                                        |
| <b>DIT07.1D</b> | 15:15 | <b>Hair removal</b><br>Peter Bjerring (Aalborg, Denmark)                                             |
| <b>DIT07.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                           |

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                            |
|-----------------|-------|--------------------------------------------------------------------------------------------|
| <b>DIT07.2</b>  |       | <b>Lasers and energy-based devices (Part 2)</b><br>Chair: Ashraf Badawi (Oakville, Canada) |
| <b>DIT07.2A</b> | 16:00 | <b>Ablative lasers</b><br>Sarah Elyoussfi (London, United Kingdom)                         |
| <b>DIT07.2B</b> | 16:20 | <b>Non-ablative lasers</b><br>Raphaël André (Genève, Switzerland)                          |
| <b>DIT07.2C</b> | 16:40 | <b>Lasers for drug delivery</b><br>Merete Haedersdal (Copenhagen, Denmark)                 |
| <b>DIT07.2D</b> | 17:00 | <b>Radiofrequency and plasma devices</b><br>Ashraf Badawi (Oakville, Canada)               |
| <b>DIT07.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                 |



*Wednesday, 30 September 2026*

Session type: **Subspecialty**

Room **Hall E2**

**European Society for Photodermatology (ESPD):  
European photodermatology update**

Chairs: Marjan Garmyn (Leuven, Belgium)  
Giovanni Leone (Roma, Italy)

08:30 **Excimer light in alopecia areata**  
Dilek Seckin (Istanbul, Türkiye)

08:37 **Fractional CO2 laser assisted MAL-PDT in grade II-III actinic keratoses**  
Antonio Fai (Parabita, Italy)

08:45 **Psychological and family impacts of EPP**  
Liesel Griffin (Manchester, United Kingdom)

08:53 **Ruxolitinib and NB-UVB: a new therapeutic synergy**  
Alessia Pacifico (Rome, Italy)

09:00 **Update on NB-UVB phototherapy by the Spanish photodermatology group and the Latin-American photobiology group**  
Jose-Manuel Carrascosa (Badalona, Spain)

09:13 **Guidelines of NB-UVB phototherapy by the photodermatology group of the Italian Society of Dermatology**  
Mariateresa Rossi (Brescia, Italy)

09:25 **The Ian Magnus memorial lecture: from photon to microbiome**  
Peter Wolf (Graz, Austria)

09:55 **The new ESPD website**  
Marco Sarzina (Brescia, Italy)



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall E2**

**Women's Dermatologic Society (WDS): Updates in Medical Dermatology**

Chairs: Cheryl Rosen (Toronto, Canada)  
Dédée Murrell (Sydney, Australia)

10:15 **Welcome**

10:20 **Blistering diseases in pregnancy**  
Aikaterini Patsatsi (Thessaloniki, Greece)

10:30 **Scabies: update**  
Carmen Maria Salavastru (Bucharest, Romania)

10:40 **Hedgehog inhibitors neoadjuvant treatment in skin cancer surgery**  
Stamatina Verykiou (Limassol, Cyprus)

10:50 **Complications begin with decisions, not needles: a risk-based approach to non-surgical aesthetic procedures**  
Pegah Dehdari (Dubai, United Arab Emirates)

11:00 **Update on bullous pemphigoid**  
Snejina Vassileva (Sofia, Bulgaria)

11:10 **Managing scarring alopecias**  
Anastasia Therianou (London, United Kingdom)

11:20 **Neglected tropical diseases in 2026**  
Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)

11:30 **Acquired pigmentary disorders in children**  
Rashmi Sarkar (Noida, India)

11:40 **Closing remarks**



**Wednesday, 30 September 2026**

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                                            |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------|
| <b>DIT08.1</b>  |       | <b>Advanced interventional cosmetic treatments</b><br>Chairs: Pierre Andre (Paris, France)                                 |
| <b>DIT08.1A</b> | 14:15 | <b>The ageing face: from analysis to treatment</b><br>Sahar Ghannam (El Asma, Egypt)                                       |
| <b>DIT08.1B</b> | 14:35 | <b>What topical treatments really work</b><br>Antonio G. Massa (Porto, Portugal)                                           |
| <b>DIT08.1C</b> | 14:55 | <b>Rejuvenation in the era of GLP-1 agonists</b><br>Dirk Groen (Berlin, Germany)                                           |
| <b>DIT08.1D</b> | 15:15 | <b>Recognition and risks of treatment in psychopathic and psychotic patients</b><br>Oliver Kreyden (Muttensz, Switzerland) |
| <b>DIT08.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                 |

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                                    |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------|
| <b>DIT08.2</b>  |       | <b>Open questions in aesthetic dermatology</b><br>Chairs: Christopher Rowland Payne (London, United Kingdom)       |
| <b>DIT08.2A</b> | 16:00 | <b>Exosomes</b><br>Todd Schlesinger (Charleston, United States)                                                    |
| <b>DIT08.2B</b> | 16:20 | <b>Low-dose long-term isotretinoin</b><br>Loredana Ungureanu (Cluj-Napoca, Romania)                                |
| <b>DIT08.2C</b> | 16:40 | <b>Low-level light therapy in aesthetic dermatology: Truth or myth?</b><br>Tilemachos Anthopoulos (Athens, Greece) |
| <b>DIT08.2D</b> | 17:00 | <b>Debate: cannula vs needle. For cannula</b><br>Leonardo Marini (Trieste, Italy)                                  |
| <b>DIT08.2E</b> | 17:20 | <b>Debate: cannula vs needle. For needle</b><br>Wayne Carey (Montreal, Canada)                                     |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall G**

**International Peeling Society (IPS)**

Chairs: Felipe Ribeiro da Silva (São Paulo, Brazil)  
Carlos Gustavo Wambier (Miami, United States)  
Marina Landau (Herzlia, Israel)

08:30 **Introduction**

08:35 **Melasma in dark skin: do peels play the role of hero or villain in this story?**  
Priscila Ventorim (Linhares, Brazil)

08:45 **How to perform a chemical peeling (video lecture)**  
Oliver Kreyden (Muttentz, Switzerland)

08:55 **Chemical peels as the ultimate treatment for skin regeneration**  
Marina Landau (Herzlia, Israel)

09:05 **Chemical peels for treatment of melasma**  
Rashmi Sarkar (Noida ,Uttar Pradesh, India)

09:15 **Is a chemical peel always the answer? When is it time for a facelift?**  
Julio Grynglas De Carvalho (São Paulo, Brazil)

09:25 **Chemical peels in skin of colour - 2026 update**  
Mukta Sachdev (Bangalore, India)

09:35 **Mechanisms of skin tightening with deep peels**  
Carlos Gustavo Wambier (Miami, United States)

09:45 **Q&A**



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall G**

**The Middle East International Dermatology & Aesthetic Medicine Association (MEIDAM)**

Chairs: Hussain Juma (manama, Bahrain)  
Ruaa Al Harithy (Riyadh, Saudi Arabia)  
Khaled Al Nuaimi (Dubai, United Arab Emirates)

10:15 **Opening remarks**  
Khaled Al Nuaimi (Dubai, United Arab Emirates)

10:18 **New profile of leishmaniasis in Morocco**  
Soumiya Chiheb (Casablanca, Morocco)

10:32 **Contact dermatitis in African setup**  
Evanston Kamuri (Nairobi, Kenya)

10:46 **GLP1 inhibitors use in dermatology**  
Vinay Singh (India)

11:00 **Clinical pearls from psoriasis clinic**  
Safiya Al Shidhani (Muscat, Oman)

11:14 **Updates from journals**  
Ameen Alwadhi (Manama, Bahrain)

11:28 **Unveiling the skin disease burden in Lagos, Nigeria: what a new dermatology clinic revealed in its first year**  
Adaeze Viola Ikebodu (Iagos, Nigeria)

11:42 **Q&A and closing remarks**  
Saad Alsogair (Khobar, Saudi Arabia)



## Wednesday, 30 September 2026

Session type: **Training and education**

Room **Hall G**

|          |       |                                                                                                                                                                        |
|----------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DIT09.1  |       | <b>Bullous diseases: diagnostic procedures and treatment guidelines</b><br>Chairs: Joost Meijer (Groningen, Netherlands)<br>Aikaterini Patsatsi (Thessaloniki, Greece) |
| DIT09.1A | 14:15 | <b>Pemphigoid</b><br>Joost Meijer (Groningen, Netherlands)                                                                                                             |
| DIT09.1B | 14:35 | <b>Pemphigus</b><br>Dipankar De (Chandigarh, India)                                                                                                                    |
| DIT09.1C | 14:55 | <b>LABD and epidermolysis bullosa acquisita</b><br>Aikaterini Patsatsi (Thessaloniki, Greece)                                                                          |
| DIT09.1D | 15:15 | <b>Dermatitis herpetiformis</b><br>Martin Shahid (Sofia, Bulgaria)                                                                                                     |
| DIT09.1E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                             |

Session type: **Training and education**

Room **Hall G**

|          |       |                                                                                                                                |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------|
| DIT09.2  |       | <b>Non-invasive skin imaging techniques</b><br>Chairs: Elisa Cinotti (Siena, Italy)<br>Alexander Navarini (Basel, Switzerland) |
| DIT09.2A | 16:00 | <b>Total body photography</b><br>Alexander Navarini (Basel, Switzerland)                                                       |
| DIT09.2B | 16:20 | <b>High-frequency ultrasound</b><br>Diana Crisan (Ulm, Germany)                                                                |
| DIT09.2C | 16:40 | <b>Line-field confocal OCT (LC-OCT)</b><br>Elisa Cinotti (Siena, Italy)                                                        |
| DIT09.2D | 17:00 | <b>Reflectance confocal microscopy</b><br>Salvador González Rodríguez (Madrid, Spain)                                          |
| DIT09.2E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                     |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall M**

**European Dermatology Nurse Task Force**

Chairs: Alberto Barea (Kingston Upon Thames, United Kingdom)  
Corinne Scicluna-Ward (Msida, Malta)

10:15 **Small patients, big therapies: from injection to follow-up in paediatric biologic care**  
Liesbet De Groote (Gent, Belgium)

10:35 **Paediatric genital skin conditions: what every dermatology nurse should know**  
Kate London (Brighouse, United Kingdom)

10:55 **Vital 5: a method for holistic health promotion**  
Lucy Moorhead (Hitchin, United Kingdom)

11:15 **Caring beyond the tumour: dermocosmetics and oncology, a nursing perspective**  
Joana Isabel Pissara Preto (Oeiras, Portugal)

11:35 **Discussion, Q&A**



Wednesday, 30 September 2026

Session type: Updates

Room Hall M

|          |       |                                                                                                                                             |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------------|
| D1T10.1  |       | <b>Bacterial skin infections</b><br>Chairs: Roderick James Hay (London, United Kingdom)<br>Markus Vincent Starink (Amstelveen, Netherlands) |
| D1T10.1A | 14:15 | <b>Diagnostic innovations for skin infections</b><br>Romain Salle (Paris, France)                                                           |
| D1T10.1B | 14:35 | <b>Treating high-priority pathogen infections</b><br>Markus Vincent Starink (Amstelveen, Netherlands)                                       |
| D1T10.1C | 14:55 | <b>Novel topical antibacterial therapies</b><br>Roderick James Hay (London, United Kingdom)                                                 |
| D1T10.1D | 15:15 | <b>New and emerging systemic antibacterial agents</b><br>Mario Fabri (Jena, Germany)                                                        |
| D1T10.1E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                                  |

Session type: Updates

Room Hall M

|          |       |                                                                                                                               |
|----------|-------|-------------------------------------------------------------------------------------------------------------------------------|
| D1T10.2  |       | <b>Dermatology of ageing skin</b><br>Chairs: Jacek C. Szepietowski (Wroclaw, Poland)<br>Paola Pasquali (Cambrils (TA), Spain) |
| D1T10.2A | 16:00 | <b>The clinical relevance of oxidative stress in skin ageing</b><br>Susana Puig (Barcelona, Spain)                            |
| D1T10.2B | 16:20 | <b>Chronic pruritus</b><br>Jacek C. Szepietowski (Wroclaw, Poland)                                                            |
| D1T10.2C | 16:40 | <b>Oral medications for hair loss in the elderly</b><br>Joachim W. Fluhr (Berlin, Germany)                                    |
| D1T10.2D | 17:00 | <b>Management of skin cancer</b><br>Paola Pasquali (Cambrils, Spain)                                                          |
| D1T10.2E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                    |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall K**

**European Reference Network for Rare Skin Diseases (ERN-Skin)**

Chairs: Christine Bodemer (Paris, France)  
Johann Bauer (Salzburg, Austria)

**08:30 ERN-Skin for you and your patients**

Christine Bodemer (Paris, France)  
Jolien van der Geugten (Amersfoort, The Netherlands)  
Antoine Gliksohn (Fontenay-sous-Bois, France)

***Focus on the diversity of rare skin diseases: concrete clinical cases and practical monitoring***

**08:45 Focus on xeroderma pigmentosum: XP and malignant tumours**

Smail Hadj-Rabia (Paris, France)

**09:05 Focus on NF1: practical management during the transition adolescent-young adult period**

Tobias Welpner (Salzburg, Austria)

**09:25 Focus on Darier's disease: recommendations**

Cristina Has (Freiburg, Germany)

**09:45 Test your knowledge and win 1 free registration for the 2028 World Congress on Rare Skin Diseases**

Johann Bauer (Salzburg, Austria)  
Branka Marinović (Zagreb, Croatia)  
Teresa Oranges (Florence, Italy)



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall K**

**Colegio Ibero-Latinoamericano de Dermatología (CILAD): Top cases in Ibero-Latin America**

Chairs: Omar Lupi (Rio De Janeiro, Brazil)  
María Ivonne Arellano Mendoza (Mexico, Mexico)  
José Manuel Ríos-Yuil (Ciudad de Panama, Panama)

10:15 **Welcome**

10:21 **Beyond skin tightening: how to manage microstomia in systemic sclerosis**  
Jose Luis Lopez-Estebarez (Madrid, Spain)

10:33 **Neglected tropical diseases. Challenges in 2026.**  
Mariel Amelia Isa Pimentel (Santo Domingo, Dominican Republic)

10:45 **Pediatric laser dermatology: tips, tricks and challenging cases**  
Monica Patricia Ramos Alvarez (Guadalajara, Mexico)

10:57 **What is new in hyperpigmentation?**  
María Ivonne Arellano Mendoza (Mexico, Mexico)

11:09 **AI in dermatology: principles and applications**  
José Manuel Ríos-Yuil (Ciudad de Panama, Panama)

11:21 **Hantavirus in dermatology**  
Omar Lupi (Rio De Janeiro, Brazil)

11:33 **Q&A**

11:39 **Closure**



## Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall K**

|                 |       |                                                                                                               |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------|
| <b>D1T11.1</b>  |       | <b>Chronic leg ulcers</b><br>Chairs: Elena Conde Montero (Madrid, Spain)<br>Jürg Hafner (Zurich, Switzerland) |
| <b>D1T11.1A</b> | 14:15 | <b>Differential diagnosis and workup</b><br>Catherine Lok (Amiens, France)                                    |
| <b>D1T11.1B</b> | 14:35 | <b>Venous ulcers</b><br>Elena Conde Montero (Madrid, Spain)                                                   |
| <b>D1T11.1C</b> | 14:55 | <b>Neuropathic ulcers</b><br>Hester Colboc (Paris, France)                                                    |
| <b>D1T11.1D</b> | 15:15 | <b>Leg ulcers in the course of systemic disease</b><br>Jürg Hafner (Zurich, Switzerland)                      |
| <b>D1T11.1E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                    |

Session type: **Updates**

Room **Hall K**

|                 |       |                                                                                                                                        |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D1T11.2</b>  |       | <b>Managing skin diseases during pregnancy</b><br>Chairs: Julia-Tatjana Maul (Zurich, Switzerland)<br>Miklos Sardy (Budapest, Hungary) |
| <b>D1T11.2A</b> | 16:00 | <b>Autoimmune blistering diseases</b><br>Miklos Sardy (Budapest, Hungary)                                                              |
| <b>D1T11.2B</b> | 16:20 | <b>Atopic dermatitis, psoriasis, and hidradenitis suppurativa</b><br>Julia-Tatjana Maul (Zurich, Switzerland)                          |
| <b>D1T11.2C</b> | 16:40 | <b>STIs during pregnancy</b><br>Brigitte Stephan (Hamburg, Germany)                                                                    |
| <b>D1T11.2D</b> | 17:00 | <b>Pregnancy-specific dermatoses</b><br>Sara Pruneddu (London, United Kingdom)                                                         |
| <b>D1T11.2E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                             |



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall N**

**Euromelanoma**

Chairs: Veronique Del Marmol (Brussels, Belgium)  
Mariano Suppa (Brussels, Belgium)  
Josep Malvehy (Barcelona, Spain)

**08:30 Welcome and introduction**

Veronique Del Marmol (Brussels, Belgium)

**08:45 Skin cancer prevention and social media**

Josep Malvehy (Barcelona, Spain)

**09:00 Shaping the future of skin cancer prevention: a policy prescription for Europe**

Mariano Suppa (Brussels, Belgium)

**09:20 EUSCAP: A European skin cancer risk database**

Wiam Al Bouzidi (Brussels, Belgium)

**09:35 Euromelanoma campaign 2026**

Veronique Del Marmol (Brussels, Belgium)

**09:45 Conclusions and future perspectives**

Veronique Del Marmol (Brussels, Belgium)



**Wednesday, 30 September 2026**

Session type: **Subspecialty**

Room **Hall N**

**European Society for Photodynamic Therapy (EURO-PDT)**

Chairs: Lasse R. Braathen (Oberhofen, Switzerland)  
Rolf-Markus Szeimies (Recklinghausen, Germany)

10:15 **Welcome & Introduction**  
Lasse R. Braathen (Oberhofen, Switzerland)

10:20 **A long term management is always needed for patients with multiple Aks**  
Piergiacomo Calzavara-Pinton (Brescia, Italy)

10:35 **Most recent experience with daylight-PDT in Scotland**  
Sally Helen Ibbotson (Dundee, United Kingdom)

10:50 **Self administration of daylight-PDT**  
Yolanda Gilaberte (Zaragoza, Spain)  
Juan Jose Garcia Alfonso (Zaragoza, Spain)

11:05 **The role of PDT in treatment of actinic cheilitis**  
Elena Sotiriou (Thessaloniki, Greece)

11:20 **PDT for aesthetic indications – really helpful?**  
Rolf-Markus Szeimies (Recklinghausen, Germany)

11:35 **Discussion & Wrap up**  
Lasse R. Braathen (Oberhofen, Switzerland)



Wednesday, 30 September 2026

Session type: **Updates**

Room **Hall N**

|          |       |                                                                                                                                       |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| D1T12.1  |       | <b>STIs</b><br>Chairs: Airi Poder (Tartu, Estonia)<br>Georg Stary (Vienna, Austria)                                                   |
| D1T12.1A | 14:15 | <b>The resurgence of syphilis in Europe: Epidemiology, diagnostics and clinical challenges</b><br>Maciej Pastuszczyk (Zabrze, Poland) |
| D1T12.1B | 14:35 | <b>Mpox and other emerging sexually transmitted infections: Lessons from recent outbreaks</b><br>Alba Catala (Barcelona, Spain)       |
| D1T12.1C | 14:55 | <b>Self-testing, home sampling and digital sexual health: Transforming STI diagnostics</b><br>Jo Gibbs (London, United Kingdom)       |
| D1T12.1D | 15:15 | <b>Oral and mucosal manifestations of sexually transmitted infections</b><br>George Sorin Tiplica (Bucharest, Romania)                |
| D1T12.1E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                            |

Session type: **Updates**

Room **Hall N**

|          |       |                                                                                                                                                       |
|----------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| D1T12.2  |       | <b>STIs</b><br>Chairs: Maciej Pastuszczyk (Zabrze, Poland)<br>Eija Hiltunen-Back (Helsinki, Finland)                                                  |
| D1T12.2A | 16:00 | <b>Sexually transmitted infections presenting as vasculitis, ulcers or nodules: A diagnostic approach</b><br>Claudia Heller-Vitouch (Vienna, Austria) |
| D1T12.2B | 16:20 | <b>Genital ulcers: Beyond herpes and syphilis – emerging infectious causes</b><br>Stephan Lautenschlager (Zürich, Switzerland)                        |
| D1T12.2C | 16:40 | <b>When STIs mimic inflammatory dermatoses: Diagnostic pitfalls for dermatologists</b><br>Eija Hiltunen-Back (Helsinki, Finland)                      |
| D1T12.2D | 17:00 | <b>Human papillomavirus infections of the skin and mucosa: What is new for dermatologists?</b><br>Suzana Ljubojevic Hadzavdic (Zagreb, Croatia)       |
| D1T12.2E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                                            |



**Thursday, 1 October 2026**

|           |                                                 |                                                       |                                                                    |                                                   |
|-----------|-------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------|---------------------------------------------------|
|           |                                                 | 12:00 – 13:00                                         |                                                                    |                                                   |
| Hall A    |                                                 | Plenary lectures<br>B                                 |                                                                    |                                                   |
|           | 08:30 – 10:00                                   | 10:15 – 11:45                                         | 14:15 – 15:45                                                      | 16:00 – 17:30                                     |
| Hall A    | Understanding psoriasis                         | Treating psoriasis                                    | Late breaking news                                                 | Late breaking news                                |
| Hall D    | Hair disorders: non-cicatricial alopecias       | Hair disorders: cicatricial alopecias                 | Nail disorders: inflammatory diseases                              | Nail disorders: tumours                           |
| Hall B    | Dermatosurgery (Part 1)                         | Dermatosurgery (Part 2)                               | Paediatric dermatology                                             | Paediatric dermatology                            |
| Hall C    | Practical diagnostic and therapeutic algorithms | Practical diagnostic and therapeutic algorithms       | Genetic diseases                                                   | Neutrophilic diseases                             |
| Hall F1   | Contact eczema                                  | Chronic hand eczema                                   | Chronic urticaria                                                  | EADV-funded projects and fellowships              |
| Hall F2   | Melanoma: diagnostic techniques                 | Melanoma: treatment                                   | Basal cell carcinoma                                               | Squamous cell carcinoma                           |
| Hall E1   | Lasers for medical indications                  | Botulinum toxin for medical reasons                   | Scars                                                              | Acne scars                                        |
| Hall E2   | Fillers for beginners (Part 1)                  | Cosmetic treatments in skin of colour                 | Fillers (Part 2)                                                   | Fillers (Part 3)                                  |
| Hall G    | Controversies I                                 | Controversies II                                      | Controversies III                                                  | Controversies IV                                  |
| Hall M    | Fungal skin infections                          | Parasitic infestations and emerging viruses           | Best papers of JEADV                                               | Best of dermatology papers 2026: a panoramic view |
| Hall K    | Drug reactions                                  | Acne: clinical variants and treatment recommendations | Atopic dermatitis: clinical variants and treatment recommendations | Eczema beyond atopic dermatitis                   |
| Hall N    | Free communication 1: atopic dermatitis/eczema  | Free communication 2: atopic dermatitis/eczema        | Free communication 3: cutaneous oncology                           | Free communication 4: hair and nail disorders     |
| 1.61-1.62 | Playing with AI in dermatology                  |                                                       | Wound healing                                                      |                                                   |
| 1.85-1.86 | Dermoscopy happy hour live                      |                                                       | Dermoscopy happy hour live                                         |                                                   |



*Thursday, 1 October 2026*

Session type: **Plenary**

Room **Hall A**


**Plenary lectures B**

Chairs: Alexander Stratigos (Athens, Greece)  
Cristina Has (Freiburg, Germany)

12:00 **Tumour microenvironment in skin cancer**  
Veli-Matti Kähäri (Turku, Finland)

12:20 **New algorithms for managing high-risk skin cancer patients**  
Ketty Peris (Rome, Italy)

12:40 **Social media for doctors. From viral posts to legal warnings**  
Sergio Vaño-Galván (Madrid, Spain)



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                                    |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------|
| <b>D2T01.1</b>  |       | <b>Understanding psoriasis</b><br>Chairs: Hervé Bachelez (Paris, France)<br>Satveer Mahil (London, United Kingdom) |
| <b>D2T01.1A</b> | 08:30 | <b>Obesity and psoriasis</b><br>Jose-Manuel Carrascosa (Badalona, Spain)                                           |
| <b>D2T01.1B</b> | 08:50 | <b>Pustular psoriasis</b><br>Johann Gudjonsson (Ann Arbor, United States)                                          |
| <b>D2T01.1C</b> | 09:10 | <b>Special areas</b><br>Satveer Mahil (London, United Kingdom)                                                     |
| <b>D2T01.1D</b> | 09:30 | <b>Learning from monogenic psoriasis</b><br>Hervé Bachelez (Paris, France)                                         |
| <b>D2T01.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                         |

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                              |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------|
| <b>D2T01.2</b>  |       | <b>Treating psoriasis</b><br>Chairs: Curdin Conrad (Lausanne, Switzerland)<br>Jo LW Lambert (Ghent, Belgium) |
| <b>D2T01.2A</b> | 10:15 | <b>Topicals</b><br>Jo LW Lambert (Ghent, Belgium)                                                            |
| <b>D2T01.2B</b> | 10:35 | <b>Biologics</b><br>Julia-Tatjana Maul (Zurich, Switzerland)                                                 |
| <b>D2T01.2C</b> | 10:55 | <b>Oral therapies</b><br>Curdin Conrad (Lausanne, Switzerland)                                               |
| <b>D2T01.2D</b> | 11:15 | <b>Disease modification</b><br>Kilian Eyerich (Freiburg, Germany)                                            |
| <b>D2T01.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                   |



Thursday, 1 October 2026

Session type: Updates

Room Hall A

|          |       |                                                                                                                                                                                                                                                                                                                          |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D2T01.3  |       | <b>Late breaking news</b><br>Chairs: Electra Nicolaidou (Athens, Greece)<br>Jan-Christoph Simon (Leipzig, Germany)                                                                                                                                                                                                       |
| D2T01.3A | 14:15 | <b>Differential Proteomic Effects of Abrocitinib and Dupilumab in Moderate-to-Severe Atopic Dermatitis: Exploratory Analysis of JADE COMPARE</b><br>Emma Guttman-Yassky (New York, NY, United States)                                                                                                                    |
| D2T01.3B | 14:30 | <b>MELAPRED: A Parsimonious Clinical-Genetic Algorithm for Melanoma Risk Prediction</b><br>Nadem Soufir (Paris, France)                                                                                                                                                                                                  |
| D2T01.3C | 14:45 | <b>The integrated 31-gene expression profile (i31-SLNB) identifies patients with a low risk of sentinel lymph node positivity and 31-GEP identifies patients with high 5-year recurrence risk: The largest prospective, multicenter study of GEP for cutaneous melanoma</b><br>Brian Martin (Friendswood, United States) |
| D2T01.3D | 15:00 | <b>Long-term efficacy of ritlecitinib in patients with alopecia areata and <math>\geq 25\%</math> scalp hair loss by severity: results from the phase 3 long-term ALLEGRO-LT study through 5 years</b><br>Brett King (Fairfield, United States)                                                                          |
| D2T01.3E | 15:15 | <b>JAKPPPOT: a feasibility trial assessing upadacitinib in palmoplantar pustulosis</b><br>David Gleeson (London, United Kingdom)                                                                                                                                                                                         |
| D2T01.3F | 15:30 | <b>Results from the 2025 British National Teledermatology Standards Audit</b><br>Soha Tawfik (London, United Kingdom)                                                                                                                                                                                                    |



Thursday, 1 October 2026

Session type: Updates

Room Hall A

|          |       |                                                                                                                                                                                                                                                                                                                                              |
|----------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D2T01.4  |       | <b>Late breaking news</b><br>Chairs: Jorge Ocampo-Candiani (Monterrey, Mexico)<br>Marie-Aleth Richard (Marseille, France)                                                                                                                                                                                                                    |
| D2T01.4A | 16:00 | <b>Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-segmental Vitiligo at Week 76 and in Combination With NB-UVB Therapy</b><br>Julien Seneschal (Bordeaux, France)                                                                                                                                        |
| D2T01.4B | 16:15 | <b>Tunnel-associated keratinocytes in Hidradenitis suppurativa have a distinct pro-inflammatory program spatially associated with TNF <math>\alpha</math> and OX40L positive cells</b><br>Johannes Griss (Vienna, Austria)                                                                                                                   |
| D2T01.4C | 16:30 | <b>Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis.</b><br>Mark G. Lebwohl (New York, United States)                                                                                                                             |
| D2T01.4D | 16:45 | <b>Lebrikizumab Showed Sustained Efficacy and Safety Through 5 Years in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the ADLong Long-Term Extension Trial</b><br>Stephan Weidinger (Bridgewater, Germany)                                                                                                                |
| D2T01.4E | 17:00 | <b>Efficacy and safety of abdakibart (ABD), a humanized high affinity and potency IgG4 anti-IL-1 <math>\beta</math> agent for treatment of moderate to severe hidradenitis suppurativa at Week 16; IHS4 subgroup and lesion type ANdT results of the Phase 2 placebo-controlled LOTUS Trial</b><br>Martina L. Porter (Boston, United States) |
| D2T01.4F | 17:15 | <b>Safety of dupilumab in pregnancy: final results of the dupilumab prospective pregnancy registry</b><br>Christina Chambers (La Jolla, United States)                                                                                                                                                                                       |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                                                    |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T02.1</b>  |       | <b>Hair disorders: non-cicatricial alopecias</b><br>Chairs: Dimitrios Ioannides (Thessaaloniki, Greece)<br>Bianca Maria Piraccini (Bologna, Italy) |
| <b>D2T02.1A</b> | 08:30 | <b>Androgenetic alopecia</b><br>Bianca Maria Piraccini (Bologna, Italy)                                                                            |
| <b>D2T02.1B</b> | 08:50 | <b>Alopecia areata</b><br>Sergio Vaño-Galván (Madrid, Spain)                                                                                       |
| <b>D2T02.1C</b> | 09:10 | <b>Chemotherapy-induced alopecia</b><br>Vincent Sibaud (Toulouse, France)                                                                          |
| <b>D2T02.1D</b> | 09:30 | <b>Telogen effluvium</b><br>Dimitrios Ioannides (Thessaloniki, Greece)                                                                             |
| <b>D2T02.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                         |

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                                    |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T02.2</b>  |       | <b>Hair disorders: cicatricial alopecias</b><br>Chairs: Alexander Katoulis (Athens, Greece)<br>Awatef Kelati (Casablanca, Morocco) |
| <b>D2T02.2A</b> | 10:15 | <b>Lichen planopilaris</b><br>Awatef Kelati (Casablanca, Morocco)                                                                  |
| <b>D2T02.2B</b> | 10:35 | <b>Frontal fibrosing alopecia</b><br>Dmitri Wall (Dublin, Ireland)                                                                 |
| <b>D2T02.2C</b> | 10:55 | <b>Folliculitis decalvans</b><br>Alexander Katoulis (Athens, Greece)                                                               |
| <b>D2T02.2D</b> | 11:15 | <b>Psoriatic alopecia: cicatricial and non-cicatricial</b><br>Antonella Tosti (Miami, United States)                               |
| <b>D2T02.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                         |



Thursday, 1 October 2026

Session type: Updates

Room Hall D

|          |       |                                                                                                                                       |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| D2T02.3  |       | <b>Nail disorders: inflammatory diseases</b><br>Chairs: Bertrand Richert (Brussels, Belgium)<br>Matilde Iorizzo (Lugano, Switzerland) |
| D2T02.3A | 14:15 | <b>Onychomycosis</b><br>Andre Lencastre (Alcabideche, Portugal)                                                                       |
| D2T02.3B | 14:35 | <b>Nail changes and systemic diseases</b><br>Matilde Iorizzo (Lugano, Switzerland)                                                    |
| D2T02.3C | 14:55 | <b>Paronychia</b><br>Bertrand Richert (Brussels, Belgium)                                                                             |
| D2T02.3D | 15:15 | <b>Subungual and periungual verruca</b><br>Marta Sar-Pomian (Warsaw, Poland)                                                          |
| D2T02.3E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                            |

Session type: Updates

Room Hall D

|          |       |                                                                                                                      |
|----------|-------|----------------------------------------------------------------------------------------------------------------------|
| D2T02.4  |       | <b>Nail disorders: tumours</b><br>Chairs: Aurora Alessandrini (Bologna, Italy)<br>Luc Thomas (Pierre Bénite, France) |
| D2T02.4A | 16:00 | <b>Subungual melanoma</b><br>Luc Thomas (Pierre Bénite, France)                                                      |
| D2T02.4B | 16:20 | <b>Subungual NMSC</b><br>Raimonds Karls (Daugmale, Latvia)                                                           |
| D2T02.4C | 16:40 | <b>Glomus tumour, onychopapilloma and onychomatricoma</b><br>Aurora Alessandrini (Bologna, Italy)                    |
| D2T02.4D | 17:00 | <b>High-frequency ultrasound in nail tumours</b><br>Priscila Giavedoni (Barcelona, Spain)                            |
| D2T02.4E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                           |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                   |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------|
| <b>D2T03.1</b>  |       | <b>Dermatosurgery (Part 1)</b><br>Chairs: Severin Lächli (Zurich, Switzerland)<br>John Paoli (Gothenburg, Sweden) |
| <b>D2T03.1A</b> | 08:30 | <b>Tips and tricks to level up your surgical skills</b><br>Eckart Haneke (Freiburg im Breisgau, Germany)          |
| <b>D2T03.1B</b> | 08:50 | <b>Managing surgical complications</b><br>Goran van Rooijen (Haarlem, Netherlands)                                |
| <b>D2T03.1C</b> | 09:10 | <b>Surgical scar revision</b><br>Ally-Khan Somani (Orland Park, United States)                                    |
| <b>D2T03.1D</b> | 09:30 | <b>The future of melanoma surgery</b><br>John Paoli (Gothenburg, Sweden)                                          |
| <b>D2T03.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                        |

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                   |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------|
| <b>D2T03.2</b>  |       | <b>Dermatosurgery (Part 2)</b><br>Chairs: Severin Lächli (Zurich, Switzerland)<br>John Paoli (Gothenburg, Sweden) |
| <b>D2T03.2A</b> | 10:15 | <b>Reconstructions: Nose I</b><br>Antoni Bennàssar Vicens (Palma de Mallorca, Spain)                              |
| <b>D2T03.2B</b> | 10:25 | <b>Reconstructions: Nose II</b><br>Severin Lächli (Zurich, Switzerland)                                           |
| <b>D2T03.2C</b> | 10:35 | <b>Reconstructions: Ear I</b><br>Joseph Alcalay (Tel Aviv, Israel)                                                |
| <b>D2T03.2D</b> | 10:45 | <b>Reconstructions: Ear II</b><br>Sweta Rai (London, United Kingdom)                                              |
| <b>D2T03.2E</b> | 10:55 | <b>Reconstructions: Forehead I</b><br>Stanislav Tolkachjov (Lewisville, United States)                            |
| <b>D2T03.2F</b> | 11:05 | <b>Reconstructions: Forehead II</b><br>Michael Mühlstädt (Geneva, Switzerland)                                    |
| <b>D2T03.2G</b> | 11:15 | <b>Reconstructions: Lips and perioral I</b><br>Olivier Cogrel (Bordeaux, France)                                  |
| <b>DT03.2H</b>  | 11:25 | <b>Reconstructions: Lips and perioral II</b><br>Elena Rossi (Modena, Italy)                                       |
| <b>D2T03.2I</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                        |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------|
| <b>D2T03.3</b>  |       | <b>Paediatric dermatology</b><br>Chairs: Cristina Has (Freiburg, Germany)<br>Christine Bodemer (Paris, France) |
| <b>D2T03.3A</b> | 14:15 | <b>Mosaic RASopathies in children</b><br>Minia Campos (Madrid, Spain)                                          |
| <b>D2T03.3B</b> | 14:35 | <b>Epidermal differentiation disorders</b><br>Cristina Has (Freiburg, Germany)                                 |
| <b>D2T03.3C</b> | 14:55 | <b>New genodermatoses</b><br>John McGrath (London, United Kingdom)                                             |
| <b>D2T03.3D</b> | 15:15 | <b>Genetic sclerodermoid conditions</b><br>Christine Bodemer (Paris, France)                                   |
| <b>D2T03.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                     |

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                      |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------|
| <b>D2T03.4</b>  |       | <b>Paediatric dermatology</b><br>Chairs: Lidija Kandolf-Sekulovic (Belgrade, Serbia)<br>Arti Nanda (Salmiya, Kuwait) |
| <b>D2T03.4A</b> | 16:00 | <b>Autoimmune connective tissue disorders in children</b><br>Cathryn Sibbald (Toronto, Canada)                       |
| <b>D2T03.4B</b> | 16:20 | <b>Lichen planus and lichenoid eruptions in children</b><br>Arti Nanda (Salmiya, Kuwait)                             |
| <b>D2T03.4C</b> | 16:40 | <b>Skin cancer in children</b><br>Lidija Kandolf-Sekulovic (Belgrade, Serbia)                                        |
| <b>D2T03.4D</b> | 17:00 | <b>Cutaneous vasculitis in children</b><br>Janis Chang (Ottawa, Canada)                                              |
| <b>D2T03.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                           |



**Thursday, 1 October 2026**

Session type: **Focus on**

Room **Hall C**

|                 |       |                                                                                                                                            |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T04.1</b>  |       | <b>Practical diagnostic and therapeutic algorithms</b><br>Chairs: Michela Starace (Bologna, Italy)<br>Andreas Wollenberg (Munich, Germany) |
| <b>D2T04.1A</b> | 08:30 | <b>European guidelines for chronic pruritus</b><br>Elke Weisshaar (Heidelberg, Germany)                                                    |
| <b>D2T04.1B</b> | 08:50 | <b>Practical recommendations for the management of folliculitis decalvans</b><br>Michela Starace (Bologna, Italy)                          |
| <b>D2T04.1C</b> | 09:10 | <b>European guidelines for hidradenitis suppurativa</b><br>Gregor Borut Jemec (Copenhagen, Denmark)                                        |
| <b>D2T04.1D</b> | 09:30 | <b>European guidelines for atopic eczema</b><br>Andreas Wollenberg (Munich, Germany)                                                       |
| <b>D2T04.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                 |

Session type: **Focus on**

Room **Hall C**

|                 |       |                                                                                                                                             |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T04.2</b>  |       | <b>Practical diagnostic and therapeutic algorithms</b><br>Chairs: Frederic Caux (Bobigny, France)<br>Lidia Rudnicka (Warsaw, Poland)        |
| <b>D2T04.2A</b> | 10:15 | <b>Expert consensus on the management of alopecia areata</b><br>Lidia Rudnicka (Warsaw, Poland)                                             |
| <b>D2T04.2B</b> | 10:35 | <b>European guidelines for the diagnosis, treatment, and prevention of actinic keratoses</b><br>Lidija Kandolf-Sekulovic (Belgrade, Serbia) |
| <b>D2T04.2C</b> | 10:55 | <b>European guidelines for the management of genital herpes</b><br>Usha Hartgill (Oslo, Norway)                                             |
| <b>D2T04.2D</b> | 11:15 | <b>European guidelines for the diagnosis and treatment of linear IgA dermatosis</b><br>Frederic Caux (Bobigny, France)                      |
| <b>D2T04.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                  |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                                  |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------|
| <b>D2T04.3</b>  |       | <b>Genetic diseases</b><br>Chairs: Johann Bauer (Salzburg, Austria)<br>Veronica Kinsler (London, United Kingdom) |
| <b>D2T04.3A</b> | 14:15 | <b>Understanding clinical variability in genetic skin diseases</b><br>Johann Bauer (Salzburg, Austria)           |
| <b>D2T04.3B</b> | 14:35 | <b>Mosaicism in the skin</b><br>Veronica Kinsler (London, United Kingdom)                                        |
| <b>D2T04.3C</b> | 14:55 | <b>Clinical trials involving gene therapy</b><br>Aleksandra Lesiak (Lodz, Poland)                                |
| <b>D2T04.3D</b> | 15:15 | <b>Clinical trials involving drug repurposing</b><br>Dédée Murrell (Sydney, Australia)                           |
| <b>D2T04.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                       |

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                                  |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------|
| <b>D2T04.4</b>  |       | <b>Neutrophilic diseases</b><br>Chairs: Angelo Valerio Marzano (Milan, Italy)<br>Tulin Ergun (Istanbul, Türkiye) |
| <b>D2T04.4A</b> | 16:00 | <b>Pustular dermatoses</b><br>Angelo Valerio Marzano (Milan, Italy)                                              |
| <b>D2T04.4B</b> | 16:20 | <b>Behçet disease</b><br>Tulin Ergun (Istanbul, Türkiye)                                                         |
| <b>D2T04.4C</b> | 16:40 | <b>Pyoderma gangrenosum</b><br>Louise Anna Andrea Gerbens (Naarden, Netherlands)                                 |
| <b>D2T04.4D</b> | 17:00 | <b>Sweet syndrome</b><br>Lorenzo Cerroni (Graz, Austria)                                                         |
| <b>D2T04.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                       |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                           |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------|
| <b>D2T05.1</b>  |       | <b>Contact eczema</b><br>Chairs: Mojca Bizjak-Suran (Golnik, Slovenia)<br>David Pesqué (Barcelona, Spain) |
| <b>D2T05.1A</b> | 08:30 | <b>Immunological understanding of contact dermatitis</b><br>Charlotte Bonefeld (Copenhagen, Denmark)      |
| <b>D2T05.1B</b> | 08:50 | <b>Emerging contact allergens</b><br>David Pesqué (Barcelona, Spain)                                      |
| <b>D2T05.1C</b> | 09:10 | <b>Relevant contact allergens in chronic hand eczema</b><br>Teofila Caplanusi (Lausanne, Switzerland)     |
| <b>D2T05.1D</b> | 09:30 | <b>Immediate contact reactions</b><br>Mojca Bizjak-Suran (Golnik, Slovenia)                               |
| <b>D2T05.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                |

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                                                           |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T05.2</b>  |       | <b>Chronic hand eczema</b><br>Chairs: Sonja Molin (Berlin, Germany)<br>Kaare Steinar Tveit (Bergen, Norway)<br>Efstratios Vakirlis (Thessaloniki, Greece) |
| <b>D2T05.2A</b> | 10:15 | <b>Diagnostic workup</b><br>Sonja Molin (Berlin, Germany)                                                                                                 |
| <b>D2T05.2B</b> | 10:35 | <b>Occupational chronic hand eczema</b><br>Sebastian Vigand Svendsen (Odense, Denmark)                                                                    |
| <b>D2T05.2C</b> | 10:55 | <b>Topical treatment strategies</b><br>Efstratios Vakirlis (Thessaloniki, Greece)                                                                         |
| <b>D2T05.2D</b> | 11:15 | <b>Systemic treatments</b><br>Kåre Steinar Tveit (Bergen, Norway)                                                                                         |
| <b>D2T05.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                 |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------|
| <b>D2T05.3</b>  |       | <b>Chronic urticaria</b><br>Chairs: Ana Maria Giménez-Arnau (Barcelona, Spain)<br>Martin Metz (Berlin, Germany) |
| <b>D2T05.3A</b> | 14:15 | <b>Understanding chronic spontaneous urticaria</b><br>Ana Maria Giménez-Arnau (Barcelona, Spain)                |
| <b>D2T05.3B</b> | 14:35 | <b>Key guidelines in urticaria</b><br>Krisztina Steuer-Hajdu (Debrecen, Hungary)                                |
| <b>D2T05.3C</b> | 14:55 | <b>Personalized urticaria care: Endotypes, biomarkers</b><br>Martin Metz (Berlin, Germany)                      |
| <b>D2T05.3D</b> | 15:15 | <b>Upcoming treatments</b><br>Torello M. Lotti (Rome, Italy)                                                    |
| <b>D2T05.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                      |

Session type: **Miscellaneous**

Room **Hall F1**

|                 |       |                                                                                                                                                                                                             |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T05.4</b>  |       | <b>EADV-funded projects and fellowships</b><br>Chairs: Emmanuella Guenova (Linz, Austria)<br>Carmen Rodríguez Cerdeira (Vigo, Spain)<br>Kevin Molloy (Dublin, Ireland)<br>Sofia Labbouz (Brussels, Belgium) |
| <b>D2T05.4A</b> | 16:00 | <b>Introduction</b><br>Emmanuella Guenova (Linz, Austria)                                                                                                                                                   |
| <b>D2T05.4B</b> | 16:05 | <b>Core outcomes for hand eczema trials: International consensus to measure signs, symptoms, control and quality of life</b><br>Henriette Roensch (Dresden, Germany)                                        |
| <b>D2T05.4C</b> | 16:20 | <b>My global health fellowship experience at the Regional Dermatology Training Center in Moshi, Tanzania</b><br>Ditte Marie L. Saunte (Virum, Denmark)                                                      |
| <b>D2T05.4D</b> | 16:35 | <b>Molecular profiling of atopic dermatitis among US-born and non-US-born adults across different ethnic groups</b><br>Gianluca Avallone (Milan, Italy)                                                     |
| <b>D2T05.4E</b> | 16:50 | <b>My Mohs fellowship experience at the Leventer Center in Bucharest, Romania</b><br>Mihaela-Anca Jian (Brasov, Romania)                                                                                    |
| <b>D2T05.4F</b> | 17:05 | <b>My clinical fellowship experience in Lausanne: Clinical and research perspectives</b><br>Gabriele Rocuzzo (Torino, Italy)                                                                                |
| <b>D2T05.4G</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                                                                                                  |



Thursday, 1 October 2026

Session type: Updates

Room Hall F2

|          |       |                                                                                                                                |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------|
| D2T06.1  |       | <b>Melanoma: diagnostic techniques</b><br>Chairs: Veronique del Marmol (Brussels, Belgium)<br>Josep Malvehy (Barcelona, Spain) |
| D2T06.1A | 08:30 | <b>Melanoma screening</b><br>Veronique del Marmol (Brussels, Belgium)                                                          |
| D2T06.1B | 08:50 | <b>Novel in vivo imaging tools</b><br>Josep Malvehy (Barcelona, Spain)                                                         |
| D2T06.1C | 09:10 | <b>Gene and protein expression profiling</b><br>Teresa Amaral (Strasbourg, France)                                             |
| D2T06.1D | 09:30 | <b>Histopathological prognostication</b><br>Istvan Balazs Nemeth (Szeged, Hungary)                                             |
| D2T06.1E | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                     |

Session type: Updates

Room Hall F2

|          |       |                                                                                                             |
|----------|-------|-------------------------------------------------------------------------------------------------------------|
| D2T06.2  |       | <b>Melanoma: treatment</b><br>Chairs: Zoe Apalla (Thessaloniki, Greece)<br>Eduardo Nagore (Valencia, Spain) |
| D2T06.2A | 10:15 | <b>Primary and adjuvant treatment</b><br>Zeljko Mijuskovic (Belgrade, Serbia)                               |
| D2T06.2B | 10:35 | <b>Surgical treatment of primary melanoma</b><br>Eduardo Nagore (Valencia, Spain)                           |
| D2T06.2C | 10:55 | <b>Lentigo maligna and acral melanoma</b><br>Zoe Apalla (Thessaloniki, Greece)                              |
| D2T06.2D | 11:15 | <b>Adverse event management</b><br>Christoffer Gebhardt (Hamburg, Germany)                                  |
| D2T06.2E | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                  |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                         |
|-----------------|-------|---------------------------------------------------------------------------------------------------------|
| <b>D2T06.3</b>  |       | <b>Basal cell carcinoma</b><br>Chairs: Norbert Kiss (Budapest, Hungary)<br>Eve Maubec (Bobigny, France) |
| <b>D2T06.3A</b> | 14:15 | <b>Pathogenesis</b><br>François Kuonen (Lausanne, Switzerland)                                          |
| <b>D2T06.3B</b> | 14:35 | <b>Imaging in BCC</b><br>Norbert Kiss (Budapest, Hungary)                                               |
| <b>D2T06.3C</b> | 14:55 | <b>Risk-adapted treatment strategies for BCC</b><br>Klara Mosterd (Maastricht, Netherlands)             |
| <b>D2T06.3D</b> | 15:15 | <b>Treatment of advanced tumours</b><br>Eve Maubec (Bobigny, France)                                    |
| <b>D2T06.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                              |

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                            |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------|
| <b>D2T06.4</b>  |       | <b>Squamous cell carcinoma</b><br>Chairs: David Moreno-Ramirez (Sevilla, Spain)<br>Marlies Wakkee (Rotterdam, Netherlands) |
| <b>D2T06.4A</b> | 16:00 | <b>What's new in prevention of skin cancer through UV protection</b><br>Hans Christian Wulf (Vedbæk, Denmark)              |
| <b>D2T06.4B</b> | 16:20 | <b>Risk-adapted treatment strategies</b><br>Marlies Wakkee (Rotterdam, Netherlands)                                        |
| <b>D2T06.4C</b> | 16:40 | <b>Surgery and non-medical therapy</b><br>David Moreno-Ramirez (Sevilla, Spain)                                            |
| <b>D2T06.4D</b> | 17:00 | <b>Systemic therapy and novelties</b><br>Simone Ribero (Torino, Italy)                                                     |
| <b>D2T06.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                 |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                              |
|-----------------|-------|----------------------------------------------------------------------------------------------|
| <b>D2T07.1</b>  |       | <b>Lasers for medical indications</b><br>Chair: Klaus Fritz (Landau, Germany)                |
| <b>D2T07.1A</b> | 08:30 | <b>Lasers for acne</b><br>Hans-Joachim Laubach (Geneva, Switzerland)                         |
| <b>D2T07.1B</b> | 08:50 | <b>Lasers for rosacea/rhinophyma</b><br>Natasha Teovska-Mitrevska (Skopje, North Macedonia)  |
| <b>D2T07.1C</b> | 09:10 | <b>Lasers for melasma/hyperpigmentation</b><br>Albert Wolkerstorfer (Amsterdam, Netherlands) |
| <b>D2T07.1D</b> | 09:30 | <b>Lasers for hair growth</b><br>Keyvan Nouri (Miami, United States)                         |
| <b>D2T07.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                   |

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                  |
|-----------------|-------|--------------------------------------------------------------------------------------------------|
| <b>D2T07.2</b>  |       | <b>Botulinum toxin for medical reasons</b><br>Chair: Hugues Cartier (Arras, France)              |
| <b>D2T07.2A</b> | 10:15 | <b>Botulinum toxin for depression</b><br>Katrien Franca (Miami, United States)                   |
| <b>D2T07.2B</b> | 10:35 | <b>Botulinum toxin in hair and scalp diseases</b><br>Inigo De Felipe Y Garate (Barcelona, Spain) |
| <b>D2T07.2C</b> | 10:55 | <b>Botulinum toxin for bruxism &amp; migraine</b><br>Svetlana Larkin (Odessa, Ukraine)           |
| <b>D2T07.2D</b> | 11:15 | <b>Other medical indications, including rosacea and scars</b><br>Ivan Bogdanov (Sofia, Bulgaria) |
| <b>D2T07.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                       |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                               |
|-----------------|-------|-----------------------------------------------------------------------------------------------|
| <b>D2T07.3</b>  |       | <b>Scars</b><br>Chair: Keyvan Nouri (Miami, United States)                                    |
| <b>D2T07.3A</b> | 14:15 | <b>Lasers for scars</b><br>Christine Dierickx (Luxembourg, Luxembourg)                        |
| <b>D2T07.3B</b> | 14:35 | <b>Scars in skin of colour</b><br>Mukta Sachdev (Bangalore, India)                            |
| <b>D2T07.3C</b> | 14:55 | <b>Fractional laser for drug delivery in scars</b><br>Merete Haedersdal (Copenhagen, Denmark) |
| <b>D2T07.3D</b> | 15:15 | <b>What's new in the treatment of scars</b><br>Brian Berman (Miami Beach, United States)      |
| <b>D2T07.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                    |

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                             |
|-----------------|-------|---------------------------------------------------------------------------------------------|
| <b>D2T04.2</b>  |       | <b>Acne scars</b><br>Chair: Brunilda Bardhi (Tirana, Albania)                               |
| <b>D2T07.4A</b> | 16:00 | <b>Hypertrophic scar treatment</b><br>Gisele Viana de Oliveira (Belo Horizonte, Brazil)     |
| <b>D2T07.4B</b> | 16:20 | <b>Post-inflammatory hyperpigmentation</b><br>Valerie Callender (Glenn Dale, United States) |
| <b>D2T07.4C</b> | 16:40 | <b>Atrophic scars</b><br>Atula Gupta (Gurugram, India)                                      |
| <b>D2T07.4D</b> | 17:00 | <b>Combination treatment in acne scar</b><br>Brunilda Bardhi (Tirana, Albania)              |
| <b>D2T07.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                  |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                    |
|-----------------|-------|----------------------------------------------------------------------------------------------------|
| <b>D2T08.1</b>  |       | <b>Fillers for beginners (Part 1)</b><br>Chair: Berthold Rzany (Wien, Austria)                     |
| <b>D2T08.1A</b> | 08:30 | <b>Anatomy</b><br>Mario Goisis (milan, Italy)                                                      |
| <b>D2T08.1B</b> | 08:50 | <b>Choosing the right filler</b><br>Pegah Dehdari (Dubai, United Arab Emirates)                    |
| <b>D2T08.1C</b> | 09:10 | <b>Holistic approach to facial rejuvenation with injectables</b><br>Dimitra Dasiou (Volos, Greece) |
| <b>D2T08.1D</b> | 09:30 | <b>Hyaluronidase: why and when</b><br>Brunilda Bardhi (Tirana, Albania)                            |
| <b>D2T08.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                         |

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                                                                                     |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T08.2</b>  |       | <b>Cosmetic treatments in skin of colour</b><br>Chair: Jaishree Sharad (Mumbai, India)                                                                              |
| <b>D2T08.2A</b> | 10:15 | <b>Physiological differences and treatment approaches for phototypes III-VI</b><br>Jorge Ocampo-Candiani (Monterrey, Mexico)                                        |
| <b>D2T08.2B</b> | 10:35 | <b>Melasma and post-inflammatory hyperpigmentation – different diagnoses with different treatments?</b><br>Miray Al-Mustafa (Oslo, Norway)                          |
| <b>D2T08.2C</b> | 10:55 | <b>Melasma treatment 2026</b><br>Claudia Borelli (Tübingen, Germany)                                                                                                |
| <b>D2T08.2D</b> | 11:15 | <b>Acanthosis nigricans, melasma, post-inflammatory hyperpigmentation and associated pigmentary anomalies</b><br>Christopher Rowland Payne (London, United Kingdom) |
| <b>D2T08.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                          |



Thursday, 1 October 2026

Session type: Updates

Room Hall E2

|          |       |                                                                                                                                      |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------------|
| D2T08.3  |       | <b>Fillers (Part 2)</b><br>Chair: Hassan Galadari (Dubai, United Arab Emirates)                                                      |
| D2T08.3A | 14:15 | <b>Facial filler rejuvenation: the challenge of a natural look</b><br>Elena Rossi (Modena, Italy)                                    |
| D2T08.3B | 14:35 | <b>Calcium hydroxylapatite and polylactic acid: synergy or conflict in facial biostimulation?</b><br>Joanna Czuwara (Warsaw, Poland) |
| D2T08.3C | 14:55 | <b>Poly-L-lactic acid &amp; calcium hydroxylapatite - fillers or biostimulators?</b><br>Berthold Rzany (Wien, Austria)               |
| D2T08.3D | 15:15 | <b>Are lip fillers easy?</b><br>Ines Verner Rashkovsky (Savyon, Israel)                                                              |
| D2T08.3E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                           |

Session type: Updates

Room Hall E2

|          |       |                                                                                                          |
|----------|-------|----------------------------------------------------------------------------------------------------------|
| D2T08.4  |       | <b>Fillers (Part 3)</b><br>Chair: Emanuel Marques (Lisbon, Portugal)                                     |
| D2T08.4A | 16:00 | <b>Tear trough fillers: Deep or superficial?</b><br>Marina Landau (Herzlia, Israel)                      |
| D2T08.4B | 16:20 | <b>Pyriform fossa filler: With or without ultrasound guidance?</b><br>Emanuel Marques (Lisbon, Portugal) |
| D2T08.4C | 16:40 | <b>Rhinoplasty by filler</b><br>Wayne Carey (montreal, Canada)                                           |
| D2T08.4D | 17:00 | <b>How to manage filler complications</b><br>Anna Medovarszki (Zurich, Switzerland)                      |
| D2T08.4E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                               |



**Thursday, 1 October 2026**

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                              |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T09.1</b>  |       | <b>Controversies I</b><br>Chairs: Elisa Cinotti (Siena, Italy)<br>Tobias Sangers (Leiden, Netherlands)                       |
| <b>D2T09.1A</b> | 08:30 | <b>Introduction</b><br>Elisa Cinotti (Siena, Italy)                                                                          |
| <b>D2T09.1B</b> | 08:35 | <b>Novel optical devices (LC-OCT, confocal): A breakthrough in dermatology? Yes</b><br>Mariano Suppa (Brussels, Belgium)     |
| <b>D2T09.1C</b> | 08:50 | <b>Novel optical devices (LC-OCT, confocal): A breakthrough in dermatology? No</b><br>Tamar Nijsten (Rotterdam, Netherlands) |
| <b>D2T09.1D</b> | 09:05 | <b>Discussion Q&amp;A</b>                                                                                                    |
| <b>D2T09.2E</b> | 09:15 | <b>Introduction</b><br>Tobias Sangers (Leiden, Netherlands)                                                                  |
| <b>D2T09.1F</b> | 09:20 | <b>Is AI superior to traditional human-based decision-making? Yes</b><br>Julia Welzel (Augsburg, Germany)                    |
| <b>D2T09.1G</b> | 09:35 | <b>Is AI superior to traditional human-based decision-making? No</b><br>Alon Scope (Ramat Gan, Israel)                       |
| <b>D2T09.1H</b> | 09:50 | <b>Discussion Q&amp;A</b>                                                                                                    |

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                                         |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T09.2</b>  |       | <b>Controversies II</b><br>Chairs: Gregor Borut Jemec (Copenhagen, Denmark)<br>Tilo Biedermann (Munich, Germany)                        |
| <b>D2T09.2A</b> | 10:15 | <b>Introduction</b><br>Gregor Borut Jemec (Copenhagen, Denmark)                                                                         |
| <b>D2T09.2B</b> | 10:20 | <b>Should we stop using antibiotics in hidradenitis suppurativa? Yes</b><br>Vincenzo Bettoli (Ferrara, Italy)                           |
| <b>D2T09.2C</b> | 10:35 | <b>Should we stop using antibiotics in hidradenitis suppurativa? No</b><br>Lukasz Matusiak (Wroclaw, Poland)                            |
| <b>D2T09.2D</b> | 10:50 | <b>Discussion Q&amp;A</b>                                                                                                               |
| <b>D2T09.2E</b> | 11:00 | <b>Introduction</b><br>Tilo Biedermann (Munich, Germany)                                                                                |
| <b>D2T09.2F</b> | 11:05 | <b>Is the microbiome a relevant therapeutic target in non-infectious diseases? Yes</b><br>Ellen van den Bogaard (Nijmegen, Netherlands) |
| <b>D2T09.2G</b> | 11:20 | <b>Is the microbiome a relevant therapeutic target in non-infectious diseases? No</b><br>Carsten Flohr (London, United Kingdom)         |
| <b>D2T09.2H</b> | 11:35 | <b>Discussion Q&amp;A</b>                                                                                                               |



**Thursday, 1 October 2026**

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                       |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------|
| <b>D2T09.3</b>  |       | <b>Controversies III</b><br>Chairs: Aimilios Lallas (Thessaloniki, Greece)<br>Rolland Gyulai (Szeged, Hungary)        |
| <b>D2T09.3A</b> | 14:15 | <b>Introduction</b><br>Rolland Gyulai (Szeged, Hungary)                                                               |
| <b>D2T09.3B</b> | 14:20 | <b>Should all BCCs be treated? Yes</b><br>Pedro Rodríguez-Jimenez (Madrid, Spain)                                     |
| <b>D2T09.3C</b> | 14:35 | <b>Should all BCCs be treated? No</b><br>Iris Zalaudek (Trieste, Italy)                                               |
| <b>D2T09.3D</b> | 14:50 | <b>Discussion Q&amp;A</b>                                                                                             |
| <b>D2T09.3E</b> | 15:00 | <b>Introduction</b><br>Aimilios Lallas (Thessaloniki, Greece)                                                         |
| <b>D2T09.3F</b> | 15:05 | <b>Non-surgical treatment as first-line approach in lentigo maligna? Yes</b><br>Ana-Maria Forsea (Bucharest, Romania) |
| <b>D2T09.3G</b> | 15:20 | <b>Non-surgical treatment as first-line approach in lentigo maligna? No</b><br>John Paoli (Gothenburg, Sweden)        |
| <b>D2T09.3I</b> | 15:35 | <b>Discussion Q&amp;A</b>                                                                                             |

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                                 |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T09.4</b>  |       | <b>Controversies IV</b><br>Chairs: Malgorzata Sokolowska-Wojdylo (Gdańsk, Poland)<br>Eszter Baltas (Szeged, Hungary)            |
| <b>D2T09.4A</b> | 16:00 | <b>Introduction</b><br>Malgorzata Sokolowska-Wojdylo (Gdańsk, Poland)                                                           |
| <b>D2T09.4B</b> | 16:05 | <b>Should we screen every patient with late-onset atopic dermatitis for CTCL? Yes</b><br>Maarten Vermeer (Leiden, Netherlands)  |
| <b>D2T09.4C</b> | 16:20 | <b>Should we screen every patient with late-onset atopic dermatitis for CTCL? No</b><br>Evangelia Papadavid (Athens, Greece)    |
| <b>D2T09.4D</b> | 16:35 | <b>Discussion Q&amp;A</b>                                                                                                       |
| <b>D2T09.4E</b> | 16:45 | <b>Introduction</b><br>Eszter Baltas (Szeged, Hungary)                                                                          |
| <b>D2T09.4F</b> | 16:50 | <b>Can we use immunosuppressive biologics in patients with recent cancer history? Yes</b><br>Matteo Megna (Naples, Italy)       |
| <b>D2T09.4G</b> | 17:05 | <b>Can we use immunosuppressive biologics in patients with recent cancer history? No</b><br>Murad Alam (Chicago, United States) |
| <b>D2T09.4H</b> | 17:20 | <b>Discussion Q&amp;A</b>                                                                                                       |



**Thursday, 1 October 2026**

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                                               |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T10.1</b>  |       | <b>Fungal skin infections</b><br>Chairs: Carmen Rodríguez Cerdeira (Vigo, Spain)<br>Daciana Elena Branisteanu (Iasi, Romania) |
| <b>D2T10.1A</b> | 08:30 | <b>Recalcitrant dermatophytosis</b><br>Shyam Verma (Vadodara, India)                                                          |
| <b>D2T10.1B</b> | 08:50 | <b>Onychomycosis: Diagnostics and modern treatment strategies</b><br>Andrzej Jaworek (Kraków, Poland)                         |
| <b>D2T10.1C</b> | 09:10 | <b>Superficial and deep cutaneous mycoses</b><br>Daciana Elena Branisteanu (Iasi, Romania)                                    |
| <b>D2T10.1D</b> | 09:30 | <b>Climate change and its impact on fungal disease</b><br>Carmen Rodríguez Cerdeira (Vigo, Spain)                             |
| <b>D2T10.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                    |

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                                                              |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D1T10.2</b>  |       | <b>Parasitic infestations and emerging viruses</b><br>Chairs: Carmen Maria Salavastru (Bucharest, Romania)<br>Alba Catala (Barcelona, Spain) |
| <b>D2T10.2A</b> | 10:15 | <b>Scabies</b><br>Carmen Maria Salavastru (Bucharest, Romania)                                                                               |
| <b>D2T10.2B</b> | 10:35 | <b>Cutaneous leishmaniasis</b><br>Soner Uzun (Antalya, Türkiye)                                                                              |
| <b>D2T10.2C</b> | 10:55 | <b>Mpox</b><br>Alba Catala (Barcelona, Spain)                                                                                                |
| <b>D2T10.2D</b> | 11:15 | <b>The impact of climate change on infectious diseases</b><br>Annika Belzer (San Francisco, United States)                                   |
| <b>D2T10.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                   |



**Thursday, 1 October 2026**

Session type: **Miscellaneous**

Room **Hall M**

|          |       |                                                                                                  |
|----------|-------|--------------------------------------------------------------------------------------------------|
| D2T10.3  |       | <b>Best papers of JEADV</b><br>Chair: Carle Paul (Toulouse, France)                              |
| D2T10.3A | 14:15 | <b>Allergology</b><br>Emek Kocatürk (Istanbul, Türkiye)                                          |
| D2T10.3B | 14:30 | <b>Manuscripts that have changed my practice in 2026</b><br>Sarah Walsh (London, United Kingdom) |
| D2T10.3C | 14:45 | <b>Dermatooncology</b><br>Christian Posch (Wien, Austria)                                        |
| D2T10.3D | 15:00 | <b>My 2026 MVPs (Most Valuable Papers)</b><br>Tom Hillary (Leuven, Belgium)                      |
| D2T10.3E | 15:15 | <b>Thinking out of the box: Innovative papers for 2026</b><br>Efthymia Soura (Athens, Greece)    |
| D2T13.3F | 15:30 | <b>Discussion, Q&amp;A</b>                                                                       |

Session type: **Miscellaneous**

Room **Hall M**

|          |       |                                                                                                  |
|----------|-------|--------------------------------------------------------------------------------------------------|
| D2T10.4  |       | <b>Best of dermatology papers 2026: a panoramic view</b><br>Chair: Carle Paul (Toulouse, France) |
| D2T10.4A | 16:00 | <b>Welcome and introduction</b><br>Carle Paul (Toulouse, France)                                 |
| D2T10.4B | 16:00 | <b>Best papers from the JAAD</b><br>Dirk Elston (Charleston, United States)                      |
| D2T10.4C | 16:15 | <b>Best papers from the BJD</b><br>John McGrath (London, United Kingdom)                         |
| D2T10.4D | 16:30 | <b>Best papers from the JID</b><br>Erwin Tschachler (Vienna, Austria)                            |
| D2T10.4E | 16:45 | <b>Best papers from the JEACP</b><br>Antonio Torrelo (Madrid, Spain)                             |
| D2T10.4F | 17:00 | <b>Best papers from the JEADV</b><br>Carle Paul (Toulouse, France)                               |
| D2T10.4G | 17:15 | <b>Discussion, Q&amp;A</b>                                                                       |



**Thursday, 1 October 2026**

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                                 |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------|
| <b>D2T11.1</b>  |       | <b>Drug reactions</b><br>Chairs: Wolfram Hoetzenecker (Linz, Austria)<br>Azael Freites Martinez (Madrid, Spain) |
| <b>D2T11.1A</b> | 08:30 | <b>Understanding the mechanism of drug eruptions</b><br>Werner Pichler (Bern, Switzerland)                      |
| <b>D2T11.1B</b> | 08:50 | <b>Diagnosing drug reactions</b><br>Wolfram Hoetzenecker (Linz, Austria)                                        |
| <b>D2T11.1C</b> | 09:10 | <b>Severe cutaneous adverse reactions (SCARs): SJS/TEN, DRESS, AGEP</b><br>Maja Mockenhaupt (Freiburg, Germany) |
| <b>D2T11.1D</b> | 09:30 | <b>Drug reactions associated with oncological therapies</b><br>Azael Freites Martinez (Madrid, Spain)           |
| <b>D2T11.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                      |

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                                                                                |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D2T11.2</b>  |       | <b>Acne: clinical variants and treatment recommendations</b><br>Chairs: Tamara Griffiths (Manchester, United Kingdom)<br>Lally Mekokishvili (Tbilisi, Georgia) |
| <b>D2T11.2A</b> | 10:15 | <b>Acne vulgaris in adults</b><br>Lally Mekokishvili (Tbilisi, Georgia)                                                                                        |
| <b>D2T11.2B</b> | 10:35 | <b>Acne in children</b><br>Tamara Griffiths (Manchester, United Kingdom)                                                                                       |
| <b>D2T11.2C</b> | 10:55 | <b>Rare forms of acne</b><br>Jerry Tan (Ontario, Canada)                                                                                                       |
| <b>D2T11.2D</b> | 11:15 | <b>Acne variants and treatment pearl</b><br>Ruta Ganceviciene (Vilnius, Lithuania)                                                                             |
| <b>D2T11.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                     |



Thursday, 1 October 2026

Session type: Training and education

Room Hall K

|          |       |                                                                                                                                                                            |
|----------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D2T11.3  |       | <b>Atopic dermatitis: clinical variants and treatment recommendations</b><br>Chairs: Marjolein de Bruin-Weller (Utrecht, Netherlands)<br>Jan Gutermuth (Brussels, Belgium) |
| D2T11.3A | 14:15 | <b>Clinical variants</b><br>Jan Gutermuth (Brussels, Belgium)                                                                                                              |
| D2T11.3B | 14:35 | <b>Atopic march</b><br>Peter Schmid-Grendelmeier (Zurich, Switzerland)                                                                                                     |
| D2T11.3C | 14:55 | <b>Treatment recommendations</b><br>Marjolein de Bruin-Weller (Utrecht, Netherlands)                                                                                       |
| D2T11.3D | 15:15 | <b>Understanding the therapeutic pipeline</b><br>Kilian Eyerich (Freiburg, Germany)                                                                                        |
| D2T11.3E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                                 |

Session type: Training and education

Room Hall K

|          |       |                                                                                                                              |
|----------|-------|------------------------------------------------------------------------------------------------------------------------------|
| D2T11.4  |       | <b>Eczema beyond atopic dermatitis</b><br>Chairs: Maria Pesonen (Helsinki, Finland)<br>Elena Sotiriou (Thessaloniki, Greece) |
| D2T11.4A | 16:00 | <b>Allergic contact dermatitis</b><br>Maria Pesonen (Helsinki, Finland)                                                      |
| D2T11.4B | 16:20 | <b>Hand eczema and its subtypes</b><br>Elena Sotiriou (Thessaloniki, Greece)                                                 |
| D2T11.4C | 16:40 | <b>Stasis dermatitis</b><br>David Pesqué (Barcelona, Spain)                                                                  |
| D2T11.4D | 17:00 | <b>Seborrheic eczema</b><br>Julia Nowowiejska-Purpurowicz (Białystok, Poland)                                                |
| D2T11.4E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                   |



Thursday, 1 October 2026

Session type: Free communication

Room Hall N

|         |       |                                                                                                                                                                                                                                                          |
|---------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC01    |       | <b>Free communication 1: atopic dermatitis / eczema</b><br>Chairs: Georg Stingl (Vienna, Austria)<br>Paola Pasquali (Cambrils, Spain)                                                                                                                    |
| FC01.1A | 08:30 | <b>Phase 2 study of novel trispecific tilrekimig (PF-07275315) in patients with moderate-severe atopic dermatitis: Interim efficacy and safety results at 16 weeks</b><br>Eric Simpson (Portland, United States)                                         |
| FC01.1B | 08:40 | <b>Initiating biologics in atopic dermatitis: Global practices and recommendations from the AMAZE project</b><br>April W. Armstrong (Los Angeles, United States)                                                                                         |
| FC01.1C | 08:50 | <b>Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPIQAL)</b><br>Sonja Molin (Berlin, Germany)                                                                                                    |
| FC01.1D | 09:00 | <b>Long-Term Efficacy and Safety of Anti-IL-4R<math>\alpha</math> Stapokibart for Adolescents With Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension Study of a Phase 3 Clinical Trial</b><br>Yan Zhao (Beijing, China)                      |
| FC01.1E | 09:10 | <b>ENV-294, a First-in-Class Oral Rac2 Modulator, Demonstrates Deep, Durable Efficacy with a Favorable Safety Profile in Moderate-to-Severe Atopic Dermatitis: Results from a Phase 1b Open-Label Study</b><br>Leon H Kircik (Louisville, United States) |
| FC01.1F | 09:20 | <b>Changes in lipidomic profile following treatment of atopic dermatitis with dupilumab and correlation with abundance of staphylococcal species</b><br>Caroline Meyer Olesen (Copenhagen, Denmark)                                                      |
| FC01.1G | 09:30 | <b>A Novel, pH-Sensitive IL-4R<math>\alpha</math> <math>\times</math> TSLP Bispecific Antibody for Dual Pathway Blockade and Extended Exposure in Atopic Dermatitis and Type 2 Inflammatory Diseases</b><br>Barry Duplantis (Somerville, United States)  |
| FC01.1H | 09:40 | <b>Risk of Cutaneous T-Cell Lymphoma and Lymphoid Malignancies With Dupilumab: A Propensity-Matched Cohort Study Across Atopic Dermatitis and other Type-2 Inflammatory Diseases</b><br>Khalaf Kridin (Nahariya, Israel)                                 |
| FC01.1I | 09:50 | <b>Upadacitinib Targets Multiple Disease-Relevant Inflammatory Pathways and Restores Skin Barrier in Atopic Dermatitis Lesions: Extending Beyond Type 2 Responses</b><br>Christopher Bunick (New Haven, United States)                                   |



Thursday, 1 October 2026

Session type: Free communication

Room Hall N

|         |       |                                                                                                                                                                                                                                                                                       |
|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC02    |       | <b>Free communication 2: atopic dermatitis / eczema</b><br>Chairs: Åke Svensson (Malmö, Sweden)<br>Rolland Gyulai (Szeged, Hungary)                                                                                                                                                   |
| FC02.1A | 10:15 | <b>Real-world use of tralokinumab in patients with atopic dermatitis involving high-burden areas: Effectiveness and impact on quality of life in the prospective, non-interventional 12-month TRACE study</b><br>Diamant Thaçi (Luebeck, Germany)                                     |
| FC02.1B | 10:25 | <b>Rezpegaldesleukin Provides Durable and Deepening Improvements in the Signs and Symptoms of Atopic Dermatitis with Monthly and Quarterly Dosing: Results from the Phase 2b REZOLVE-AD Maintenance Part of Study</b><br>Thomas Bieber (Feldafing, Germany)                           |
| FC02.1C | 10:35 | <b>A Th17-enriched pain endotype in atopic dermatitis: evidence from a coculture with circulating memory CLA<sup>+</sup> T-cell responses</b><br>Ignasi Figueras-Nart (Barcelona, Spain)                                                                                              |
| FC02.1D | 10:45 | <b>Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis.</b><br>Matthias Augustin (Hamburg, Germany)                                                    |
| FC02.1E | 10:55 | <b>Gut-Derived Metabolites, Intestinal Barrier Dysfunction, and Food Sensitization in Adult Atopic Dermatitis</b><br>Leszek Blicharz (Warsaw, Poland)                                                                                                                                 |
| FC02.1F | 11:05 | <b>Incident psoriasis in atopic dermatitis: A large-scale cohort study of disease- and treatment-associated risks</b><br>Ralf Ludwig (Lübeck, Germany)                                                                                                                                |
| FC02.1G | 11:15 | <b>Comparative Effects of Itch, Skin Lesion Severity, and Treatment on Sleep Disturbance in Atopic Dermatitis and Prurigo Nodularis</b><br>Franz J. Legat (Graz, Austria)                                                                                                             |
| FC02.1H | 11:25 | <b>Treatment with delgocitinib cream improves health-related quality of life in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN; a randomized, double-blind, vehicle-controlled phase 3 trial</b><br>Lawrence Eichenfield (San Diego, United States) |
| FC02.1I | 11:35 | <b>Paediatric Adverse Event Signals Associated with OTC Cosmeceutical Skincare Ingredients in FAERS: A Pharmacovigilance Disproportionality Analysis Coinciding with the TikTok Skincare Boom</b><br>Silvia Halteh (Jerusalem, Palestine)                                             |



Thursday, 1 October 2026

Session type: Free communication

Room Hall N

|         |       |                                                                                                                                                                                                                                                |
|---------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC03    |       | <b>Free communication 3: cutaneous oncology</b><br>Chairs: Vincent Sibaud (Toulouse, France)<br>Norbert Wikonkal (Budapest, Hungary)                                                                                                           |
| FC03.1A | 14:15 | <b>Incomplete reporting and interobserver variability of histopathological risk factors in cutaneous squamous cell carcinoma: implications for identifying high risk patients</b><br>Olivia Steijlen (Rotterdam, Netherlands)                  |
| FC03.1B | 14:25 | <b>Real-world effectiveness of mogamulizumab and prognostic value of sustained response (ORR4) in mycosis fungoides and Sézary syndrome: the FIL-MOGA study</b><br>Gabriele Rocuzzo (Torino, Italy)                                            |
| FC03.1C | 14:35 | <b>Bridging the Evidence Gap in Advanced MF/SS: Stage-Stratified Treatment Patterns and Outcomes from PROCLIP</b><br>Abraham E. Bashir (Birmingham, United Kingdom)                                                                            |
| FC03.1D | 14:45 | <b>Analysis of the Clinical and Pathological Characteristics of Single-center Cutaneous Squamous Cell Carcinoma and Construction of a Prognostic Risk Model</b><br>Songmei Geng (Xi'an, China)                                                 |
| FC03.1E | 14:55 | <b>Diagnostic accuracy and clinical impact of LC-OCT for the diagnosis of melanoma: a prospective study on 1,818 equivocal melanocytic lesions</b><br>Daniele Traini (Roma, Italy)                                                             |
| FC03.1F | 15:05 | <b>Immune Status and Merkel Cell Carcinoma: Lessons from a 25-Year Institutional experience</b><br>Adi Raviv (Tel Aviv, Israel)                                                                                                                |
| FC03.1G | 15:15 | <b>Non-Alcoholic Beverage Intake and Risk of Cutaneous Malignancies: A Systematic Review</b><br>Kim Tran (Edmonton, Canada)                                                                                                                    |
| FC03.1H | 15:25 | <b>Melanoma in CDKN2A Mutation Carriers: Longitudinal Real-World Data From a Melanoma Unit in Spain</b><br>Amalia Luna (Barcelona, Spain)                                                                                                      |
| FC03.1I | 15:35 | <b>Real-world use and safety of sonidegib in locally advanced basal cell carcinoma (laBCC) from the post-authorisation study NISSO: Cross-country differences between Germany, Italy and Spain cohorts</b><br>Josep Malvehy (Barcelona, Spain) |



Thursday, 1 October 2026

Session type: Free communication

Room Hall N

|         |       |                                                                                                                                                                                                                                                               |
|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC04    |       | <b>Free communication 4: hair and nail disorders</b><br>Chairs: Asja Prohić (Sarajevo, Bosnia and Herzegovina)<br>Matilde Iorizzo (Lugano, Switzerland)                                                                                                       |
| FC04.1A | 16:00 | <b>Inflammatory infiltrate precedes collapse of the immune privilege in human Alopecia areata</b><br>Sophie Frech (Vienna, Austria)                                                                                                                           |
| FC04.1B | 16:10 | <b>Clinicodermoscopic–Histopathological Correlations and Long-Term Outcomes in Onychopapilloma: A Retrospective Longitudinal Study</b><br>Merve Alizada (Ankara, Türkiye)                                                                                     |
| FC04.1C | 16:20 | <b>The Trichoceutical Paradox: a Systematic Review of Oral Nutraceuticals in Alopecia</b><br>Christine Rachelle Prescendo Chaves (Porto Alegre, Brazil)<br>Michele Kreuz / (Novo Hamburgo, Brazil)                                                            |
| FC04.1D | 16:30 | <b>Rezpegaldesleukin, a Novel Regulatory T Cell-Inducing Biologic, Demonstrates Efficacy and Safety in Severe-to-Very-Severe Alopecia Areata: 52-Week Results from the Phase 2b REZOLVE-AA Study</b><br>David Rosmarin (Indianapolis, Indiana, United States) |
| FC04.1E | 16:40 | <b>Impact of Upadacitinib on Clinician- and Patient-Reported Outcomes Assessing Visible Hair Loss at Key Sites in Patients With Severe Alopecia Areata: Results From Two Replicate Phase 3 Trials</b><br>Arash Mostaghimi (Boston, United States)             |
| FC04.1F | 16:50 | <b>Safety of deuruxolitinib with up to 2 years of treatment in adults with severe alopecia areata: Long-term results from an open-label extension study</b><br>Athanasios Tsianakas (Bad Bentheim, Germany)                                                   |
| FC04.1G | 17:00 | <b>Association between GLP-1 receptor agonists and scalp involvement: results from a multinational case-control study</b><br>Bruno Halioua (Paris, France)                                                                                                    |
| FC04.1H | 17:10 | <b>Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Efficacy and Safety Results from Week 52 of the UP-AA1 and UP-AA2 Phase 3 Clinical Trials</b><br>Arash Mostaghimi (Boston, United States)                                              |
| FC04.1I | 17:20 | <b>Association between GLP-1 receptor agonists and nail disorders: results from a multinational case-control study</b><br>Bianca Maria Piraccini (Bologna, Italy)                                                                                             |



**Friday, 2 October 2026**

|           | 08:30 – 10:00                                                                     | 10:15 – 11:45                                                     | 14:15 – 15:45                                                            | 16:00 – 17:30                                                                                             |
|-----------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Hall A    | Atopic dermatitis in children                                                     | Atopic dermatitis in adults                                       | Late breaking news                                                       | Late breaking news                                                                                        |
| Hall D    | Dermoscopy for keratinocytic tumours                                              | Dermoscopy for melanoma and melanocytic naevi                     | Nail and hair dermoscopy                                                 | Trichoscopy                                                                                               |
| Hall B    | Pigmentary disorders: hyperpigmentation                                           | Pigmentary disorders: hypopigmentation                            | Merkel cell carcinoma and cutaneous sarcomas                             | Cutaneous lymphomas                                                                                       |
| Hall C    | Cutaneous manifestations of internal diseases                                     | Cutaneous and systemic lupus erythematosus                        | Joint EADV / JDA session: Faces of skin diseases from East to West       | Lichen planus                                                                                             |
| Hall F1   | Invisible burden, visible impact: improving mental health outcomes in dermatology | Wound healing                                                     | Adverse events in new anti-cancer therapy                                | Sarcoidosis and other granulomatous diseases                                                              |
| Hall F2   | Top advances in 2026 presented by ESDR                                            | Hot topics in Dermatology selected by the EADV President          | Best of European and American dermatology                                | Best of European and American dermatology                                                                 |
| Hall E1   | AI strategies in dermatological practice                                          | Controversies VI                                                  | Dermatology in skin of colour patients                                   | Global health                                                                                             |
| Hall E2   | Mesotherapy and regenerative medicine                                             | Longevity: pillars of longevity medicine in aesthetic dermatology | Complications in aesthetic dermatology                                   | Skin tightening and rejuvenation                                                                          |
| Hall G    | Controversies V                                                                   |                                                                   | Controversies VII                                                        | Controversies VIII                                                                                        |
| Hall M    | Botulinum toxin for beginners                                                     | Botulinum toxin advanced                                          | Setting up a cosmetic practice                                           | Low cost non-laser pearls in cosmetic dermatology. My favourite non-EBD pearls from 4 experienced experts |
| Hall K    | Surgical therapy                                                                  | Psoriasis                                                         | Dermato-oncology                                                         | Paediatric dermatology                                                                                    |
| Hall N    | Free communication 5: psoriasis                                                   | Free communication 6: pruritus / adverse drug reactions           | Free communication 7: acne / hidradenitis suppurativa / bullous diseases | Free communication 8: diagnostic procedures / targeted therapies                                          |
| 1.61-1.62 | Use of botulinum toxin in cosmetic and medical dermatology                        |                                                                   | Confocal microscopy and LC-OCT                                           |                                                                                                           |
| 1.85-1.86 | Phlebology for beginners                                                          |                                                                   | Surgery: beginners                                                       |                                                                                                           |
| Foyer L   |                                                                                   |                                                                   |                                                                          | <b>EADV GAMES</b>                                                                                         |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                                                       |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T01.1</b>  |       | <b>Atopic dermatitis in children</b><br>Chairs: Andreas Wollenberg (Munich, Germany)<br>Juliette Mazereeuw-Hautier (Toulouse, France) |
| <b>D3T01.1A</b> | 08:30 | <b>Treatment of atopic dermatitis in pre-school children</b><br>Lawrence Eichenfield (San Diego, United States)                       |
| <b>D3T01.1B</b> | 08:50 | <b>Vaccination in children with atopic dermatitis</b><br>Andreas Wollenberg (Munich, Germany)                                         |
| <b>D3T01.1C</b> | 09:10 | <b>Systemic treatment of congenital eczematous disorders in childhood</b><br>Juliette Mazereeuw-Hautier (Toulouse, France)            |
| <b>D3T01.1D</b> | 09:30 | <b>Contact allergy in children with atopic dermatitis</b><br>Anna Belloni Fortina (Padua, Italy)                                      |
| <b>D3T01.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                            |

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                                                        |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T01.2</b>  |       | <b>Atopic dermatitis in adults</b><br>Chairs: Emma Guttman-Yassky (New York, NY, United States)<br>Magdalena Trzeciak (Gdansk, Poland) |
| <b>D3T01.2A</b> | 10:15 | <b>Impact of environment, food and contact allergens</b><br>Charlotte G. Mortz (Odense, Denmark)                                       |
| <b>D3T01.2B</b> | 10:35 | <b>Late-onset atopic dermatitis</b><br>Emma Guttman-Yassky (New York, United States)                                                   |
| <b>D3T01.2C</b> | 10:55 | <b>Topical and systemic therapies</b><br>Ignasi Figueras-Nart (Barcelona, Spain)                                                       |
| <b>D3T01.2D</b> | 11:15 | <b>Upcoming therapies and disease modification</b><br>Magdalena Trzeciak (Gdansk, Poland)                                              |
| <b>D3T01.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                             |



Friday, 2 October 2026

Session type: Updates

Room Hall A

|          |       |                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3T01.3  |       | <b>Late breaking news</b><br>Chairs: Katarina Zak Stangeland (Stavanger, Norway)<br>Tamara Jovovic Sadikovic (Sarajevo, Bosnia and Herzegovina)                                                                                                                                                                                                                                         |
| D3T01.3A | 14:15 | <b>The Interferon Signaling Pathway Plays a Key Role in Hailey-Hailey Disease and is Effectively Targeted by Ruxolitinib</b><br>Alain Hovnanian (Paris, France)                                                                                                                                                                                                                         |
| D3T01.3B | 14:30 | <b>Targeting hair-follicle regulatory mechanisms beyond established approaches: a translational evaluation of MEV-miRNAs/iSFPI gel</b><br>Apostolos Pappas (Branchburg, United States)                                                                                                                                                                                                  |
| D3T01.3C | 14:45 | <b>Long-term Durability and Safety of the Targeted Oral Peptide Icotrokinra for High-Impact Site Psoriasis: 2-year Findings From the ICONIC-TOTAL Randomized Controlled Trial</b><br>Richard B. Warren (Manchester, United Kingdom)                                                                                                                                                     |
| D3T01.3D | 15:00 | <b>Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates superior skin clearance (PASI 100) versus an approved oral TYK2 inhibitor, deucravacitinib, and a consistent safety profile in moderate-to-severe plaque psoriasis: results from a randomized phase 3 intraclass head-to-head trial (LATITUDE Atlas)</b><br>Linda Stein Gold (Michigan, United States) |
| D3T01.3E | 15:15 | <b>Clinical study of RLS-1496 topical cream: targeting senescence and oxidative stress via GPX4 inhibition in patients with actinic keratosis</b><br>Mary Spellman (Silicon Valley, CA, United States)                                                                                                                                                                                  |
| D3T01.3F | 15:30 | <b>Efficacy and safety of Telikibart, a novel anti-IL-4R <math>\alpha</math> monoclonal antibody, for moderate-to-severe atopic dermatitis: 52-week outcomes and prespecified subgroup analyses from a randomized, placebo-controlled phase III trial</b><br>Shangshang Wang (Shanghai, China)                                                                                          |



Friday, 2 October 2026

Session type: Updates

Room Hall A

|          |       |                                                                                                                                                                                                                                                                                 |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3T01.4  |       | <b>Late breaking news</b><br>Chairs: Igor Bartenjev (Ljubljana, Slovenia)<br>Francesca Prignano (Florence, Italy)                                                                                                                                                               |
| D3T01.4A | 16:00 | <b>A Previously Undrugged Target in Immune Therapeutics: Oral ENV-294 Provides First Clinical and Molecular Proof of Concept for RAC2 Modulation in Atopic Dermatitis</b><br>Ester Del Duca (New York, United States)                                                           |
| D3T01.4B | 16:15 | <b>Hypogammaglobulinemia, Late-Onset Neutropenia and Infection After Rituximab in Pemphigus, with Divergent Desmoglein Antibody and Immunoglobulin Kinetics: A Retrospective Cohort Study</b><br>Mert Bardak (Izmir, Türkiye)                                                   |
| D3T01.4C | 16:30 | <b>Golidocitinib Plus Brentuximab Vedotin for Brentuximab Vedotin-Refractory/Relapsed Advanced Folliculotropic Mycosis Fungoides and Sézary Syndrome: A Retrospective Cohort Study</b><br>Wenyu Wu (Shanghai, China)                                                            |
| D3T01.4D | 16:45 | <b>Real-world effectiveness and safety of avelumab in an older, clinically heterogeneous population with advanced Merkel cell carcinoma: a nationwide Austrian multicentre study</b><br>Magdalena Forstinger (Wien, Austria)                                                    |
| D3T01.4E | 17:00 | <b>Rapid Dose-Related Responses to an Oral MRGPRX2 Partial Inverse Agonist in Chronic Spontaneous Urticaria</b><br>Shuguang Yuan (Allschwil, Switzerland)                                                                                                                       |
| D3T01.4F | 17:15 | <b>Efficacy and safety of ritlecitinib in patients with nonsegmental vitiligo (NSV): results from the Tranquillo 2 Part Ia and Tranquillo Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trials</b><br>Iltefat Hamzavi (Clinton twp, United States) |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                           |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------|
| <b>D3T02.1</b>  |       | <b>Dermoscopy for keratinocytic tumours</b><br>Chairs: Caterina Longo (Modena, Italy)<br>Josep Malvehy (Barcelona, Spain) |
| <b>D3T02.1A</b> | 08:30 | <b>Histopathological subtypes</b><br>Caterina Longo (Modena, Italy)                                                       |
| <b>D3T02.1B</b> | 08:50 | <b>Squamous cell carcinoma</b><br>Bengü Nisa Akay (Ankara, Türkiye)                                                       |
| <b>D3T02.1C</b> | 09:10 | <b>AI in dermoscopy for keratinocytic tumours</b><br>Josep Malvehy (Barcelona, Spain)                                     |
| <b>D3T02.1D</b> | 09:30 | <b>Ultraviolet-induced fluorescent dermoscopy</b><br>Luis Sanchez (Guadalajara, Mexico)                                   |
| <b>D3T02.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                |

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                                       |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T02.2</b>  |       | <b>Dermoscopy for melanoma and melanocytic naevi</b><br>Chairs: Giuseppe Argenziano (Naples, Italy)<br>Danica Todorovic (Nis, Serbia) |
| <b>D3T02.2A</b> | 10:15 | <b>Dermoscopic algorithms</b><br>Giuseppe Argenziano (Naples, Italy)                                                                  |
| <b>D3T02.2B</b> | 10:35 | <b>AI and digital monitoring of nevi</b><br>Cristina Carrera (Barcelona, Spain)                                                       |
| <b>D3T02.2C</b> | 10:55 | <b>Recognition of very early melanomas and pink tumours</b><br>Danica Todorovic (Nis, Serbia)                                         |
| <b>D3T02.2D</b> | 11:15 | <b>Melanonychia</b><br>Luc Thomas (Pierre-Bénite, France)                                                                             |
| <b>D3T02.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                            |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                  |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------|
| <b>D3T02.3</b>  |       | <b>Nail and hair dermoscopy</b><br>Chairs: Michela Starace (Bologna, Italy)<br>Marta Sar-Pomian (Warsaw, Poland) |
| <b>D3T02.3A</b> | 14:15 | <b>What's new in trichoscopy?</b><br>Asmahane Souissi (Chazela Ariana, Tunisia)                                  |
| <b>D3T02.3B</b> | 14:35 | <b>What's new in nail dermoscopy?</b><br>Michela Starace (Bologna, Italy)                                        |
| <b>D3T02.3C</b> | 14:55 | <b>New and emerging equipment for hair and nail dermoscopy</b><br>Marta Sar-Pomian (Warsaw, Poland)              |
| <b>D3T02.3D</b> | 15:15 | <b>Automated image analysis for hair and nail dermoscopy?</b><br>Marija Buljan (Zagreb, Croatia)                 |
| <b>D3T02.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                       |

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                         |
|-----------------|-------|---------------------------------------------------------------------------------------------------------|
| <b>D3T02.4</b>  |       | <b>Trichoscopy</b><br>Chairs: Adriana Rakowska (Warsaw, Poland)<br>Ana Filipa Pedrosa (Porto, Portugal) |
| <b>D3T02.4A</b> | 16:00 | <b>Trichoscopy in focal hair loss</b><br>Daniel Asz Sigall (Mexico City, Mexico)                        |
| <b>D3T02.4B</b> | 16:20 | <b>Trichoscopy in diffuse hair loss</b><br>Adriana Rakowska (Warsaw, Poland)                            |
| <b>D3T02.4C</b> | 16:40 | <b>Inflammatory scalp diseases</b><br>Ana Filipa Pedrosa (Porto, Portugal)                              |
| <b>D3T02.4D</b> | 17:00 | <b>Tumour metastases to the scalp</b><br>Andrea Sechi (Milano, Italy)                                   |
| <b>D3T02.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                              |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                                            |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T03.1</b>  |       | <b>Pigmentary disorders: hyperpigmentation</b><br>Chairs: Thierry Passeron (Nice, France)<br>Jelena Stojkovic-Filipovic (Belgrade, Serbia) |
| <b>D3T03.1A</b> | 08:30 | <b>Inflammation-related hyperpigmentation</b><br>Khaled Ezzedine (Créteil, France)                                                         |
| <b>D3T03.1B</b> | 08:50 | <b>Drug-induced hyperpigmentation</b><br>Tasneem Mohammad (Detroit, United States)                                                         |
| <b>D3T03.1C</b> | 09:10 | <b>Melasma</b><br>Thierry Passeron (Nice, France)                                                                                          |
| <b>D3T03.1D</b> | 09:30 | <b>Reticulate hyperpigmentation disorders</b><br>Jelena Stojkovic-Filipovic (Belgrade, Serbia)                                             |
| <b>D3T03.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                 |

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                                                          |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T03.2</b>  |       | <b>Pigmentary disorders: hypopigmentation</b><br>Chairs: Nanja van Geel (Gent, Belgium)<br>Albert Wolkerstorfer (Amsterdam, Netherlands) |
| <b>D3T03.2A</b> | 10:15 | <b>Inherited hypopigmentation disorders</b><br>Fanny Morice-Picard (Bordeaux, France)                                                    |
| <b>D3T03.2B</b> | 10:35 | <b>Contact-induced hypopigmentation</b><br>Nanja van Geel (Gent, Belgium)                                                                |
| <b>D3T03.2C</b> | 10:55 | <b>Drug-induced hypopigmentation</b><br>Mauro Picardo (Rome, Italy)                                                                      |
| <b>D3T03.2D</b> | 11:15 | <b>Novel approaches to the treatment of hypopigmentation</b><br>Albert Wolkerstorfer (Amsterdam, Netherlands)                            |
| <b>D3T03.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                               |



Friday, 2 October 2026

Session type: Updates

Room Hall B

|          |       |                                                                                                                                      |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------------|
| D3T03.3  |       | <b>Merkel cell carcinoma and cutaneous sarcomas</b><br>Chairs: Alexander Stratigos (Athens, Greece)<br>Mahtab Samimi (Tours, France) |
| D3T03.3A | 14:15 | <b>Merkel cell carcinoma: biology and extension assessment</b><br>Mahtab Samimi (Tours, France)                                      |
| D3T03.3B | 14:35 | <b>Merkel cell carcinoma: management</b><br>Grażyna Kamińska-Winciorek (Gliwice, Poland)                                             |
| D3T03.3C | 14:55 | <b>Dermatofibrosarcoma protuberans</b><br>Alexander Stratigos (Athens, Greece)                                                       |
| D3T03.3D | 15:15 | <b>Kaposi sarcoma</b><br>Petr Arenberger (Prague, Czech Republic)                                                                    |
| D3T03.3E | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                           |

Session type: Updates

Room Hall B

|          |       |                                                                                                                 |
|----------|-------|-----------------------------------------------------------------------------------------------------------------|
| D3T03.4  |       | <b>Cutaneous lymphomas</b><br>Chairs: Emmanuella Guenova (Linz, Austria)<br>Martine Bagot Robin (Paris, France) |
| D3T03.4A | 16:00 | <b>CTCL</b><br>Martine Bagot Robin (Paris, France)                                                              |
| D3T03.4B | 16:20 | <b>CBCL</b><br>Rudolf Stadler (Minden, Germany)                                                                 |
| D3T03.4C | 16:40 | <b>Cutaneous manifestations of systemic lymphomas</b><br>Emmanuella Guenova (Linz, Austria)                     |
| D3T03.4D | 17:00 | <b>Paediatric cutaneous lymphomas</b><br>Emmilia Hodak (Petah Tikva, Israel)                                    |
| D3T03.4E | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                      |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                                                        |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T04.1</b>  |       | <b>Cutaneous manifestations of internal diseases</b><br>Chairs: Martine Grosber (Brussels, Belgium)<br>Selim Aractingi (Paris, France) |
| <b>D3T04.1A</b> | 08:30 | <b>Diabetic skin manifestations</b><br>Slavomir Urbancek (Banska Bystrica, Slovakia)                                                   |
| <b>D3T04.1B</b> | 08:50 | <b>Thyroid disorders</b><br>Martine Grosber (Brussels, Belgium)                                                                        |
| <b>D3T04.1C</b> | 09:10 | <b>Endocrinopathies</b><br>Selim Aractingi (Paris, France)                                                                             |
| <b>D3T04.1D</b> | 09:30 | <b>Inflammatory bowel disease</b><br>Luca Stingeni (Corciano, Italy)                                                                   |
| <b>D3T04.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                             |

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                                                         |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T04.2</b>  |       | <b>Cutaneous manifestations of lupus erythematosus</b><br>Chairs: Adriana Polanska (Poznań, Poland)<br>Miloš Nikolić (Belgrade, Serbia) |
| <b>D3T04.2A</b> | 10:15 | <b>New biomarkers in lupus erythematosus</b><br>Adriana Polanska (Poznań, Poland)                                                       |
| <b>D3T04.2B</b> | 10:35 | <b>Advances in diagnosing and scoring cutaneous and systemic lupus erythematosus</b><br>Francois Chasset (Paris, France)                |
| <b>D3T04.2C</b> | 10:55 | <b>Neonatal and paediatric lupus erythematosus</b><br>Elena Moraitis (London, United Kingdom)                                           |
| <b>D3T04.2D</b> | 11:15 | <b>Recent recommendations for the treatment of lupus erythematosus</b><br>Miloš Nikolić (Belgrade, Serbia)                              |
| <b>D3T04.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                              |



**Friday, 2 October 2026**Session type: **Updates**Room **Hall C**

|                 |       |                                                                                                                                                    |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T04.3</b>  |       | <b>Joint EADV / JDA – Faces of skin diseases from East to West</b><br>Chairs: Manabu Fujimoto (Osaka, Japan)<br>Branka Marinovic (Zagreb, Croatia) |
| <b>D3T04.3A</b> | 14:15 | <b>New therapeutic targets and pathomechanism for pruritus</b><br>Kenji Kabashima (Kyoto, Japan)                                                   |
| <b>D3T04.3B</b> | 14:35 | <b>The changing landscape of genodermatoses</b><br>Eli Sprecher (Tel Aviv, Israel)                                                                 |
| <b>D3T04.3C</b> | 14:55 | <b>Recent advances in severe cutaneous adverse reactions: From clinical practice to disease mechanisms</b><br>Riichiro Abe (Niigata, Japan)        |
| <b>D3T04.3D</b> | 15:15 | <b>The immunological topography of human skin. Why does location matter?</b><br>Andrea Szegedi (Debrecen, Hungary)                                 |
| <b>D3T04.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                                         |

Session type: **Updates**Room **Hall C**

|                 |       |                                                                                                       |
|-----------------|-------|-------------------------------------------------------------------------------------------------------|
| <b>D3T04.4</b>  |       | <b>Lichen planus</b><br>Chairs: Monika Fida (Tirana, Albania)<br>Gaspar Krisztian (Debrecen, Hungary) |
| <b>D3T04.4A</b> | 16:00 | <b>Oral lichen planus</b><br>Marta Kurzeja (Warsaw, Poland)                                           |
| <b>D3T04.4B</b> | 16:20 | <b>Genital lichen planus</b><br>Fiona Lewis (London, United Kingdom)                                  |
| <b>D3T04.4C</b> | 16:40 | <b>Lichen planopilaris</b><br>Monika Fida (Tirana, Albania)                                           |
| <b>D3T04.4D</b> | 17:00 | <b>Lichenoid drug eruptions</b><br>Gaspar Krisztian (Debrecen, Hungary)                               |
| <b>D3T04.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                            |



Friday, 2 October 2026

Session type: **Miscellaneous**

Room **Hall F1**

|          |       |                                                                                                                                                                                                                              |
|----------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3T05.1  |       | <b>Invisible burden, visible impact: improving mental health outcomes in dermatology</b><br>Chairs: Catherine van Montfrans (Rotterdam, Netherlands)<br>Tammi Shipowick (Ottawa, Canada)<br>Aleksandra Lesiak (Lodz, Poland) |
| D3T05.1A | 08:30 | <b>Welcome</b><br>Catherine van Montfrans (Rotterdam, Netherlands)                                                                                                                                                           |
| D3T05.1B | 08:33 | <b>Towards personalized care in dermatology: insights into mental health, stigma and psychosocial burden in chronic skin conditions</b><br>Sylvia van Beugen (Leiden, Netherlands)                                           |
| D3T05.1C | 08:43 | <b>Mental health and well-being support for individuals living with skin conditions</b><br>Tammi Shipowick (Ottawa, Canada)                                                                                                  |
| D3T05.1D | 08:50 | <b>Partnering with HCPs in caring for skin patients' mental health</b>                                                                                                                                                       |
| D3T05.1E | 08:50 | <b>Introduction of panelists and topic</b><br>Aleksandra Lesiak (Lodz, Poland)<br>Catherine van Montfrans (Rotterdam, Netherlands)                                                                                           |
| D3T05.1F | 08:55 | <b>Measuring the mental health impact of living with a skin disease - Using a validated tool in your practice</b><br>Jennifer Austin (Ottawa, Canada)<br>Matthias Augustin (Hamburg, Germany)                                |
|          | 09:10 | <b>Q&amp;A</b>                                                                                                                                                                                                               |
|          | 09:13 | <b>The perceived quality of life in adult patients with inherited ichthyosis: a qualitative interview study</b><br>Fauve van Veen (Maastricht, Netherlands)<br>Jolien van der Geugten (Amersfoort, Netherlands)              |
|          | 09:28 | <b>Q&amp;A</b>                                                                                                                                                                                                               |
|          | 09:31 | <b>Living with epidermolysis bullosa: integrating research and lived experience to understand psychological burden</b><br>Gudrun Salamon (Vienna, Austria)<br>Lena Riedl (Vienna, Austria)                                   |
|          | 09:46 | <b>Q&amp;A</b>                                                                                                                                                                                                               |
|          | 09:50 | <b>Closing remarks</b><br>Catherine van Montfrans (Rotterdam, Netherlands)                                                                                                                                                   |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                       |
|-----------------|-------|-------------------------------------------------------------------------------------------------------|
| <b>D3T05.2</b>  |       | <b>Wound healing</b><br>Chairs: Birgitte Visch (Arnhem, Netherlands)<br>Marco Romanelli (Pisa, Italy) |
| <b>D3T05.2A</b> | 10:15 | <b>Venous ulcers</b><br>Marco Romanelli (Pisa, Italy)                                                 |
| <b>D3T05.2B</b> | 10:35 | <b>Diabetic foot</b><br>Birgitte Visch (Arnhem, Netherlands)                                          |
| <b>D3T05.2C</b> | 10:55 | <b>Inflammatory skin diseases</b><br>Degovics Doniz (Szeged, Hungary)                                 |
| <b>D3T05.2D</b> | 11:15 | <b>Pressure ulcer</b><br>Valentina Dini (Pisa, Italy)                                                 |
| <b>D3T05.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                            |

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                                  |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T05.3</b>  |       | <b>Adverse events in new anti-cancer therapy</b><br>Chairs: Lukas Flatz (Tübingen, Germany)<br>Vincent Sibaud (Toulouse, France) |
| <b>D3T05.3A</b> | 14:15 | <b>Targeted therapies</b><br>Peter Kölblinger (Salzburg, Austria)                                                                |
| <b>D3T05.3B</b> | 14:35 | <b>Immune checkpoint inhibitors: pathogenesis and classification</b><br>Lukas Flatz (Tübingen, Germany)                          |
| <b>D3T05.3C</b> | 14:55 | <b>Immune checkpoint inhibitors: therapy and outcome</b><br>Yevgeniy Semenov (Boston, United States)                             |
| <b>D3T05.3D</b> | 15:15 | <b>CAR T-cell therapy</b><br>Vincent Sibaud (Toulouse, France)                                                                   |
| <b>D3T05.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                       |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                                   |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T05.4</b>  |       | <b>Sarcoidosis and other granulomatous diseases</b><br>Chairs: Nicolas Kluger (Kerava, Finland)<br>Enzo Errichetti (Udine, Italy) |
| <b>D3T05.4A</b> | 16:00 | <b>Sarcoidosis</b><br>Nicolas Kluger (Kerava, Finland)                                                                            |
| <b>D3T05.4B</b> | 16:20 | <b>Interstitial granulomatous dermatitis</b><br>Afsaneh Alavi (Rochester, United States)                                          |
| <b>D3T05.4C</b> | 16:40 | <b>Necrobiosis lipoidica</b><br>Barbara Binder (Graz, Austria)                                                                    |
| <b>D3T05.4D</b> | 17:00 | <b>Granuloma annulare</b><br>Enzo Errichetti (Udine, Italy)                                                                       |
| <b>D3T05.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                        |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                                               |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T06.1</b>  |       | <b>Top advances in 2026 presented by ESDR</b><br>Chairs: Kilian Eyerich (Freiburg, Germany)<br>Beatrice Dyring-Andersen (Copenhagen, Denmark) |
| <b>D3T06.1A</b> | 08:30 | <b>Multimodal data integration to identify mechanisms of chronicity and resolution in psoriasis</b><br>Liv Eidsmo (Solna, Sweden)             |
| <b>D3T06.1B</b> | 08:50 | <b>Expanding the spectrum of sebaceous gland-associated diseases</b><br>Daniel Torocsik (Debrecen, Hungary)                                   |
| <b>D3T06.1C</b> | 09:10 | <b>Novel therapies for Sturge-Weber syndrome</b><br>Veronica Kinsler (London, United Kingdom)                                                 |
| <b>D3T06.1D</b> | 09:30 | <b>The role of keratins in skin immune tolerance</b><br>Ines Sequeira (London, United Kingdom)                                                |
| <b>D3T06.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                    |

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                                                                                               |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T06.2</b>  |       | <b>Hot topics in dermatology selected by the EADV President</b><br>Chairs: Branka Marinovic (Zagreb, Croatia)<br>Marie-Aleth Richard (Marseille, France)<br>Martin Röcken (Tübingen, Germany) |
| <b>D3T06.2A</b> | 10:15 | <b>Diagnostic and therapeutic pearls in the skin of colour</b><br>Susan Taylor (Philadelphia, United States)                                                                                  |
| <b>D3T06.2B</b> | 10:40 | <b>New insights into the atopic inflammation</b><br>Kenji Kabashima (Kyoto, Japan)                                                                                                            |
| <b>D3T06.2C</b> | 11:05 | <b>Mesenchymal stem cells in chronic wounds and tissue regeneration</b><br>Selim Aractingi (Paris, France)                                                                                    |
| <b>D3T06.2D</b> | 11:30 | <b>Discussion, Q&amp;A</b>                                                                                                                                                                    |
| <b>D3T06.2A</b> | 10:15 | <b>Diagnostic and therapeutic pearls in the skin of colour</b><br>Susan Taylor (Philadelphia, United States)                                                                                  |



Friday, 2 October 2026

Session type: Updates

Room Hall F2

|          |       |                                                                                                                                                         |
|----------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| D3T06.3  |       | <b>Best of European and American dermatology</b><br>Chairs: Lidia Rudnicka (Warsaw, Poland)<br>Robert Kirsner (Miami, United States)                    |
| D3T06.3A | 14:15 | <b>Making teledermatology work in 2026. Pinpointing the when and how.</b><br>Paola Pasquali (Cambrils, Spain)                                           |
| D3T06.3B | 14:45 | <b>What's new with infection disease for dermatologists</b><br>Erik Stratman (Marshfield, United States)                                                |
| D3T06.3C | 15:15 | <b>Hidradenitis suppurativa in the era of targeted therapies: indications for surgery and long-term outcomes</b><br>Thrasyvoulos Tzellos (Bodø, Norway) |

Session type: Updates

Room Hall F2

|          |       |                                                                                                                                      |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------------|
| D3T06.4  |       | <b>Best of European and American dermatology</b><br>Chairs: Lidia Rudnicka (Warsaw, Poland)<br>Robert Kirsner (Miami, United States) |
| D3T06.4A | 16:00 | <b>What's new In calciphylaxis</b><br>Daniela Kroshinsky (Durham, United States)                                                     |
| D3T06.4B | 16:30 | <b>Epidermolysis bullosa: from molecular mechanisms to future therapies</b><br>Cristina Has (Freiburg, Germany)                      |
| D3T06.4C | 17:00 | <b>Red, hot and painful: the curious syndrome of erythromelalgia</b><br>Mark Davis (Rochester, United States)                        |



## Friday, 2 October 2026

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                                                                  |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T07.1</b>  |       | <b>AI strategies in dermatological practice</b><br>Chairs: Maria del Mar Llamas Velasco (Madrid, Spain)<br>Amanda Oakley (Hamilton, New Zealand) |
| <b>D3T07.1A</b> | 08:30 | <b>AI for 3D total body photography and digital monitoring</b><br>Aimilios Lallas (Thessaloniki, Greece)                                         |
| <b>D3T07.1B</b> | 08:50 | <b>AI-based tools in daily dermatology practice</b><br>Philipp Tschandl (Vienna, Austria)                                                        |
| <b>D3T07.1C</b> | 09:10 | <b>The role of AI in dermatopathology</b><br>Maria del Mar Llamas Velasco (Madrid, Spain)                                                        |
| <b>D3T07.1D</b> | 09:30 | <b>AI in teledermatology</b><br>Amanda Oakley (Hamilton, New Zealand)                                                                            |
| <b>D3T07.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                       |

Session type: **Controversies**

Room **Hall E1**

|                 |       |                                                                                                                                    |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T07.2</b>  |       | <b>Controversies VI</b><br>Chairs: Ximena Wortsman (Santiago, Chile)<br>Lukas Flatz (Tübingen, Germany)                            |
| <b>D3T07.2A</b> | 10:15 | <b>Introduction</b><br>Ximena Wortsman (Santiago, Chile)                                                                           |
| <b>D3T07.2B</b> | 10:20 | <b>Is ultrasound a state-of-the-art diagnostic method in dermatology? Yes</b><br>Priscila Giavedoni (Barcelona, Spain)             |
| <b>D3T07.2C</b> | 10:35 | <b>Is ultrasound a state-of-the-art diagnostic method in dermatology? No</b><br>Linda Tognetti (Siena, Italy)                      |
| <b>D3T07.2D</b> | 10:50 | <b>Discussion Q&amp;A</b>                                                                                                          |
| <b>D3T07.2E</b> | 11:00 | <b>Introduction</b><br>Lukas Flatz (Tübingen, Germany)                                                                             |
| <b>D3T07.2F</b> | 11:05 | <b>Is liquid biopsy, as a new tool for early cancer detection, a game changer? Yes</b><br>Goran Micevic (New Haven, United States) |
| <b>D3T07.2G</b> | 11:20 | <b>Is liquid biopsy, as a new tool for early cancer detection, a game changer? No</b><br>Christoffer Gebhardt (Hamburg, Germany)   |
| <b>D3T07.2H</b> | 11:35 | <b>Discussion Q&amp;A</b>                                                                                                          |

## Friday, 2 October 2026



Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                                                       |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T07.3</b>  |       | <b>Dermatology in skin of colour patients</b><br>Chairs: Daudi Mavura (Moshi, Tanzania)<br>Andrew F. Alexis (New York, United States) |
| <b>D3T07.3A</b> | 14:15 | <b>Management of melasma in skin of colour</b><br>Aseem Sharma (Mumbai, India)                                                        |
| <b>D3T07.3B</b> | 14:35 | <b>Dermoscopy in skin of colour</b><br>Enzo Errichetti (Udine, Italy)                                                                 |
| <b>D3T07.3C</b> | 14:55 | <b>Atopic dermatitis in skin of colour</b><br>Daudi Mavura (Moshi, Tanzania)                                                          |
| <b>D3T07.3D</b> | 15:15 | <b>How to manage acne in skin of colour</b><br>Andrew F. Alexis (New York, United States)                                             |
| <b>D3T07.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                            |

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                    |
|-----------------|-------|----------------------------------------------------------------------------------------------------|
| <b>D3T07.4</b>  |       | <b>Global health</b><br>Chairs: Valeska Padovese (Msida, Malta)<br>Antonio Torrelo (Madrid, Spain) |
| <b>D3T07.4A</b> | 16:00 | <b>Viral exanthems in pandemics</b><br>Esther Freeman (Boston, United States)                      |
| <b>D3T07.4B</b> | 16:20 | <b>Migration and imported diseases in Europe</b><br>Valeska Padovese (Msida, Malta)                |
| <b>D3T07.4C</b> | 16:40 | <b>Skin infections in children worldwide</b><br>Antonio Torrelo (Madrid, Spain)                    |
| <b>D3T07.4D</b> | 17:00 | <b>WHO essential medicines for skin</b><br>José-Antonio Ruiz-Postigo (Geneva, Switzerland)         |
| <b>D3T07.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                         |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                             |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------|
| <b>D3T08.1</b>  |       | <b>Mesotherapy and regenerative medicine</b><br>Chair: Inigo De Felipe Y Garate (Barcelona, Spain)          |
| <b>D3T08.1A</b> | 08:30 | <b>Platelet-rich plasma and platelet-rich fibrin – the evidence?</b><br>Panagiotis Polyzois (Lamia, Greece) |
| <b>D3T08.1B</b> | 08:50 | <b>Thread lifting</b><br>Anthony Benedetto (Philadelphia, United States)                                    |
| <b>D3T08.1C</b> | 09:10 | <b>Salmon sperm, poly-L-lactic acid and other subdermal boosters</b><br>Samar Khalil (Beirut, Lebanon)      |
| <b>D3T08.1D</b> | 09:30 | <b>Meso for male and female androgenetic alopecia</b><br>Lidiya Todorova (Plovdiv, Bulgaria)                |
| <b>D3T08.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                  |

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                                                                                    |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T08.2</b>  |       | <b>Longevity pillars of longevity medicine in aesthetic dermatology</b><br>Chair: Liliana Sytnyk (Kyiv, Ukraine)                                                   |
| <b>D3T08.2A</b> | 10:15 | <b>Who is the villain: carbohydrate or saturated fat?</b><br>Eckart Haneke (Freiburg im Breisgau, Germany)                                                         |
| <b>D3T08.2B</b> | 10:35 | <b>Insulin resistance, weight management and longevity</b><br>Pantelis Souvatzidis (Thessaloniki, Greece)                                                          |
| <b>D3T08.2C</b> | 10:55 | <b>PEMOS (PolyEndocrine Metabolic Ovarian Syndrome): What every dermatologist should know - A longevity medicine perspective</b><br>Liliana Sytnyk (Kyiv, Ukraine) |
| <b>D3T08.2D</b> | 11:15 | <b>Longevity medicine: its importance for aesthetic dermatology</b><br>Leonardo Marini (Trieste, Italy)                                                            |
| <b>D3T08.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                                                         |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall E2**

|                 |              |                                                                                                 |
|-----------------|--------------|-------------------------------------------------------------------------------------------------|
| <b>D3T08.1</b>  |              | <b>Complications in aesthetic dermatology</b><br>Chair: Leonardo Marini (Trieste, Italy)        |
| <b>D3T08.3A</b> | <b>14:15</b> | <b>Complications of energy-based device treatments</b><br>Mihaela Leventer (Bucharest, Romania) |
| <b>D3T08.3B</b> | <b>14:35</b> | <b>Complications of fillers</b><br>Pierre Andre (Paris, France)                                 |
| <b>D3T08.3C</b> | <b>14:55</b> | <b>Complications of neurotoxins</b><br>Magdolna Gaal (Szeged, Hungary)                          |
| <b>D3T08.3D</b> | <b>15:15</b> | <b>Complications of chemical peels</b><br>Carlos Wambier (West Palm Beach, United States)       |
| <b>D3T08.3E</b> | <b>15:35</b> | <b>Discussion, Q&amp;A</b>                                                                      |

Session type: **Updates**

Room **Hall E2**

|                 |              |                                                                                                                      |
|-----------------|--------------|----------------------------------------------------------------------------------------------------------------------|
| <b>D3T08.2</b>  |              | <b>Skin tightening and rejuvenation</b><br>Chair: Moshe Lapidoth (Ramat-Gan, Israel)                                 |
| <b>D3T08.4A</b> | <b>16:00</b> | <b>Energy-based devices and focused ultrasound for skin tightening</b><br>Luigi Leonardo Polla (Geneva, Switzerland) |
| <b>D3T08.4B</b> | <b>16:20</b> | <b>Emerging therapies in body contouring</b><br>Lillit Garibyan (Boston, United States)                              |
| <b>D3T08.4C</b> | <b>16:40</b> | <b>PDT and light therapy for skin rejuvenation</b><br>Maria M. Tsoukas (Chicago, United States)                      |
| <b>D3T08.4D</b> | <b>17:00</b> | <b>Combination treatments for skin tightening and rejuvenation</b><br>George Kroumpouzou (Milton, United States)     |
| <b>D3T08.4E</b> | <b>17:20</b> | <b>Discussion, Q&amp;A</b>                                                                                           |



**Friday, 2 October 2026**

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                        |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------|
| <b>D3T09.1</b>  |       | <b>Controversies V</b><br>Chairs: Menno de Rie (Breukelen, Netherlands)<br>Henry W. Lim (Grosse Pointe, United States) |
| <b>D3T09.1A</b> | 08:30 | <b>Introduction</b><br>Menno de Rie (Breukelen, Netherlands)                                                           |
| <b>D3T09.1B</b> | 08:35 | <b>Biological treatment as first-line therapy for psoriasis: Yes</b><br>Carle Paul (Toulouse, France)                  |
| <b>D3T09.1C</b> | 08:50 | <b>Biological treatment as first-line therapy for psoriasis: No</b><br>Martin Röcken (Tübingen, Germany)               |
| <b>D3T09.1D</b> | 09:05 | <b>Discussion Q&amp;A</b>                                                                                              |
| <b>D3T09.1E</b> | 09:15 | <b>Introduction</b><br>Henry W. Lim (Grosse Pointe, United States)                                                     |
| <b>D3T09.1F</b> | 09:20 | <b>Is phototherapy in the era of biologics still relevant? Yes</b><br>Mark Berneburg (Regensburg, Germany)             |
| <b>D3T09.1G</b> | 09:35 | <b>Is phototherapy in the era of biologics still relevant? No</b><br>Lev Pavlovsky (Petach Tikva, Israel)              |
| <b>D2T09.1H</b> | 09:50 | <b>Discussion Q&amp;A</b>                                                                                              |

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                            |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------|
| <b>D3T09.3</b>  |       | <b>Controversies VI</b><br>Chairs: Paolo Gisondi (Verona, Italy)<br>Michel Gilliet (Lausanne, Switzerland)                 |
| <b>D3T09.3A</b> | 14:15 | <b>Introduction</b><br>Michel Gilliet (Lausanne, Switzerland)                                                              |
| <b>D3T09.3B</b> | 14:20 | <b>Should systemic therapy for psoriasis continue indefinitely in responders? Yes</b><br>Lluís Puig (Barcelona, Spain)     |
| <b>D3T09.3C</b> | 14:35 | <b>Should systemic therapy for psoriasis continue indefinitely in responders? No</b><br>Jo LW Lambert (Ghent, Belgium)     |
| <b>D3T09.3D</b> | 14:50 | <b>Discussion Q&amp;A</b>                                                                                                  |
| <b>D3T09.3E</b> | 15:00 | <b>Introduction</b><br>Paolo Gisondi (Verona, Italy)                                                                       |
| <b>D3T09.3F</b> | 15:05 | <b>Is it time to routinely use biomarkers for psoriasis treatment choice? Yes</b><br>Anna Lopez-Ferrer (Barcelona, Spain)  |
| <b>D3T09.3G</b> | 15:20 | <b>Is it time to routinely use biomarkers for psoriasis treatment choice? No</b><br>Pedro Mendes-Bastos (Lisbon, Portugal) |
| <b>D3T09.3H</b> | 15:35 | <b>Discussion Q&amp;A</b>                                                                                                  |



**Friday, 2 October 2026**

Session type: **Controversies**

Room **Hall G**

|                 |       |                                                                                                                 |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------|
| <b>D3T09.4</b>  |       | <b>Controversies VII</b><br>Chairs: Johannes Ring (Munich, Germany)<br>Pavel Chernyshov (Kyiv, Ukraine)         |
| <b>D3T09.4A</b> | 16:00 | <b>Introduction</b><br>Johannes Ring (Munich, Germany)                                                          |
| <b>D3T09.4B</b> | 16:05 | <b>Should we always follow the guidelines in atopic dermatitis? Yes</b><br>Matthias Augustin (Hamburg, Germany) |
| <b>D3T09.4C</b> | 16:20 | <b>Should we always follow the guidelines in atopic dermatitis? No</b><br>Andrea Szegedi (Debrecen, Hungary)    |
| <b>D3T09.4D</b> | 16:35 | <b>Discussion Q&amp;A</b>                                                                                       |
| <b>D3T09.4E</b> | 16:45 | <b>Introduction</b><br>Pavel Chernyshov (Kyiv, Ukraine)                                                         |
| <b>D3T09.4F</b> | 16:50 | <b>Is nutrition part of acne management? Yes</b><br>Brigitte Dréno (Nantes, France)                             |
| <b>D3T09.4G</b> | 17:05 | <b>Is nutrition part of acne management? No</b><br>Tadas Raudonis (Vilnius, Lithuania)                          |
| <b>D3T09.4H</b> | 17:20 | <b>Discussion Q&amp;A</b>                                                                                       |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                            |
|-----------------|-------|--------------------------------------------------------------------------------------------|
| <b>D3T10.1</b>  |       | <b>Botulinum toxin for beginners</b><br>Chair: Andreas Katsambas (Athens, Greece)          |
| <b>D3T10.1A</b> | 08:30 | <b>Anatomy</b><br>Larisa Stojanovic (Ljubljana, Slovenia)                                  |
| <b>D3T10.1B</b> | 08:50 | <b>Upper face</b><br>Mara Madalina Mihai (Bucharest, Romania)                              |
| <b>D3T10.1C</b> | 09:10 | <b>Lower face &amp; neck</b><br>Christina Fotiadou (Thessaloniki, Greece)                  |
| <b>D3T10.1D</b> | 09:30 | <b>My top tips for starting a botulinum practice</b><br>Andreas Katsambas (Athens, Greece) |
| <b>D3T10.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                 |

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                       |
|-----------------|-------|-------------------------------------------------------------------------------------------------------|
| <b>D3T10.2</b>  |       | <b>Botulinum toxin advanced</b><br>Chair: Anthony Benedetto (Philadelphia, PA, United States)         |
| <b>D3T10.2A</b> | 10:15 | <b>Botulinum toxin: Lifetime experience</b><br>Anthony Benedetto (Philadelphia, PA, United States)    |
| <b>D3T10.2B</b> | 10:35 | <b>Botulinum toxin for hyperhidrosis</b><br>Konstantinos Kalokasidis (Thessaloniki, Greece)           |
| <b>D3T10.2C</b> | 10:55 | <b>Botulinum toxin advanced lifting techniques for the upper face</b><br>Daisy Kopera (Graz, Austria) |
| <b>D3T10.2D</b> | 11:15 | <b>Botulinum toxin pitfalls and their management</b><br>Seher Eren (Landau in der Pfalz, Germany)     |
| <b>D3T10.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                            |



**Friday, 2 October 2026**

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                                                        |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T10.3</b>  |       | <b>Setting up a cosmetic practice</b><br>Chairs: Monika Arenbergerova (Prague, Czech Republic)                                         |
| <b>D3T10.3A</b> | 14:15 | <b>Setting up your office</b><br>Panagiotis Polyzois (Lamia, Greece)                                                                   |
| <b>D3T10.3B</b> | 14:35 | <b>How to equip your practice without spending money on energy-based devices</b><br>Christopher Rowland Payne (London, United Kingdom) |
| <b>D3T10.3C</b> | 14:55 | <b>Using social media to market your practice</b><br>Karim Gabr (waldshut, Germany)                                                    |
| <b>D3T10.3D</b> | 15:15 | <b>Emergencies in cosmetic dermatology</b><br>Tanja Fischer (Potsdam, Germany)                                                         |
| <b>D3T10.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                                             |

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                                                                                   |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D3T10.4</b>  |       | <b>Low cost non-laser pearls in cosmetic dermatology. My favourite non-EBD pearls from 4 experienced experts</b><br>Chair: Oliver Kreyden (Muttentz, Switzerland) |
| <b>D3T10.4A</b> | 16:00 | <b>My favourite non-EBD</b><br>Hassan Galadari (Dubai, United Arab Emirates)                                                                                      |
| <b>D3T10.4B</b> | 16:20 | <b>My favourite non-EBD</b><br>Leonardo Marini (Trieste, Italy)                                                                                                   |
| <b>D3T10.4C</b> | 16:40 | <b>My favourite non-EBD</b><br>Jaishree Sharad (Mumbai, India)                                                                                                    |
| <b>D3T10.4D</b> | 16:40 | <b>My favourite non-EBD</b><br>Oliver Kreyden (Muttentz, Switzerland)                                                                                             |
| <b>D3T10.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                                                                        |



**Friday, 2 October 2026**

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                                             |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------|
| <b>D3T11.1</b>  |       | <b>Surgical therapy</b><br>Chairs: Anne-Marte Henriksen (Tromsø, Norway)<br>Myrto-Georgia Trakatelli (Thessaloniki, Greece) |
| <b>D3T11.1A</b> | 08:30 | <b>How to biopsy correctly</b><br>William Hunt (Bristol, United Kingdom)                                                    |
| <b>D3T11.1B</b> | 08:50 | <b>Cryosurgery</b><br>Eva Backman (Gothenburg, Sweden)                                                                      |
| <b>D3T11.1C</b> | 09:10 | <b>Incision and drainage/deroofting of fistulas</b><br>Anne-Marte Henriksen (Tromsø, Norway)                                |
| <b>D3T11.1D</b> | 09:30 | <b>Nail surgery</b><br>Myrto-Georgia Trakatelli (Thessaloniki, Greece)                                                      |
| <b>D3T11.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                  |

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                          |
|-----------------|-------|----------------------------------------------------------------------------------------------------------|
| <b>D3T11.2</b>  |       | <b>Psoriasis</b><br>Chairs: Diamant Thaçi (Luebeck, Germany)<br>Catherine Smith (London, United Kingdom) |
| <b>D3T11.2A</b> | 10:15 | <b>Clinical subtypes</b><br>Vali Mateeva (Sofia, Bulgaria)                                               |
| <b>D3T11.2B</b> | 10:35 | <b>Evaluation of disease severity</b><br>Diamant Thaçi (Luebeck, Germany)                                |
| <b>D3T11.2C</b> | 10:55 | <b>Comorbidities</b><br>Álvaro González-Cantero (Madrid, Spain)                                          |
| <b>D3T11.2D</b> | 11:15 | <b>Treatment</b><br>Catherine Smith (London, United Kingdom)                                             |
| <b>D3T11.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                               |



**Friday, 2 October 2026**

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                               |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------|
| <b>D3T11.3</b>  |       | <b>Dermato-oncology</b><br>Chairs: Eszter Baltas (Szeged, Hungary)<br>Christoffer Gebhardt (Hamburg, Germany) |
| <b>D3T11.3A</b> | 14:15 | <b>Keratinocyte tumours</b><br>Eszter Baltas (Szeged, Hungary)                                                |
| <b>D3T11.3B</b> | 14:35 | <b>Melanoma</b><br>Christoffer Gebhardt (Hamburg, Germany)                                                    |
| <b>D3T11.3C</b> | 14:55 | <b>Cutaneous lymphomas</b><br>Pablo Luis Ortiz Romero (Madrid, Spain)                                         |
| <b>D3T11.3D</b> | 15:15 | <b>Merkel cell carcinoma</b><br>Emmanuella Guenova (Linz, Austria)                                            |
| <b>D3T11.3E</b> | 15:35 | <b>Discussion, Q&amp;A</b>                                                                                    |

Session type: **Training and education**

Room **Hall K**

|                 |       |                                                                                                                         |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------------------|
| <b>D2T11.4</b>  |       | <b>Paediatric dermatology</b><br>Chairs: Caroline Colmant (Leuven, Belgium, Belgium)<br>Andrea Diociaiuti (Roma, Italy) |
| <b>D3T11.4A</b> | 16:00 | <b>Newborns with vesicles and pustules: when to worry</b><br>Lisa Weibel (Zurich, Switzerland)                          |
| <b>D3T11.4B</b> | 16:20 | <b>Lumps and bumps in newborns and infants - diagnostic approach</b><br>Caroline Colmant (Leuven, Belgium)              |
| <b>D3T11.4C</b> | 16:40 | <b>Histiocytoses in newborns and infants</b><br>Martin Theiler (Zurich, Switzerland)                                    |
| <b>D3T11.4D</b> | 17:00 | <b>Vascular anomalies in newborns</b><br>Andrea Diociaiuti (Roma, Italy)                                                |
| <b>D3T11.4E</b> | 17:20 | <b>Discussion, Q&amp;A</b>                                                                                              |



Friday, 2 October 2026

Session type: Free communication

Room Hall N

|         |       |                                                                                                                                                                                                                                                                                                                                                   |
|---------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC05    |       | <b>Free Communication 5: psoriasis</b><br>Chairs: Maria-Angeliki Gkini (London, United Kingdom)<br>Richard Langley (Halifax, Canada)                                                                                                                                                                                                              |
| FC05.1A | 08:30 | <b>Efficacy and safety of SHR-1139, a novel anti-IL-23p19/IL-36R bispecific antibody, in patients with moderate-to-severe plaque psoriasis: interim results from a randomized, double-blind, placebo-controlled phase 2 trial</b><br>Yuling Shi (China)                                                                                           |
| FC05.1B | 08:40 | <b>TDRKH-mediated piRNA regulation sustains pro-inflammatory M1 macrophage polarization in psoriasis</b><br>Yulin Zou (Göttingen, Germany)                                                                                                                                                                                                        |
| FC05.1C | 08:50 | <b>eGEPARD as a Digital Self-Screening Tool to Support Early Detection of Psoriatic Arthritis in Psoriasis Patients: A Prospective Study</b><br>Anastasia Fleyder (Hamburg, Germany)                                                                                                                                                              |
| FC05.1D | 09:00 | <b>Early PASI Response Predicts Long-Term Complete Skin Clearance with Risankizumab: A Five-Year Real-World ROC Analysis</b><br>Luciano Ibba (Milan, Italy)                                                                                                                                                                                       |
| FC05.1E | 09:10 | <b>Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates durable efficacy for up to 60 weeks in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)</b><br>April W. Armstrong (Los Angeles, United States)                                           |
| FC05.1F | 09:20 | <b>Once-daily oral zasocitinib, a highly selective TYK2 inhibitor, demonstrates rapid improvements in skin clearance, quality of life and psoriasis symptoms in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)</b><br>Melinda Gooderham (Peterborough, Ontario, Canada) |
| FC05.1G | 09:30 | <b>Efficacy of Picankibart among Different BMI and Body Weight in Adult Plaque Psoriasis: Subgroup Analyses of the Phase 3 CLEAR-2 Study</b><br>Yuling Shi (Shanghai, China)                                                                                                                                                                      |
| FC05.1H | 09:40 | <b>Patient-Reported Outcomes With Upadacitinib in Adults and Adolescents With Nonsegmental Vitiligo: Pooled Results From Two Phase 3 Trials (Viti-Up 1&amp;2) Through Week 48</b><br>Khaled Ezzedine (Créteil, France)                                                                                                                            |
| FC05.1I | 09:50 | <b>Comparative Efficacy of Oral Icotrokinra versus Injectable IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis</b><br>Sana Gupta (Ottawa, Canada)                                                                                                                                                                |



**Friday, 2 October 2026**

Session type: **Free communication**

Room **Hall N**

|                |       |                                                                                                                                                                                                                                                         |
|----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>FC06</b>    |       | <b>Free Communication 6: pruritus / adverse drug reactions</b><br>Chairs: Cristina Has (Freiburg, Germany)<br>Leticia Szadai (Szeged, Hungary)                                                                                                          |
| <b>FC06.1A</b> | 10:15 | <b>Does the European definition of chronic prurigo fit real-world patient characteristics? - Evidence from the German National Prurigo Registry CPGBest</b><br>Felix Witte (Münster, Germany)                                                           |
| <b>FC06.1B</b> | 10:25 | <b>Efficacy and Safety of SHR-1819 in Adult Patients with Prurigo Nodularis : Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial (The Results of the Phase II Trial)</b><br>Jianzhong Zhang (Beijing, China) |
| <b>FC06.1C</b> | 10:35 | <b>Which instruments can optimise teledermatology follow-up in vitiligo? A nationwide survey with dual patient-dermatologist perspective</b><br>Emmanuel Mahe (Argenteuil, France)                                                                      |
| <b>FC06.1D</b> | 10:45 | <b>Dupilumab and nemolizumab for chronic pruritus in cancer patients under oncologic treatment – a multicentric retrospective study from the EADV Task Force dermatology for cancer patients</b><br>Ariadna Ortiz Brugués (Barcelona, Spain)            |
| <b>FC06.1E</b> | 10:55 | <b>Unmet Needs and Disease Burden: Perspectives from Adults with Psoriasis and Clinicians Treating Psoriasis in Germany and the US</b><br>Matthias Augustin (Hamburg, Germany)                                                                          |
| <b>FC06.1F</b> | 11:05 | <b>Cytokine profiling reveals marked inter-individual immune heterogeneity in chronic spontaneous urticaria: Early findings of the MECSU project</b><br>Yi-Kui Xiang (Berlin, Germany)                                                                  |
| <b>FC06.1G</b> | 11:15 | <b>Etanercept versus Systemic Corticosteroids for Generalized Bullous Fixed Drug Eruption: A Comparative Cohort Study</b><br>Chun-Bing Chen (Taoyuan, Taiwan)                                                                                           |
| <b>FC06.1H</b> | 11:25 | <b>Acneiform Rash from EGFR Inhibitor Therapy: Durable, Mechanism-Directed Reduction with Topical LUT014 (B-RAF Inhibitor) in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial</b><br>Anisha B. Patel (Houston, United States)             |
| <b>FC06.1I</b> | 11:35 | <b>Analysis of test performance and documentation quality of patch testing patient's own material: Results of the 317b-research project</b><br>Sven Malte John (Osnabrueck, Germany)                                                                    |



Friday, 2 October 2026

Session type: **Free communication**

Room **Hall N**

|         |       |                                                                                                                                                                                                                                                                          |
|---------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC07    |       | <b>Free communication 7: acne / hidradenitis suppurativa / bullous diseases</b><br>Chairs: Monika Fida (Tirana, Albania)<br>Snejina Vassileva (Sofia, Bulgaria)                                                                                                          |
| FC07.1A | 14:15 | <b>Maintenance and Deepening of IHS4 Clinical Response With Upadacitinib Treatment in Adult Patients With Moderate-to-Severe Hidradenitis Suppurativa</b><br>Thrasyvoulos Tzellos (Bodø, Norway)                                                                         |
| FC07.1B | 14:25 | <b>Efficacy of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: A patient subgroup analysis from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study</b><br>Martina L. Porter (Boston, United States) |
| FC07.1C | 14:35 | <b>Sonelokimab reduces lesion drainage in patients with moderate-to-severe HS: pooled analysis of the VELA-1 and VELA-2 Phase 3 trials</b><br>Martina L. Porter (Boston, United States)                                                                                  |
| FC07.1D | 14:45 | <b>Magnitude and predictors of the placebo response in randomized controlled trials of immunomodulatory drugs for hidradenitis suppurativa: a systematic review and meta-analysis</b><br>Nina Xiyu Qiu (Copenhagen, Denmark)                                             |
| FC07.1E | 14:55 | <b>Multi-marker serum signature of intestinal barrier alteration in rosacea: severity-independent D-lactate and claudin-3 elevation along the gut-skin axis</b><br>Gozde Simsek (Ankara, Türkiye)                                                                        |
| FC07.1F | 15:05 | <b>Epitope distribution and diagnostic performance of target antigens in autoimmune bullous diseases: a systematic review</b><br>Xun Feng (Chengdu, China)                                                                                                               |
| FC07.1G | 15:15 | <b>Clinical and Inflammatory Predictors of Severe Disease Activity in Geriatric Bullous Pemphigoid: A Multicentre Retrospective Cohort Study</b><br>Selen Taner Akbay (Hatay, Türkiye)                                                                                   |
| FC07.1H | 15:25 | <b>Translating Genetic Findings into Care: COL7A1 Variant Spectrum as a Foundation for Personalized DEB Treatment in Germany</b><br>Johanna Zandanell (Freiburg, Germany)<br>G Min Zou (Chengdu, China)                                                                  |
| FC07.1I | 15:35 | <b>Clinical And Immunological Profiles of Immune Checkpoint Inhibitor-Related Bullous Pemphigoid: A Cohort Study from Register Database</b><br>Min Zou (Chengdu, China)                                                                                                  |



Friday, 2 October 2026

Session type: **Free communication**

Room **Hall N**

|         |       |                                                                                                                                                                                                                                                            |
|---------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FC08    |       | <b>Free communication 8: diagnostic procedures / targeted therapies</b><br>Chairs: Nejib Doss (Tunis, Tunisia)<br>Eli Sprecher (Tel Aviv, Israel)                                                                                                          |
| FC08.1A | 16:00 | <b>Line-Field Confocal Optical Coherence Tomography Improves Diagnostic Accuracy and Reduces Inappropriate Management: A Multi-Reader Pre-Post Study</b><br>Maria Luísa Santos e Silva Caldeira Marques (Santa Cruz de Tenerife, Spain)                    |
| FC08.1B | 16:10 | <b>Handheld Reflectance Confocal Microscopy for Head and Neck Basal Cell Carcinoma: Diagnostic Performance, Subtyping, and Potential to Replace Presurgical Biopsies</b><br>Yannick Elshot (Amsterdam, Netherlands)                                        |
| FC08.1C | 16:20 | <b>High-Frequency Ultrasound for Hyaluronic Acid Filler Complications: Pattern Recognition and a Practical Diagnostic Algorithm from 160 Cases</b><br>Maria Lúcia Paysano (Rio de Janeiro, Brazil)                                                         |
| FC08.1D | 16:30 | <b>Comparison of a Vision Transformer (ViT)-based Artificial Intelligence Model and a Large Cohort of Dermatologists in Dermoscopic Image Classification: A Multicenter Study</b><br>Arcan Kıvanç Çapçı (Yozgat, Türkiye)                                  |
| FC08.1E | 16:40 | <b>Clinical, biochemical and genetic characterization of familial porphyria cutanea tarda and hepatoerythropoietic porphyria</b><br>Pablo Balado-Simó (Barcelona, Spain)                                                                                   |
| FC08.1F | 16:50 | <b>Topical sirolimus 0.1% for cutaneous microcystic lymphatic malformations in children and adults (TOPICAL trial): a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial</b><br>Sophie Leducq (Tours, France) |
| FC08.1G | 17:00 | <b>Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, in moderate-to-severe palmoplantar pustulosis: Efficacy, safety, and translational results from the open-label Phase 2 LEDA trial</b><br>Nina Magnolo (Muenster, Germany)                  |
| FC08.1H | 17:10 | <b>Omics-Based Biomarker Discovery in Plasma and Finger Sweat for Individualized Anti-PD-1 and CTLA-4 Treatment Stratification in Melanoma</b><br>Verena Paulitschke (Vienna, Austria)                                                                     |
| FC08.1I | 17:20 | <b>Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus (CLE): 52-week results of the Phase 2 Study, AMETHYST Part A</b><br>Joseph F. Merola (Dallas, United States)                                                                        |



**Saturday, 3 October 2026**

|           |                                                       |                                   |                                                               |                                                                               |
|-----------|-------------------------------------------------------|-----------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------|
|           |                                                       | 12:00 – 13:00                     |                                                               |                                                                               |
| Hall A    |                                                       | Plenary lectures<br>C             |                                                               |                                                                               |
|           | 08:30 – 10:00                                         | 10:15 – 11:45                     | 14:15 – 15:45                                                 | 16:00 – 17:30                                                                 |
| Hall A    | Understanding acne                                    | Treating acne                     |                                                               |                                                                               |
| Hall D    | Drug reactions                                        | Clinical-pathological correlation |                                                               |                                                                               |
| Hall B    | Itch                                                  | Chronic prurigo                   |                                                               |                                                                               |
| Hall C    | Autoimmune bullous diseases                           | Pemphigoid                        |                                                               |                                                                               |
| Hall F1   | Multidisciplinary approach and personalised treatment | Vasculitis and vasculopathies     |                                                               |                                                                               |
| Hall F2   | Emergencies in dermatology                            | Actinic keratosis                 |                                                               |                                                                               |
| Hall E1   | Imaging / AI in aesthetic dermatology                 | Emerging aesthetic technologies   |                                                               |                                                                               |
| Hall E2   | Cellulite and fat                                     | Peels                             | ESTP (European Society of Tattoo and Pigment research)        | Pan-Arab League of Dermatologists (PALD)                                      |
| Hall G    | Hair disorders                                        | Urticaria                         | European Society of Dermatopathology (ESDP)                   | Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) |
| Hall M    | Sclerotic skin diseases                               | Genital diseases                  | European Society for Dermatology and Psychiatry (ESDaP)       | European Society for Dermatology and Psychiatry (ESDaP)                       |
| Hall K    | Task force highlights                                 | Task force highlights             | Saudi Society of Dermatology and Dermatologic Surgery (SSDDS) | African and Tunisian Societies of Dermatology and Venereology                 |
| Hall N    | Clinical cases                                        | Clinical cases                    | International Eczema Council (IEC)                            | International Eczema Council (IEC)                                            |
| 1.61-1.62 | Laser treatment for beginners                         |                                   | Dealing with complications of aesthetic procedures            |                                                                               |
| 1.85-1.86 | Surgery: intermediate                                 |                                   | Diagnostic procedures in hair loss                            |                                                                               |



*Saturday, 3 October 2026*

Session type: **Plenary**

Room **Hall A**


**Plenary lectures C**

Chairs: Luca Borradori (Bern, Switzerland)  
Rolland Gyulai (Szeged, Hungary)

12:00 **RTF plenary lecture: Personalized treatment for skin IMIDs**  
Michel Gilliet (Lausanne, Switzerland)

12:20 **ESDR Plenary lecture: Genetic mechanisms in eczema: relevance to the patient and clinician**  
Sara Brown (Edinburgh, United Kingdom)

12:40 **The misfiring alarm: Lessons from fibromyalgia for stress-driven skin disease**  
Jose Antonio Pereira da Silva (Coimbra, Portugal)



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                      |
|-----------------|-------|------------------------------------------------------------------------------------------------------|
| <b>D4T01.1</b>  |       | <b>Understanding acne</b><br>Chairs: Clio Dessinioti (Athens, Greece)<br>Mauro Picardo (Rome, Italy) |
| <b>D4T01.1A</b> | 08:30 | <b>Acne beyond adolescence</b><br>Dae Hun Suh (Seoul, Korea, Rep. of South)                          |
| <b>D4T01.1B</b> | 08:50 | <b>Understanding severe acne forms</b><br>Clio Dessinioti (Athens, Greece)                           |
| <b>D4T01.1C</b> | 09:10 | <b>Acne-associated diseases</b><br>Mauro Picardo (Rome, Italy)                                       |
| <b>D4T01.1D</b> | 09:30 | <b>Novel outcome measures</b><br>Stefana Cretu (Bucharest, Romania)                                  |
| <b>D4T01.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                           |

Session type: **Updates**

Room **Hall A**

|                 |       |                                                                                                         |
|-----------------|-------|---------------------------------------------------------------------------------------------------------|
| <b>D4T01.2</b>  |       | <b>Treating acne</b><br>Chairs: Brigitte Dréno (Nantes, France)<br>Alison Layton (York, United Kingdom) |
| <b>D4T01.2A</b> | 10:15 | <b>Optimising combination therapy</b><br>Alexander Katoulis (Athens, Greece)                            |
| <b>D4T01.2B</b> | 10:35 | <b>Optimising isotretinoin use</b><br>Brigitte Dréno (Nantes, France)                                   |
| <b>D4T01.2C</b> | 10:55 | <b>What to do when isotretinoin fails</b><br>Alison Layton (York, United Kingdom)                       |
| <b>D4T01.2D</b> | 11:15 | <b>New and upcoming treatments</b><br>Christos C. Zouboulis (Dessau, Germany)                           |
| <b>D4T01.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                              |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                                       |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------|
| <b>D4T02.1</b>  |       | <b>Drug reactions</b><br>Chairs: Michael Arden-Jones (Southampton, United Kingdom)<br>Maja Mockenhaupt (Freiburg, Germany)            |
| <b>D4T02.1A</b> | 08:30 | <b>Danger signs in drug hypersensitivity – when to expect a severe reaction?</b><br>Michael Arden-Jones (Southampton, United Kingdom) |
| <b>D4T02.1B</b> | 08:50 | <b>What is new in severe cutaneous adverse reactions?</b><br>Maja Mockenhaupt (Freiburg, Germany)                                     |
| <b>D4T02.1C</b> | 09:10 | <b>Which are the critical drugs in dermatology?</b><br>Saskia Oro (Créteil, France)                                                   |
| <b>D4T02.1D</b> | 09:30 | <b>Current perspective of acute generalized exanthematous pustulosis (AGEP)</b><br>Chia-Yu Chu (Taipei, Taiwan)                       |
| <b>D4T02.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                            |

Session type: **Updates**

Room **Hall D**

|                 |       |                                                                                                                                         |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------|
| <b>D4T02.2</b>  |       | <b>Clinical-pathological correlation</b><br>Chairs: Lluís Puig (Barcelona, Spain)<br>Maria Teresa Fernández-Figueras (Barcelona, Spain) |
| <b>D4T02.2A</b> | 10:15 | <b>Psoriasiform lesions</b><br>Lluís Puig (Barcelona, Spain)                                                                            |
| <b>D4T02.2B</b> | 10:35 | <b>Pyoderma gangrenosum lesions</b><br>Malcolm Rustin (London, United Kingdom)                                                          |
| <b>D4T02.2C</b> | 10:55 | <b>Melanocytic proliferations</b><br>Hans Peter Soyer (Brisbane, Australia)                                                             |
| <b>D4T02.2D</b> | 11:15 | <b>Panniculitis-like lesions</b><br>Maria Teresa Fernández-Figueras (Barcelona, Spain)                                                  |
| <b>D4T02.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                                              |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                  |
|-----------------|-------|--------------------------------------------------------------------------------------------------|
| <b>D4T03.1</b>  |       | <b>Itch</b><br>Chairs: Laurent Misery (Brest, France)<br>Jacek C. Szepietowski (Wroclaw, Poland) |
| <b>D4T03.1A</b> | 08:30 | <b>Itch in the elderly</b><br>Juliette Bollemeijer (Rotterdam, Netherlands)                      |
| <b>D4T03.1B</b> | 08:50 | <b>Psychological factors</b><br>Laurent Misery (Brest, France)                                   |
| <b>D4T03.1C</b> | 09:10 | <b>Neuro-immune axis</b><br>Bernhard Homey (Düsseldorf, Germany)                                 |
| <b>D4T03.1D</b> | 09:30 | <b>Itch in malignancy</b><br>Jacek C. Szepietowski (Wroclaw, Poland)                             |
| <b>D4T03.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                       |

Session type: **Updates**

Room **Hall B**

|                 |       |                                                                                                             |
|-----------------|-------|-------------------------------------------------------------------------------------------------------------|
| <b>D4T03.2</b>  |       | <b>Chronic prurigo</b><br>Chairs: Sonja Ständer (Münster, Germany)<br>Margarida Gonçalo (Coimbra, Portugal) |
| <b>D4T03.2A</b> | 10:15 | <b>Definition and subtypes</b><br>Sonja Ständer (Münster, Germany)                                          |
| <b>D4T03.2B</b> | 10:35 | <b>Diagnostic workup and mimickers</b><br>Adam Reich (Rzeszów, Poland)                                      |
| <b>D4T03.2C</b> | 10:55 | <b>Treatment algorithm</b><br>Margarida Gonçalo (Coimbra, Portugal)                                         |
| <b>D4T03.2D</b> | 11:15 | <b>Upcoming therapies</b><br>Gil Yosipovitch (Miami, FL, United States)                                     |
| <b>D4T03.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                  |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                                                 |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------------------------|
| <b>D4T04.1</b>  |       | <b>Autoimmune bullous diseases</b><br>Chairs: Dédée Murrell (Sydney, Australia)<br>Pascal Joly (Rouen, France)                  |
| <b>D4T04.1A</b> | 08:30 | <b>Novel developments in the diagnosis of autoimmune blistering diseases</b><br>Enno Schmidt (Lübeck, Germany)                  |
| <b>D4T04.1B</b> | 08:50 | <b>Ocular involvement in autoimmune bullous diseases</b><br>Marta Kurzeja (Warsaw, Poland)                                      |
| <b>D4T04.1C</b> | 09:10 | <b>Autoimmune bullous diseases in children</b><br>Dédée Murrell (Sydney, Australia)                                             |
| <b>D4T04.1D</b> | 09:30 | <b>Biological drugs and JAK inhibitors in autoimmune bullous diseases. What is the evidence?</b><br>Pascal Joly (Rouen, France) |
| <b>D4T04.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                      |

Session type: **Updates**

Room **Hall C**

|                 |       |                                                                                                       |
|-----------------|-------|-------------------------------------------------------------------------------------------------------|
| <b>D4T04.2</b>  |       | <b>Pemphigoid</b><br>Chairs: Branka Marinovic (Zagreb, Croatia)<br>Luca Borradori (Bern, Switzerland) |
| <b>D4T04.2A</b> | 10:15 | <b>Pemphigoid subtypes</b><br>Branka Marinovic (Zagreb, Croatia)                                      |
| <b>D4T04.2B</b> | 10:35 | <b>Management of pemphigoid</b><br>Luca Borradori (Bern, Switzerland)                                 |
| <b>D4T04.2C</b> | 10:55 | <b>Pemphigoid and comorbidities</b><br>Barbara Horvath (Groningen, Netherlands)                       |
| <b>D4T04.2D</b> | 11:15 | <b>Monitoring, relapse prevention, and long-term outcomes</b><br>Nina van Beek (Lübeck, Germany)      |
| <b>D4T04.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                            |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                                                              |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>D4T05.1</b>  |       | <b>Multidisciplinary approach and personalised treatment</b><br>Chairs: Pavel Chernyshov (Kyiv, Ukraine)<br>Catherine van Montfrans (Rotterdam, Netherlands) |
| <b>D4T05.1A</b> | 08:30 | <b>Multimodal approaches to psoriasis</b><br>Maria-Angeliki Gkini (London, United Kingdom)                                                                   |
| <b>D4T05.1B</b> | 08:50 | <b>Motivational interviewing in daily practice</b><br>Catherine van Montfrans (Rotterdam, Netherlands)                                                       |
| <b>D4T05.1C</b> | 09:10 | <b>Methods to improve the quality of life in dermatologic patients</b><br>Pavel Chernyshov (Kyiv, Ukraine)                                                   |
| <b>D4T05.1D</b> | 09:30 | <b>Precision dermatology in skin cancer</b><br>Yevgeniy Semenov (Boston, United States)                                                                      |
| <b>D4T05.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                                                                   |

Session type: **Updates**

Room **Hall F1**

|                 |       |                                                                                                                      |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------------|
| <b>D4T05.2</b>  |       | <b>Vasculitis and vasculopathies</b><br>Chairs: Karoline Krause (Berlin, Germany)<br>Erkan Alpsoy (Antalya, Türkiye) |
| <b>D4T05.2A</b> | 10:15 | <b>Urticarial Vasculitis</b><br>Karoline Krause (Berlin, Germany)                                                    |
| <b>D4T05.2B</b> | 10:35 | <b>ANCA-associated vasculitides</b><br>Marie Jachiet (Paris, France)                                                 |
| <b>D4T05.2C</b> | 10:55 | <b>Novel approaches to the treatment of small vessel vasculitis</b><br>Erkan Alpsoy (Antalya, Türkiye)               |
| <b>D4T05.2D</b> | 11:15 | <b>Vasculopathies</b><br>Angelo Valerio Marzano (Milan, Italy)                                                       |
| <b>D4T05.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                           |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                        |
|-----------------|-------|------------------------------------------------------------------------------------------------------------------------|
| <b>D4T06.1</b>  |       | <b>Emergencies in dermatology</b><br>Chairs: Gudrun Ratzinger (Innsbruck, Austria)<br>Olivier Chosidow (Paris, France) |
| <b>D4T06.1A</b> | 08:30 | <b>Toxic epidermal necrolysis/SJS</b><br>Riichiro Abe (Niigata, Japan)                                                 |
| <b>D4T06.1B</b> | 08:50 | <b>Fever and purpura</b><br>Gudrun Ratzinger (Innsbruck, Austria)                                                      |
| <b>D4T06.1C</b> | 09:10 | <b>Soft tissue infections</b><br>Olivier Chosidow (Paris, France)                                                      |
| <b>D4T06.1D</b> | 09:30 | <b>Erythroderma in a neonate</b><br>Zsuzsanna Szalai (Budapest, Hungary)                                               |
| <b>D4T06.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                             |

Session type: **Updates**

Room **Hall F2**

|                 |       |                                                                                                                |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------|
| <b>D4T06.2</b>  |       | <b>Actinic keratosis</b><br>Chairs: Iris Zalaudek (Trieste, Italy)<br>Petr Arenberger (Prague, Czech Republic) |
| <b>D4T06.2A</b> | 10:15 | <b>The journey from keratinocytes to carcinoma</b><br>Iris Zalaudek (Trieste, Italy)                           |
| <b>D4T06.2B</b> | 10:35 | <b>Primary and secondary prevention</b><br>Yolanda Gilaberte Calzada (Zaragoza, Spain)                         |
| <b>D4T06.2C</b> | 10:55 | <b>Non-invasive diagnostic modalities</b><br>Mariano Suppa (Brussels, Belgium)                                 |
| <b>D4T06.2D</b> | 11:15 | <b>Management and treatment</b><br>Petr Arenberger (Prague, Czech Republic)                                    |
| <b>D4T06.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                     |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                          |
|-----------------|-------|----------------------------------------------------------------------------------------------------------|
| <b>D4T07.1</b>  |       | <b>Imaging / AI in aesthetic dermatology</b><br>Chair: Peter Velthuis (Rotterdam, Netherlands)           |
| <b>D4T07.1A</b> | 08:30 | <b>Ultrasound imaging for injectables</b><br>Peter Velthuis (Rotterdam, Netherlands)                     |
| <b>D4T07.1B</b> | 08:50 | <b>Ultrasound for management of injectable complications</b><br>Claudia Gonzalez Diaz (Bogota, Colombia) |
| <b>D4T07.1C</b> | 09:10 | <b>Imaging devices in aesthetic dermatology</b><br>Merete Haedersdal (Copenhagen, Denmark)               |
| <b>D4T07.1D</b> | 09:30 | <b>AI in aesthetic dermatology</b><br>Diala Haykal (Palaiseau, France)                                   |
| <b>D4T07.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                               |

Session type: **Updates**

Room **Hall E1**

|                 |       |                                                                                                     |
|-----------------|-------|-----------------------------------------------------------------------------------------------------|
| <b>D4T07.2</b>  |       | <b>Emerging aesthetic technologies</b><br>Chair: Ines Verner Rashkovsky (Savyon, Israel)            |
| <b>D4T07.2A</b> | 10:15 | <b>Emerging laser technologies</b><br>Tillemachos Anthopoulos (Athens, Greece)                      |
| <b>D4T07.2B</b> | 10:35 | <b>Emerging toxins</b><br>Hugues Cartier (Arras, France)                                            |
| <b>D4T07.2C</b> | 10:55 | <b>Emerging biostimulators</b><br>Hassan Galadari (Dubai, United Arab Emirates)                     |
| <b>D4T07.2D</b> | 11:15 | <b>Emerging body tightening and lipolysis devices</b><br>Luigi Leonardo Polla (Geneva, Switzerland) |
| <b>D4T07.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                          |



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                                       |
|-----------------|-------|-----------------------------------------------------------------------------------------------------------------------|
| <b>D4T08.1</b>  |       | <b>Cellulite and fat</b><br>Chair: Ioannis Peros (Zurich, Switzerland)                                                |
| <b>D4T08.1A</b> | 08:30 | <b>Cellulite: What is it, why is it &amp; how is it prevented and treated?</b><br>Ioannis Peros (Zurich, Switzerland) |
| <b>D4T08.1B</b> | 08:50 | <b>Medical fat reduction: diet &amp; GLP-1 agonists</b><br>Filiz Cebeci (Istanbul, Türkiye)                           |
| <b>D4T08.1C</b> | 09:10 | <b>Injection lipolysis and EBD</b><br>Klaus Fritz (Landau, Germany)                                                   |
| <b>D4T08.1D</b> | 09:30 | <b>Tumescent anaesthesia, liposuction &amp; lipotransfer</b><br>Louis Habbema (Amsterdam, Netherlands)                |
| <b>D4T08.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                            |

Session type: **Updates**

Room **Hall E2**

|                 |       |                                                                                                  |
|-----------------|-------|--------------------------------------------------------------------------------------------------|
| <b>D4T08.2</b>  |       | <b>Peels</b><br>Chair: Marina Landau (Herzlia, Israel)                                           |
| <b>D4T08.2A</b> | 10:15 | <b>Chemical peels from A to Z</b><br>Fotini Bageorgou (Athens, Greece)                           |
| <b>D4T08.2B</b> | 10:35 | <b>Chemical peeling for medical indications</b><br>Monika Arenbergerova (Prague, Czech Republic) |
| <b>D4T08.2C</b> | 10:55 | <b>Superficial peels for acne and melasma</b><br>Chytra V. Anand (Bangalore, India)              |
| <b>D4T08.2D</b> | 11:15 | <b>Deep peels: what we should know</b><br>Marina Landau (Herzlia, Israel)                        |
| <b>D4T08.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                       |



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall E2**

**ESTP (European Society of Tattoo and Pigment research)**

Chairs: Christa de Cuyper (Bruges, Belgium)  
Ines Schreiber (Berlin, Germany)  
Katrina Hutton Carlsen (Copenhagen, Denmark)

14:15 **Tattoo complications: the clinic**  
Christa de Cuyper (Bruges, Belgium)

14:35 **Itchy reds and other tattoo complications: how to find the cause of persistent health risks for a colourful future**  
Ines Schreiber (Berlin, Germany)

14:50 **Tattoo complications requiring surgery**  
Katrina Hutton Carlsen (Copenhagen, Denmark)

15:05 **MRI & tattoos – From myths to clinical insight**  
Kasper Alsing (Copenhagen, Denmark)

15:20 **The chemistry behind modern tattoo inks – From raw materials to finished formulation**  
Michael Dirks (Ludersdorf-Wilfersdorf, Austria)

15:35 **Conclusion**  
Ines Schreiber (Berlin, Germany)



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall E2**

**Pan-Arab League of Dermatologists (PALD)**

Chairs: Gamal Elduweb (Benghazi, Libya)  
Samira Zobiri (Algiers, Algeria)  
Mohamed Bengazil (Tripoli, Libya)

16:00 **Clinical cases from Syria: diagnostic challenges**  
Fouz Hassan (Latakia, Syria, Arab Rep.)

16:09 **Nail pigmentation between benign to malignant spectrum**  
Mohamed El-Khalawany (Cairo, Egypt)

16:18 **Psoriasis: endotypes and biomarkers**  
Ibrahim Almukahhal (Benghazi, Libya)

16:27 **Efficacy and safety of the 577 nm pro-yellow laser in the treatment of steroid-induced rosacea**  
Muhsin Al Dhalimi (Najaf, Iraq)

16:36 **NAD + and the aging skin: where immunity meets longevity**  
Heba Saeed Mohamed Adly Abdelrazek (Charbia, Egypt)

16:45 **Cannabinoids in dermatology**  
Siham Dikhaie (OUJDA, Morocco)

16:54 **Dermoscopy in daily practice: challenging cases**  
Hakim Hammadi (Algiers, Algeria)

17:03 **Biology of ageing**  
Hassan Galadari (Dubai, United Arab Emirates)

17:12 **Atypical papular mucinosis with thyroid cancer: comparison of isotretinoin and erbium:YAG laser treatment**  
Bana Aburajab (Hebron, Palestine)

17:21 **Management of non-melanoma skin cancers: evidence-based updates**  
Tarik Enaairi (Misrata, Libya)



**Saturday, 3 October 2026**

Session type: **Training and education**

Room **Hall G**

|                 |       |                                                                                                                    |
|-----------------|-------|--------------------------------------------------------------------------------------------------------------------|
| <b>D4T09.1</b>  |       | <b>Hair disorders</b><br>Chairs: Bianca Maria Piraccini (Bologna, Italy)<br>David Saceda-Corralo (Madrid, Spain)   |
| <b>D4T09.1A</b> | 08:30 | <b>Diagnostic methods in hair loss</b><br>Bianca Maria Piraccini (Bologna, Italy)                                  |
| <b>D4T09.1B</b> | 08:50 | <b>Non-cicatricial alopecia. Case-based learning.</b><br>Ulrike Blume-Peytavi (Berlin, Germany)                    |
| <b>D4T09.1C</b> | 09:10 | <b>Cicatricial alopecia. Case-based learning.</b><br>Adriana Rakowska (Warsaw, Poland)                             |
| <b>D4T09.1D</b> | 09:30 | <b>Non-pharmacologic treatment in hair diseases. What is the evidence?</b><br>David Saceda-Corralo (Madrid, Spain) |
| <b>D4T09.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                         |

Session type: **Training and education**

Room **Hall G**

|                 |       |                                                                                                   |
|-----------------|-------|---------------------------------------------------------------------------------------------------|
| <b>D4T09.1</b>  |       | <b>Urticaria</b><br>Chairs: Emek Kocatürk (Istanbul, Türkiye)<br>Manuel Pereira (Berlin, Germany) |
| <b>D4T09.2A</b> | 10:15 | <b>Classification</b><br>Anna Zalewska-Janowska (Lodz, Poland)                                    |
| <b>D4T09.2B</b> | 10:35 | <b>Diagnostic workup</b><br>Ana Maria Giménez-Arnau (Barcelona, Spain)                            |
| <b>D4T09.2C</b> | 10:55 | <b>Mimickers of urticaria</b><br>Emek Kocatürk (Istanbul, Türkiye)                                |
| <b>D4T09.2D</b> | 11:15 | <b>Treatment: now and future</b><br>Manuel Pereira (Berlin, Germany)                              |
| <b>D4T09.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                        |



*Saturday, 3 October 2026*

Session type: **Subspecialty**

Room **Hall G**

**European Society of Dermatopathology (ESDP)**

Chairs: Carlo Francesco Tomasini (Pavia, Italy)  
Gürkan Kaya (Geneva, Switzerland)

14:15 **Welcome**


14:20 **European Society of Dermatopathology**  
Gürkan Kaya (Geneva, Switzerland)

14:30 **European Diploma of Dermatopathology**  
Carlo Francesco Tomasini (Pavia, Italy)

14:40 **Test yourself - Dermatopathology quiz**  
Carlo Francesco Tomasini (Pavia, Italy)

15:10 **Test yourself - Dermatopathology quiz**  
Gürkan Kaya (Geneva, Switzerland)

15:40 **Discussion – Concluding remarks**



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall G**

**Indian Association of Dermatologists, Venereologists and Leprologists (IADVL)**

Chairs: Vinay Singh (India)  
Shital Poojary (Mumbai, India)

16:00 **Picosecond lasers in Indian skin: beyond the hype - Four years of Real-World Experience (Clinical insights into wavelength selection 532/785/1064, indications, combination therapies, safety, outcomes, and cost-effectiveness in Fitzpatrick IV–V skin)**  
Punit Saraogi (Mumbai, India)

16:08 **Recent advances in the management of psoriasis - An Indian perspective**  
Abhishek De (Kolkata, India)

16:15 **Assessing vitiligo stability: integrating clinical evaluation, immunohistochemistry and cytokine profiling**  
Pranavi Katike (Hyderabad, India)

16:22 **A study on the blood mRNA expression of specific inflammatory cytokines in Atopic Dermatitis**  
Fida Anjum (Mangalore, India)

16:30 **Managing pigmentation - 2026 the way forward**  
Mukta Sachdev (Bangalore, India)

16:37 **Beyond the skin: facial pigmentation through the lens of psychodermatology**  
Anupam Das (Kolkata, West Bengal, India)

16:45 **Social media dermatology: how Instagram is changing acne care and management**  
Shashank Bhargava (Ujjain, India)

16:52 **Decoding skin longevity: senolytics to epigenetic reprogramming**  
Hardik Pitroda (Ahmedabad, India)

17:00 **Tiny molecules, big impact**  
Priyanka Magia (Nagpur, India)

17:07 **Topical drug delivery system**  
Khushboo Gupta (Jaipur, India)

17:15 **Next-generation therapeutics for facial hyperpigmentation: novel topicals, systemics, and nano-formulations**  
Shraddha Ingole (Nagpur, India)

17:22 **Post-acne hyperpigmentation**  
Kiran Vasant Godse (Navi Mumbai, India)



**Saturday, 3 October 2026**

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                                |
|-----------------|-------|----------------------------------------------------------------------------------------------------------------|
| <b>D4T10.1</b>  |       | <b>Sclerotic skin diseases</b><br>Chairs: Thomas Krieg (Cologne, Germany)<br>Franco Rongioletti (Milan, Italy) |
| <b>D4T10.1A</b> | 08:30 | <b>Morphea (localized scleroderma)</b><br>Hirotsugu Oda (Lübeck, Germany)                                      |
| <b>D4T10.1B</b> | 08:50 | <b>Systemic sclerosis</b><br>Thomas Krieg (Cologne, Germany)                                                   |
| <b>D4T10.1C</b> | 09:10 | <b>Scleredema and scleremyxedema</b><br>Franco Rongioletti (Milan, Italy)                                      |
| <b>D4T10.1D</b> | 09:30 | <b>Overlap syndromes</b><br>Marija Geroldinger-Simic (Krems, Austria)                                          |
| <b>D4T10.1E</b> | 09:50 | <b>Discussion, Q&amp;A</b>                                                                                     |

Session type: **Updates**

Room **Hall M**

|                 |       |                                                                                                               |
|-----------------|-------|---------------------------------------------------------------------------------------------------------------|
| <b>D4T10.2</b>  |       | <b>Genital diseases</b><br>Chairs: Arne Vikström (Stockholm, Sweden)<br>Carmen Lisboa Silva (Porto, Portugal) |
| <b>D4T10.2A</b> | 10:15 | <b>Urethritis</b><br>George Sorin Tiplica (Bucharest, Romania)                                                |
| <b>D4T10.2B</b> | 10:35 | <b>HPV associated genital diseases</b><br>Arne Vikström (Stockholm, Sweden)                                   |
| <b>D4T10.2C</b> | 10:55 | <b>Vulvovaginal infections</b><br>Carmen Lisboa Silva (Porto, Portugal)                                       |
| <b>D4T10.2D</b> | 11:15 | <b>Lichen sclerosus</b><br>Christopher Barry Bunker (London, United Kingdom)                                  |
| <b>D4T10.2E</b> | 11:35 | <b>Discussion, Q&amp;A</b>                                                                                    |



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall M**

**European Society for Dermatology and Psychiatry (ESDaP)**

Chairs: Laurent Misery (Brest, France)  
Francesca Sampogna (Rome, Italy)  
Marta García Bustínduy (Tenerife, Spain)

14:15 **Topical steroid withdrawal: where are we now?**  
Maria-Angeliki Gkini (London, United Kingdom)

14:26 **Vitiligo - visible on the skin - bothering life**  
Uwe Gieler (Giessen, Germany)

14:37 **Tattooing as paradigmatic technique for constituting identity and its implications for psychodermatology**  
Ulla Schmid (Basel, Switzerland)

14:48 **Psychodermatology of women**  
Mohammad Jafferany (Saginaw, United States)

14:59 **Psychodermatology in the aging patient: from diagnosis to management**  
Ayberk Aktaran (Istanbul, Türkiye)  
Ilknur Altunay (Istanbul, Türkiye)

15:10 **Body dysmorphic disorder and illness acceptance in relation to body modifications in patients with chronic dermatoses**  
Justyna Putek (Wrocław, Poland)  
Jacek C. Szepietowski (Wroclaw, Poland)

15:21 **How is narcissistic personality disorder related to aesthetic dermatology care and body dysmorphic disorder?**  
Eszter Szlavicz (Pécs, Hungary)

15:32 **Nail appearance anxiety as an underrecognized psychocutaneous phenomenon: a cross-sectional study**  
Vitaliia Popovych (Uzhhorod, Ukraine)



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall M**

**European Society for Dermatology and Psychiatry (ESDaP)**

Chairs: Laurent Misery (Brest, France)  
Francesca Sampogna (Rome, Italy)  
Marta García Bustínduy (Tenerife, Spain)

16:00 **Psychiatric morbidity and unmet mental health needs after melanoma diagnosis**  
Piotr Krajewski (Wrocław, Poland)

16:11 **Sleep quality and stress in hidradenitis suppurativa patients**  
Marta García Bustínduy (Tenerife, Spain)  
Vania Alexandra Lukoviek Araya (San Cristóbal de La Laguna, Spain)  
Jezabel Bravo-Medina / (Spain)

16:22 **Comorbidities in acne and possible interactions with itching formation**  
Elizaveta Sidorenko (Rostov-on-Don, Russian Federation)  
Andrei Lvov / (Moscow, Russian Federation)

16:33 **Painful black tongue- when topical therapy is not sufficient**  
Razvigor Darlenski (Sofia, Bulgaria)

16:44 **The role of stress in occupational dermatology**  
Maurice Waitek (Heidelberg, Germany)  
Elke Weisshaar (Heidelberg, Germany)

16:55 **The skin that speaks when pain cannot: a childhood case of congenital insensitivity to pain with anhidrosis (CIPA)**  
Lamyaa Elmubarak (Abu Dhabi, United Arab Emirates)

17:06 **Neuromodulation in psychodermatology**  
Haiping Zhang (Beijing, China)

17:15 **Q&A**



**Saturday, 3 October 2026**

Session type: **Miscellaneous**

Room **Hall K**

|          |       |                                                                                                                                         |
|----------|-------|-----------------------------------------------------------------------------------------------------------------------------------------|
| D4T11.1  |       | <b>Task force highlights</b><br>Chairs: Arne Vikström (Stockholm, Sweden)<br>Torsten Zuberbier (Berlin, Germany)                        |
| D4T11.1A | 08:30 | <b>The enigma of the genital HPV-infections in the paediatric and adolescent age</b><br>Mihael Skerlev (Zagreb, Croatia)                |
| D4T11.1B | 08:44 | <b>HPV and malignancies beyond „standard“</b><br>Arne Vikström (Stockholm, Sweden)                                                      |
| D4T11.1C | 08:58 | <b>HPV and the anal lesions: a novel approach and the utmost significance of dermatology</b><br>Alexander Kreuter (Oberhausen, Germany) |
| D4T11.1D | 09:12 | <b>Update on urticaria guidelines: what changed, what remained?</b><br>Torsten Zuberbier (Berlin, Germany)                              |
| D4T11.1E | 09:26 | <b>Is pediatric urticaria same as adult urticaria?</b><br>Pavel Kolkhir (Berlin, Germany)                                               |
| D4T11.1F | 09:40 | <b>Endotypes of urticaria and the role of precision medicine</b><br>Emek Kocatürk (Istanbul, Türkiye)                                   |
| D4T11.1G | 09:54 | <b>Discussion, Q&amp;A</b>                                                                                                              |

Session type: **Miscellaneous**

Room **Hall K**

|          |       |                                                                                                           |
|----------|-------|-----------------------------------------------------------------------------------------------------------|
| D4T11.2  |       | <b>Task force highlights</b><br>Chairs: Enno Schmidt (Lübeck, Germany)<br>Dirk Van Gysel (Aalst, Belgium) |
| D4T11.2A | 10:15 | <b>Future trends in the therapy of pemphigus</b><br>Enno Schmidt (Lübeck, Germany)                        |
| D4T11.2B | 10:29 | <b>Bullous pemphigoid and combined targeted treatments</b><br>Aikaterini Patsatsi (Thessaloniki, Greece)  |
| D4T11.2C | 10:43 | <b>What we need for the diagnosis of mucous membrane pemphigoid</b><br>Emiliano Antiga (Florence, Italy)  |
| D4T11.2D | 10:57 | <b>News in pediatric dermoscopy</b><br>Vincenzo Piccolo (Naples, Italy)                                   |
| D4T11.2E | 11:11 | <b>What's new in vascular anomalies</b><br>Dirk Van Gysel (Aalst, Belgium)                                |
| D4T11.2F | 11:25 | <b>Update on alopecia areata in children</b><br>Ramon Grimalt (Barcelona, Spain)                          |
| D4T11.2G | 11:39 | <b>Discussion, Q&amp;A</b>                                                                                |



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall K**

**Saudi Society of Dermatology and Dermatologic Surgery (SSDDS)**

Chairs: Abdullah Alakeel (Riyadh, Saudi Arabia)  
Maysa Tariq Eshmawi (Jeddah, Saudi Arabia)  
Dana Alessa (Saudi Arabia)

14:15 **Complex medical dermatology; 20 years evolution**  
Yousef Binamer (Riyadh, Saudi Arabia)

14:28 **Laser therapy for resistant pigmentary disorders**  
Abdulmajeed Alajlan (Riyadh, Saudi Arabia)

14:41 **Pediatric vascular anomalies: diagnostic and therapeutic pearls from Boston Children's Hospital**  
Nujood Alzahrani (Saudi Arabia)

14:54 **Skin longevity; parameters to consider when approaching a patient**  
Lama Altawil (Riyadh, Saudi Arabia)

15:07 **Alopecia areata Saudi consensus**  
Ruaa Al Harithy (Riyadh, Saudi Arabia)

15:20 **Mastering facial vascular laser: a practical guide for clinicians**  
Ahmed Alissa (Riyadh, Saudi Arabia)

15:33 **How we treat vitiligo in 2026: evidence-based and emerging therapies**  
Mohammed Alqahtani (Jeddah, Saudi Arabia)

15:40 **Q&A**



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall K**

**African Society of Dermatology and Venereology / Tunisian Society of Dermatology and Venereology**

Chairs: Moez Ben Salem (HammamLif, Tunisia)  
Fatimata Ly (Senegal)  
Asmahane Souissi (Chazela Ariana, Tunisia)

16:00 **New entities in vascular anomalies and their treatments**  
Aicha Salhi (Tizi Ouzou, Algeria)

16:10 **Clinical, dermoscopic and histological aspects of exogenous ochronosis**  
Kayitesi Kayitenkore (KIGALI, Rwanda)

16:20 **Capillaroscopy in black skin**  
Fatimata Ly (Senegal)

16:30 **PLLA versus PDLLA: when polymer chemistry shapes clinical outcomes**  
Ayda Khaled (Tunisia)

16:40 **LED biomodulation in the treatment of acute shingles**  
Soumiya Chiheb (Casablanca, Morocco)

16:50 **Laser and energy based devices for treatment of female pattern hair loss**  
Moataz Nosseir (Cairo, Egypt)

17:00 **Hyperhidrosis, botox vs surgery**  
Moez Ben Salem (HammamLif, Tunisia)

17:10 **Beyond the usual: challenging trichoscopy cases**  
Nadia Gharani (Tunisia)  
Meriem Mhiri / (Sousse, Tunisia)

17:20 **Q&A**



**Saturday, 3 October 2026**

Session type: **Clinical cases**

Room **Hall N**

|          |       |                                                                                                                                                                                                                                  |
|----------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4T12.1  |       | <b>Clinical cases</b><br>Chairs: Leticia Szadai (Szeged, Hungary)<br>Matthias Schmuth (Innsbruck, Austria)                                                                                                                       |
| D4T12.1A | 08:30 | <b>Same Look, Different Story: Differential Diagnosis in Mimicking Disorders</b><br>Anil Bhokare (Malegaon, India)                                                                                                               |
| D4T12.1B | 08:40 | <b>Transient emergence of peripheral globules in melanocytic nevi under melanocyte-stimulating hormone drive: report of two cases — pregnancy and intense sun exposure</b><br>Thais Bello di Giacomo (Sao Paulo, Brazil)         |
| D4T12.1C | 08:50 | <b>Delayed Inflammatory Reaction to Hyaluronic Acid Fillers Triggered by Dupilumab: A Novel Case Report Suggesting an Immune-Mediated Mechanism</b><br>Abdullah Almeziny (Riyadh, Saudi Arabia)                                  |
| D4T12.1D | 09:00 | <b>Utilizing Margin Control for a Technically Challenging Melanoma in Situ Case of an Acral Surface</b><br>Dimitra Xenopoulou (Brooklyn, United States)                                                                          |
| D4T12.1E | 09:10 | <b>Acute Bullous Iododerma with Cryptococcoid Neutrophilic Dermatitis</b><br>Helen-Yiwen Li (Decatur, United States)                                                                                                             |
| D4T12.1F | 09:20 | <b>Cutaneous extramedullary hematopoiesis: a rare diagnostic challenge in advanced myelofibrosis</b><br>Assia El Bouhmadi (Casablanca, Morocco)                                                                                  |
| D4T12.1G | 09:30 | <b>Feasibility and Safety of Surgical Excision in Patients with Hidradenitis Suppurativa and High Risk of Post-operative Complications: A Case Series and Review of the Literature</b><br>Emma Brogaard (Copenhagen NV, Denmark) |
| D4T12.1H | 09:40 | <b>GLP-1 agonist as an adjunct therapy in benign familial chronic pemphigus (Hailey–Hailey disease)</b><br>Christian Puttinger (Salzburg, Austria)                                                                               |
| D4T12.1I | 09:50 | <b>A novel mucocutaneous syndrome associated with homozygous ZNF750 frameshift mutation</b><br>Ibrahim Akcay (Izmir, Türkiye)                                                                                                    |

**Saturday, 3 October 2026**



Session type: **Clinical cases**

Room **Hall N**

|          |       |                                                                                                                                                                                                                    |
|----------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| D4T12.2  |       | <b>Clinical cases</b><br>Chairs: Aikaterini I. Liakou (Athens, Greece)<br>Dagmar Simon (Bern, Switzerland)                                                                                                         |
| D4T12.2A | 10:15 | <b>The impact of unconscious bias in diagnosing hair disorders: the role of trichoscopy and clinicopathological correlation</b><br>Salwa Owasil (United Kingdom)                                                   |
| D4T12.2B | 10:25 | <b>Self mutilating behavior in a 2 year old girl unveiling the diagnosis of a rare entity- MiTES</b><br>Fida Anjum (Mangalore, India)                                                                              |
| D4T12.2C | 10:35 | <b>Dual IL-17A/F and BTK Inhibition in Refractory Hidradenitis Suppurativa: A Case Report</b><br>Maneli Doroudian Tehrani (Boston, United States)                                                                  |
| D4T12.2D | 10:45 | <b>Acneiform eruption induced by gefitinib in EGFR-mutated lung squamous cell carcinoma: successful management with doxycycline and topical therapy</b><br>Julia Cascardo Géo de Siqueira (Rio de Janeiro, Brazil) |
| D4T12.2E | 10:55 | <b>A case of type III hereditary angioedema with a MYOF variant of uncertain significance successfully treated with omalizumab</b><br>Qiying Zhang (Jinhua, China)                                                 |
| D4T12.2F | 11:05 | <b>Misdiagnosed Temporal Triangular Alopecia as Alopecia Areata Delaying Hair Transplantation: A Diagnostic Pitfall with Therapeutic Implications</b><br>Ana Lígia Scotti Alérico (Santos, Brazil)                 |
| D4T12.2G | 11:15 | <b>Atypical hand-foot-mouth disease in a pediatric patient: the importance of early recognition.</b><br>Elisandra Barbara Pontes Carlos (Botucatu, Brazil)                                                         |
| D4T12.2H | 11:25 | <b>The First Documented Case of Depigmented Fixed Food Eruption</b><br>Lam Quang Nguyen (Ho Chi Minh, Viet Nam)                                                                                                    |
| D4T12.2I | 11:35 | <b>Symptom Relief and Disease Stabilization with Roflumilast Foam in LPP Spectrum Disorders: A Case Series</b><br>Wei Jing Loo (London, Canada)                                                                    |



**Saturday, 3 October 2026**

Session type: **Subspecialty**

Room **Hall N**

**International Eczema Council (IEC): The relevance of clinical trials and Real-World Data**

Chairs: Thomas Bieber (Feldafing, Germany)  
Kenji Kabashima (Kyoto, Japan)

14:15 **Welcome from the IEC**  
Alan Irvine (Dublin, Ireland)

14:25 **Programme overview**

***Part 1: Clinical trials: what have we learned?***

14:30 **From protocol to patient: mastering the logistics of clinical trial setup**  
Robert Bissonnette (Montreal, Canada)

14:45 **Designing late-phase trials**  
Andrew Blauvelt (Annapolis, Maryland, United States)

15:00 **Children first? The complex reality of paediatric trials in Atopic Dermatitis**  
Alan Irvine (Dublin, Ireland)

***Part 2: Real-World Data: effectiveness, safety, and treatment patterns***

15:15 **From cytokine circuits to clinical outcomes: how clinical trials have redefined Atopic Dermatitis**  
Kenji Kabashima (Kyoto, Japan)

15:30 **Q&A**

Session type: **Subspecialty**

Room **Hall N**

**International Eczema Council (IEC): The relevance of clinical trials and Real-World Data**

Chairs: Thomas Bieber (Feldafing, Germany)  
Kenji Kabashima (Kyoto, Japan)

***Part 3: Bridging trials and Real-World Evidence***

16:00 **Drawback of clinical decision making based on clinical trial data and challenges of RWE**  
Marjolein de Bruin-Weller (Utrecht, Netherlands)

16:30 **The long and challenging way to “regulatory grade” data in registries and Real-World Evidence**  
Thomas Bieber (Feldafing, Germany)

17:00 **Q&A**

17:20 **Programme summary and concluding remarks**




## Practical workshops

All workshops require pre-registration and pre-payment. Class sizes are limited, and registrants are accepted on a first-paid, first-served basis. More info [here](#)

**References to brands:** Commercial names of medical devices/software/equipment may appear in this content because they are linked to specific medical procedures, which are the focus of this training material. Other products in the market can be used to perform the aforementioned medical procedures. The educational provider does not endorse any particular product.


### Wednesday, 30 September 2026



#### STI diagnosis and treatment

**Chair:** Georg Stary (AT)

**Instructors:** Valeska Padovese (IT), Gemma Martin Ezquerro (ES), Simona Saluzzo (AT)



#### Allergology: Skin environmental induced contact dermatitis and urticaria

**Chair:** Ana Maria Gimenez Arnau (ES)

**Instructors:** Sabine Altrichter (AT), Mette Sommerlund (DK)



#### Dermal Fillers

**Chair:** Bertrand Richert (BE)

**Instructors:** Pauline Lecerf (BE), Elena Rossi (IT)



#### Basics of ultrasound imaging in dermatology

**Chair:** Hugues Cartier (FR)

**Instructors:** Ximena Wortsman (CL), Peter Velthuis (NL), Diana Crisan (DE), Audrey Melin (FR), Antonio Martorell Calatayud (ES)

### Thursday, 1 October 2026



#### Playing with AI in dermatology

**Chair:** Harald Kittler (AT)

**Instructors:** Alexander Navarini (CH), Philipp Tschandl (AT)



#### Dermoscopy – Happy hour live \*

**Chair:** Giuseppe Argenziano (IT)

**Instructors:** Aimilios Lallas (GR), Gabriella Brancaccio (IT), Michela Starace (IT)

\* This workshop will be available at two different times on the same day



#### Wound healing

**Chair:** Elena Conde Montero (ES)

**Instructors:** Kirsi Isoherranen (FI), George Sorin Tiplica (RO), Damien Pastor (CH)




## Friday, 2 October 2026



### Use of Botulinum Toxin in cosmetic and medical dermatology

**Chair:** Samira Baharlou (BE)


**Instructors:** Armanda Onderdijk (NL), Sanjay Rajpara (UK)



### Phlebology for beginners

**Chair:** Felizitas Pannier (DE)

**Instructors:** Liselot Vink (NL), Laura Fischer (DE), Eberhard Rabe (DE)



### Confocal Microscopy and LC-OCT

**Chairs:** Salvador González (ES), Mariano Suppa (BE), Marco Ardigò (IT), Elisa Cinotti (IT), Linda Tognetti (IT)

**Instructors:** Mario Valenti (IT), Lucas Boussingault (BE)



### Surgery – Beginners

**Chair:** Victoria Marmgren (SE)

**Instructors:** Marcus Muche (NL), Frida Appelqvist (SE), Stephanie Steeman (NL)


## Saturday, 3 October 2026



### Laser treatment for beginners

**Chair:** Albert Wolkerstorfer (NL)


**Instructors:** Pablo Boixeda (ES), Keyvan Nouri (US)



### Surgery - Intermediate

**Chair:** Victoria Marmgren (SE)


**Instructors:** Marcus Muche (NL), Frida Appelqvist (SE), Stephanie Steeman (NL)



### Dealing with Complications of Aesthetic Procedures

**Chair:** Monika Fida (AL)

**Instructors:** Hasan Galadari (AE), Elena Rossi (IT), Brunilda Bardhi (AL)



### Diagnostic procedures in hair loss

**Chair:** Matilde Iorizzo (CH)

**Instructors:** Michela Starace (IT), Daniel Asz Sigall (MX), Daniel Fernandes Melo (BR)



## Patient organisations area

EADV actively works to develop a synergic action between the patient community and key healthcare providers.

We invite all Congress attendees to visit the **Patient Organisations Area** taking place from 30 September to 2 October 2026 in **Foyer D, Level -2** of the Austria Center Vienna.

The Patient Organisation Area serves as a **meeting point** to foster connections, encourage the exchange of experiences, and support the development of meaningful partnerships, all with the shared goal of advancing patient care and promoting patient rights.

EADV invites all Congress participants to **connect**, either onsite or virtually through the Congress platform, **with delegates from a wide range of patient organisations**.

The opening hours of the Area, during which participating Patient Organisations will be present, are provided below:

Wednesday, 30 September  
09:30 - 17:30

Thursday, 1 October  
09:00 - 17:30

Friday, 2 October  
09:00 - 17:30

We acknowledge and thank the following patient organisations for their commitment and involvement during this year's Congress.



## General information

### Congress venue

The EADV Congress 2026 will be held at the Austria Center Vienna (ACV)

➔ Bruno-Kreisky-Platz 1, 1220 Wien – [See map](#)

### Venue opening hours

- Tuesday 29 Sep 14:00 – 18:00 \*
- Wednesday 30 Sep 07:00 – 22:30
- Thursday 1 Oct 07:00 – 21:30
- Friday 2 Oct 07:00 – 20:00
- Saturday 3 Oct 07:00 – 19:00

\* Badge pick-up area and Speaker preview room only

### First aid room and emergency numbers

In case of need please visit the First aid room **0.98** managed by Arbeiter Samariter Bund, located on level 0.

Emergency number on site: +43 676 319 95 61

General emergency number: 112

Closest hospital: AUVA Trauma Centre Vienna, Donaueschingenstraße 13,  
1200 - Vienna  
Distance: 3,6 km

### Onsite facilities and opening hours

#### Badge pick-up area

The badge pick-up area is located on level 0 of the ACV and will be open as follows:

- Tuesday 29 Sep 14:00 – 18:00 \*
- Wednesday 30 Sep 07:30 – 18:00
- Thursday 1 Oct 07:30 – 16:30
- Friday 2 Oct 07:30 – 16:30
- Saturday 3 Oct 07:30 – 16:30

\* Badge pick-up area and Speaker preview room only

#### MyEADV area

The MyEADV area is located in Hall X1 on level -2 of the ACV. This is your go-to spot for all questions related to upcoming events, membership, courses, and publications.

More info: [eadv.org/congress/members](https://eadv.org/congress/members)



## *Other services*

**Cloakroom** - The Cloakroom is located on level -2 of the ACV and will be open as follows:

- Wednesday 30 Sep 07:30 – 22.00
- Thursday 1 Oct 07:00 – 21.30
- Friday 2 Oct 07:00 – 20.00
- Saturday 3 Oct 07:00 – 19.00

**Lost & found** - Please hand in all found items and ask for lost items at the ACV info desk, located in the Entrance Hall on level 0.

**Catering facilities** - Lunch and coffee breaks are not included in the registration fees. Meals and snacks can be purchased within the Congress venue during the opening hours in various catering areas.

## *Childcare facility*

An on-site professional childcare service for children aged 6 months to 14 years old is available upon registration. The childcare facility is located on level 0 of the ACV and will be open as follows:


- Wednesday 30 Sep 08:00 – 19.30
- Thursday 1 Oct 08:00 – 18.00
- Friday 2 Oct 08:00 – 18.00
- Saturday 20 Sep 08:00 – 18.00

More info: [eadv.org/congress/childcare-facility](https://eadv.org/congress/childcare-facility)




## Venue floor plans

### Level -2




**Level 0**




- |  |                       |  |                                  |
|--|-----------------------|--|----------------------------------|
|  | Session rooms         |  | Industry meeting rooms & lounges |
|  | Session room overflow |  | EADV meeting rooms               |
|  | Workshops             |  | Press area                       |
|  | Exhibition            |  | Working area / Seating area      |
|  | Industry expert hubs  |  | Childcare                        |




Level 1




- |                       |                                  |
|-----------------------|----------------------------------|
| Session rooms         | Industry meeting rooms & lounges |
| Session room overflow | EADV meeting rooms               |
| Workshops             | Press area                       |
| Exhibition            | Working area / Seating area      |
| Industry expert hubs  | Childcare                        |




## Level 2




- |                                                                                     |                       |                                                                                     |                                  |
|-------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------|----------------------------------|
|  | Session rooms         |  | Industry meeting rooms & lounges |
|  | Session room overflow |  | EADV meeting rooms               |
|  | Workshops             |  | Press area                       |
|  | Exhibition            |  | Working area / Seating area      |
|  | Industry expert hubs  |  | Childcare                        |



## Level 3



- |                                                                                                           |                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
|  Session rooms         |  Industry meeting rooms & lounges |
|  Session room overflow |  EADV meeting rooms               |
|  Workshops             |  Press area                       |
|  Exhibition            |  Working area / Seating area      |
|  Industry expert hubs  |  Childcare                        |



## Scientific information

### *Official language*

English is the official language of the EADV Congress. No simultaneous translation will be provided at any EADV scientific session.

### *Session access*

Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close the access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.



The use of mobile phones as well as audio and video recording devices are strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session. Photography is not permitted.

### *Abstracts and ePosters*

Selected abstracts will be published as electronic posters during the Congress and made available for viewing in the ePoster area, located on level 1 of the ACV.

30 big screens are provided and configured exclusively to display the ePosters.

The ePosters can be viewed sequentially by number, submission topic or searched individually by title, key word, or author.

The ePoster area will be open as follows:

- Wednesday 30 Sep 07:30 – 18.30
- Thursday 1 Oct 07:30 – 18.30
- Friday 2 Oct 07:30 – 18.30
- Saturday 3 Oct 07:30 – 12.00

Accepted abstracts will be made available on the [EADV website](#) after the event.



## Certificates and accreditation

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session.
- A **CME-CPD Certificate** is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms.
- An **ePoster Certificate** is available for all leading ePoster authors.
- An **Oral presentation Certificate** is available for all presenters of an abstract accepted for an oral presentation.
- A **Speaker presentation Certificate** is available for all presenters who have delivered a lecture in a scientific session
- A **Workshop Certificate** is available for all Workshop participants.

The certificates are not sent out automatically. They can be downloaded from the EADV membership platform (MyEADV) by entering the email address and password used during the registration process or the EADV member log-in details (if a EADV member).

More info and login URL: <https://eadv.org/congress/>

## Speaker information

All presentations must be in English. Speakers should also verify in the online programme that the name of the room and the time of the session have not changed.

Speakers must upload their presentation 3 hours (minimum) before the lecture if it has not already been uploaded.

Speakers with a presentation during the first time slot of the morning are requested to upload their PowerPoint presentation the day before.

## Speaker preview room

The speaker preview room is located in room 0.12 on level 0 of the ACV and will be open as follows:

- |             |        |               |
|-------------|--------|---------------|
| • Tuesday   | 29 Sep | 14:00 – 18:00 |
| • Wednesday | 30 Sep | 07:30 – 18:00 |
| • Thursday  | 1 Oct  | 07:30 – 17:00 |
| • Friday    | 2 Oct  | 07:30 – 17:00 |
| • Saturday  | 3 Oct  | 07:30 – 16:00 |



## Registration

Anyone interested in registering for the EADV Congress can do so online via the registration system available at [eadv.org/congress/registration](https://eadv.org/congress/registration). Fees, deadlines, policies, and other important information are also published on the same site.

The EADV Congress offers **3 ticket options** to participate with flexibility.

### The EADV Congress **Full Ticket** includes:

- Admission to live Congress Scientific Sessions
- Access to the virtual Congress Platform
- Admission to the Networking Symposium on Wednesday, 30 September 2026 (No entertainment)
- Access to Subspecialty Society Meetings
- Access to the ePoster area, MyEADV booth and Patient Advocacy Booth
- For Healthcare Professionals and Non-Members (INDUSTRY) access to the Exhibition Hall
- Access to Satellite Symposia Sessions and Industry Expert Hub sessions \*
- Eligibility to claim ECMEC Credits for participating in the live Scientific Sessions
- Transportation pass (read more on [eadv.org/congress/about/the-venue](https://eadv.org/congress/about/the-venue))
- **Along with all the benefits of the virtual registration**

### The EADV Congress **Virtual Ticket** includes:

- Access to the virtual Congress Platform with live-streamed scientific sessions
- Access to all on-demand content until 31 December 2026
- Access to the streaming of Subspecialty Society Meetings
- Access to the online library of ePosters and abstracts
- Access to the online EADV area and Patient Organisation Hub
- For Healthcare Professionals and Non-Members (INDUSTRY) access to the exhibiting company profiles
- Live-streaming of selected Satellite Symposia Sessions and Industry Expert Hub \*
- Eligibility to claim ECMEC Credits for participating in the live-streamed Scientific Sessions

### EADV Congress **1-Day Ticket**

A 1-Day Ticket is limited to one ticket per participant and is available for on-site attendance only. To attend the Congress for more than one day, a Full Ticket valid for the entire duration of the event must be purchased. Transportation pass and Virtual Access after the event are not included.

*\* IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserves the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.*

*A 1-Day Ticket is only valid for 1 of the 4 days of the Congress and is limited to one ticket per participant.*



## Registration

### Name Badge

Registered participants are invited to print out their badge at the self-printing machines on arrival at the Registration area. The name badge is the official EADV Congress identification document and must be worn at all times to gain entry to the various Congress areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

The badge includes a QR code containing your full address and email. It is the participant's decision to disclose these details to the Industry Session's organisers with a scanner.

### *Press information for journalists and media representatives*

Journalists who are working for and representing recognised news organisations are encouraged to attend the Congress as Press. To register, journalists must complete the online application, upload a valid press card, and confirm adherence to the Embargo policy.

All registered Press members must adhere to the EADV Press & Media Guidelines, Embargo Policy and Filming/Photography/Recording Policy for Professionals. Registered Press can access all scientific sessions, but not the Exhibition Area, Satellite Symposia or Industry Expert Hub sessions. Only specialised press representatives can access the Exhibition area.

For further registration information, the EADV Press and Media Guidelines and the Embargo Policy, please visit the press page on our website [eadv.org/congress/press](https://eadv.org/congress/press).



# Healthcare Professional information and definition

## 1. Important note to Healthcare and Non-Healthcare Professionals

As a multidisciplinary audience will attend the EADV Congress, the EADV will assign different classes to Healthcare Professionals (HCPs) and Non-Healthcare Professionals (non-HCPs) to ensure compliance with the Austrian Pharmaceutical industry (PHARMIG) [Code of Conduct](#) and the medical device industry code of conduct (AUSTROMED) ([Kodex und Statuten der AUSTROMED – Erklärvideo](#)).

Please read the description below to ensure that you (or your delegates) comply with the regulations in place.

**EADV members are not automatically considered Healthcare Professionals.**

Please select the correct status (HCP or non-HCP) during registration.

## 2. HCP Definition

The PHARMIG code defines Healthcare Professionals as follows (art. 2.2):

“Healthcare Professional:

*“...any natural person(s) authorized to administer, to dispense, and to prescribe medicinal products such as doctors, pharmacists, dental practitioners, veterinarians, dentists, midwives, nursing professionals, medical technicians, medical service professionals, and other medical services organizations, provided that such medicinal products are necessary for the discharge of their duties.”*

**Medical students** are not considered Healthcare Professionals under the current guidelines and will be automatically classified as Non-Healthcare Professionals.

## 3. Industry sessions

Satellite Symposia and Industry Hub Sessions presenting data on the development, research, or other issues related to prescription medicine is restricted to Healthcare Professionals and *Non Member (INDUSTRY)* as indicated by the Industry Session Organizer.

All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs.

Industry Session organisers can limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to achieving the session's intended purpose. The organising company reserves the right to refuse single categories, particularly if they are not adequately related to the session's objective and purpose.

The industry session organiser is responsible for compliance with the session.



## Privacy

### **Use of private data**

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read the full EADV Privacy Policy on [eadv.org/privacy-policy](https://eadv.org/privacy-policy).

### **Transferring the data to the industry session organiser**

During the EADV Congress, you have the right to transfer the data collected by EADV to another controller ("the Industry session organiser", "Industry"). It may occur through scanning a badge, QR code, or other means at any industry session at the Congress, the participant authorises the EADV to transfer the participant's data to the Industry.

The EADV is obliged to make this process possible, but does not take any responsibility for what happens with the data after it is transferred to the Industry session organiser. We advise making sure that the Industry presents a Privacy Policy and read it carefully. Purposes described by the Industry Exhibitor might include the promotion of pharmaceutical products and similar.

Transfer of the data from the EADV to the exhibiting Industry does not mean the removal of original data from EADV. If you wish for the data to be removed or have any requests or questions, please contact us at any time by writing to [eadvoffice@eadv.org](mailto:eadvoffice@eadv.org).

### **Third-party registration**

The EADV does not officially support or authorise any third-party organisation that creates registrations for individuals or groups. We strongly advise registering accordingly to official fees and only on the EADV official websites.

### **Liability disclaimer**

The Organisers cannot be held liable for any hindrance or disruption to the EADV Congress arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress or during all tours and events. Registration of a participant entails acceptance of these conditions.



# Exhibition

The Congress will host an exhibition of more than 14,000sqm, located on levels 0 and -2 of the ACV. Access points are show in the [venue floor plans](#).

The exhibition hall is open to Healthcare Professionals (HCPs) only, as prescription medical products will be advertised.

The exhibition hall will be open during the following hours:

- Wednesday 30 Sep 12:00 – 17:30
- Thursday 1 Oct 09:00 – 17:30
- Friday 2 Oct 09:00 – 17:30
- Saturday 3 Oct 09:00 – 12:00


## Exhibition floor plans

### ONLINE INTERACTIVE FLOOR PLANS


LEVEL

0

Hall  
**X5**




Hall  
**X4**




LEVEL

-2

Hall  
**X2**



Hall  
**X3**



## Exhibitor list

|                                |                |                                 |         |                                               |                    |
|--------------------------------|----------------|---------------------------------|---------|-----------------------------------------------|--------------------|
| A.D.O. MEDICAL S.R.L.          | X2201          | Cantabria Labs                  | X505    | FotoFinder Systems GmbH and DermLite LLC      | X301               |
| AbbVie Inc.                    | X511<br>X521   | Caregen Co., Ltd.               | X2324   | Galderma                                      | X412               |
| ACM Laboratoire Dermatologique | X503           | Castle Biosciences Inc.         | X2011   | GALENICUM DERMA                               | X2311              |
| Adamo Srl                      | X2405          | CATALYSIS, S. L.                | X2116   | GENOSS CO., Ltd                               | X2411              |
| Almirall                       | X304<br>X306   | Celimax                         | X2005   | Glenmark Pharma                               | X548               |
| Alphyn Biologics, Inc.         | X2036          | Celldex Therapeutics            | X2017   | GME German Medical Engineering GmbH           | X2207              |
| Altruist                       | X2200-C        | CeraVe                          | X303-B  | Head & Shoulders                              | X2103-A<br>X2103-B |
| Alumis Inc.                    | X2004          | CHA Meditech Co. Ltd.,          | X2316   | HEINE Optotechnik                             | X2104              |
| AMI Inc                        | X2020          | ChoiceTech Korea Co. Ltd        | X2101-A | Helmholtz Munich                              | X2200-A            |
| Aniva International S.A.       | X2013          | Cortex Technology               | X2203   | Hoenle Medical GmbH                           | X2028              |
| Apogee Therapeutics            | X534           | Cosmed Cosmeceuticals           | X2200-D | ILLUCO                                        | X2404              |
| APS -TRICOPAT                  | X2106          | COSMEDICIAN KOREA               | X2211   | Incyte                                        | X311               |
| Archidemia                     | X2008          | Courage+Khazaka electronic GmbH | X2018   | Indero                                        | X2313              |
| argenx                         | X2407<br>X2408 | Daavlin                         | X2213   | INMODE LTD                                    | X331               |
| Avalo Therapeutics             | X2205          | Damae Medical                   | X2040   | ISDIN                                         | X2306              |
| Axonlab                        | X2016          | Derma Medical Systems           | X2109   | ISISPHARMA                                    | X2412              |
| Beauté Pacifique Aps           | X2321          | DERMACTIVE GLOBAL LLC           | X2209   | Isocell Nutra                                 | X2208              |
| BeautyTECH                     | X2319          | DERMADROP MED                   | X2315   | JBP Korea Co., Ltd.                           | X2003              |
| Beiersdorf AG                  | X525<br>X526   | DERMASENCE   Medicos Kosmetik   | X2001   | JEOMED İLAÇ VE SAĞLIK ÜRÜNLERİ ANONİM ŞİRKETİ | X2414              |
| Belle.ai                       | X2002          | Dermavision Solutions           | X2413   | Johnson & Johnson                             | X402               |
| Biogen                         | X2206          | DermEngine by MetaOptima        | X2406   | Karo Healthcare                               | X2108              |
| BIOGENED SA                    | X2112          | Dermofarm SAU                   | X308-B  | Kenvue                                        | X313               |
| BODERM S.A.                    | X323           | DERMOGALENIC EXPERT SL          | X2305   | Ker Sun                                       | X2322              |
| Brymill Cryogenic Systems      | X2308          | Dermus Kft.                     | X2010   | KERNEL MEDICAL EQUIPMENT CO.LTD               | X2202              |
| Canfield Scientific GmbH       | X411           | Eli Lilly and Company           | X527    |                                               |                    |



|                                           |              |                                                           |              |                                          |                      |
|-------------------------------------------|--------------|-----------------------------------------------------------|--------------|------------------------------------------|----------------------|
| KLS Martin Group                          | X329         | NAOS / Laboratoire BIODERMA                               | X317         | MEICET                                   | X2200-B              |
| Kymera Therapeutics                       | X2102        | NeoStrata Company, Inc.                                   | X315         | Shanghai Shangmei Cosmetics Co., Ltd     | X2416<br>X2418       |
| LABORATOIRE SVR                           | X531         | NoIR InSight                                              | X2024        | Skin Analytics                           | X2038                |
| LABORATOIRES BAILLEUL GIULIANI GROUP      | X2210        | NOREVA LED                                                | X2111        | Speclipse Europe GmbH                    | X2022                |
| Laboratoires Dermatologiques D'Uriage     | X546         | NORSAN GmbH                                               | X2403        | SquareMind                               | X2310                |
| Laboratoires Dermatologiques Gamarde      | X2026        | Novartis Pharma AG                                        | X401<br>X403 | Swiss4ward                               | X321                 |
| Laboratorios Babé S.L                     | X2309        | OCULO-PLASTIK, INC.                                       | X2014        | Symbio Research                          | X2105                |
| Laboratorios Viñas                        | X2114        | OPATRA LONDON                                             | X319         | Takeda Pharmaceuticals                   | X501                 |
| LA ROCHE-POSAY LABORATOIRE DERMATOLOGIQUE | X303-A       | Oruka Therapeutics                                        | X2009        | terraplasma medical                      | X2320                |
| LASERVISION GmbH & Co. KG                 | X2030        | Pfizer                                                    | X404         | TOOsonix A/S                             | X2314                |
| LEO Pharma A/S                            | X414<br>X416 | Pharmaceris                                               | X2307        | TOPICREM - Laboratoire Dermatologique    | X2302                |
| L'Oreal Dermatological Beauty             | X303-C       | Pierre Fabre Laboratory                                   | X305         | Triple C Fashion GmbH                    | X2101-D              |
| Louis Widmer                              | X2402        | QuantifiCare                                              | X2107        | UCB                                      | X522<br>X532<br>X542 |
| MartiDerm                                 | X2410        | R&D Pharma                                                | X2409        | VICHY LABORATOIRES                       | X303-D               |
| medac GmbH                                | X2007        | Regeneron                                                 | X544         | VICTOR SURGICAL INSTRUMENTS              | X2303                |
| MESOESTETIC PHARMA GROUP                  | X2317        | Replior AB                                                | X2110        | VivaScope GmbH                           | X406                 |
| Mirka Ltd                                 | X2401        | Rilastil - Istituto Ganassini S.p.A. di Ricerche Chimiche | X308-A       | Wisepress Medical Bookshop               | X2006                |
| MITOCHON S.r.l.                           | X2312        | RoC Skincare                                              | X2204        | Zero Gravity skin                        | X2015                |
| MoonLake Immunotherapeutics               | X2301        | Sanofi                                                    | X523         | ZHENGZHOU BESTVIEW LASER CO.,LTD         | X2032                |
| MSD                                       | X2318        | Sanofi Regeneron                                          | X524         | Zhuhai Yasha Medical Instrument Co., Ltd | X2012                |
| MTP e. U.                                 | X2304        | Sanos Laser                                               | X2101-C      |                                          |                      |



## Sponsors

### PLATINUM SPONSORS

**sanofi** | **REGENERON**  
**sanofi**



**abbvie**

### GOLD SPONSORS

**Lilly**  
A MEDICINE COMPANY

**Pfizer**

**NOVARTIS**

**LEO**

**L'ORÉAL**  
Dermatological Beauty

**Johnson&Johnson**

**almirall**

### SILVER SPONSORS

**GALDERMA**  
EST. 1981

**Eucerin®**

**LABORATOIRES**  
**Pierre Fabre**

**Incyte**

**NAOS**

**AMGEN**

**Takeda**

**REGENERON®**

### BRONZE SPONSORS

**kenvue**

**GANASSINI**  
LABORATOIRES DERMATOLOGIQUES

**cantabria labs**  
celebrate life

IMAGING EXCELLENCE FROM  
**CANFIELD**  
**VIVASCOPE**

**FotoFinder | dermLite D**

**SVR**  
LABORATOIRE DERMATOLOGIQUE

**URIAGE**  
EAU THERMALE

**medac**  
improving human health

**argenx**

**MSD**

### WORKSHOP SPONSORS

#### ALLERGOLOGY: SKIN ENVIRONMENTAL INDUCED CONTACT DERMATITIS AND URTICARIA

**CHEMOTECNIQUE**  
DIAGNOSTICS

**MOXIE**

**SmartPractice**  
Bringing patients closer to diagnosis

#### DERMOSCOPY HAPPY HOUR LIVE

**CASIO**

**D'Z IMAGE**

**HEINE**

**FotoFinder | dermLite D**

#### BASICS OF ULTRASOUND IMAGING AND ECHO GUIDED INJECTIONS

**clarius** Ultrasound Anywhere

**SIBUS-IN**  
ECHO GUIDED INJECTIONS

#### PHLEBOLOGY FOR BEGINNERS

**clarius** Ultrasound Anywhere

**kreussler**  
PHARMA

#### CONFOCAL MICROSCOPY AND LC-OCT

**DAMAE MEDICAL**  
see beyond appearances

**VIVASCOPE**

#### WOUND HEALING

**BRAUN**  
SHARING EXPERTISE

**Coloplast**

**essity**

**SmithNephew**

**solventum**

**URGO**  
MEDICAL  
Healing people

### EADV CONGRESS HIGHLIGHTS SPONSOR

**almirall**

